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ABSTRACT 
 
Pulmonary arterial hypertension (PAH) and Adams-Oliver syndrome (AOS) are 
rare vascular disorders, characterised by severe late-onset and developmental 
cardiac abnormalities respectively. Both of them are clinically associated in a 
proportion of cases. PAH is a progressive condition that is clinically characterized 
by sustained elevation in mean pulmonary artery pressure, through vascular 
remodelling with luminal obliteration of small vessels and increased vascular 
resistance. In addition, monoclonal proliferation and uncontrolled growth in 
pulmonary artery endothelial (PAEC) and smooth muscle (PASMC) cells result in 
perturbation and muscularization of the arterial tone. The disease may be 
hereditary (HPAH), idiopathic (IPAH) or associated with other conditions, for 
example AOS. Most of HPAH and 25% of IPAH cases are associated with 
heterozygous mutations of a TGF-β superfamily member transmembrane 
receptor type-II, known as BMPR2 on chromosome 2q33. The majority of 
mutations suggest haploinsufficiency as the molecular mechanism of disease. 
While previous immunohistochemical studies of patient’s lung sections have 
reported further loss of BMPR-II than explained by haploinsufficiency, novel 
experimentation reported Jun activation domain-binding protein 1 (JAB1) as a 
BMPR-II interacting partner. This study has progressed understanding of this 
functional interaction in both physiological pathways and in the context of PAH. 
AOS disease displays multiple modes of inheritance and it is characterized by 
congenital limb defects and scalp cutis aplasia, with notable pulmonary and 
cardiovascular involvement in a proportion of cases. Despite advances in 
understanding the genetic basis of AOS, for the majority of affected subjects the 
underlined causative basis of disease remains poorly characterised. Recent 
novel identification of 10 mutations (3 frameshifts, 6 missense and 1 nonsense) 
of the NOTCH1 gene in patients clinically characterized with AOS, indicates 
NOTCH1 plays a key role in the AOS pathogenesis, and in particular, AOS-
associated with congenital heart anomalies. This investigation comprises two 
main avenues of research. First, to provide further insight into JAB1 mediated 
BMPR-II down-regulation and degradation via the proteasomal pathway and 
determination of JAB1 dysregulation and role in the aggressive mitogenic 
proliferation potential, through reduction of SMAD signalling and consequently 
p38 MAPK and TAK1 activation observed in PAH cells. Second, to assess 
dysregulation of the Notch signalling pathway by assessment of NOTCH1 target 
genes HEY1 and HES1 expression. Finally, a signalling cross-talk between BMP 
and NOTCH1 pathways has been investigated to assess the impact of NOTCH1 
AOS-associated mutations on BMP signalling cascade. 
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1.1 PULMONARY VASCULAR DEVELOPMENT 
 
The two distinct morphological events of vasculogenesis and angiogenesis are 
crucial to embryonic blood vessel development. Vasculogenesis is defined by the 
in situ differentiation of the mesodermal cells, angioblasts, into endothelial cells 
which proliferate, migrate, differentiate and organise into a vascular plexus that 
forms the foundation for the early vascular system. The hemangioblast, also 
derived from the embryonic mesoderm, is considered to be a common precursor 
cell contributing to both the definitive hematopoietic stem cells and the vascular 
endothelium. Angiogenesis is the process of branching growth from existing 
vessels and is essential to the elaboration of primitive vascular structures. The 
vascular wall is developed by the recruitment of additional cellular and 
extracellular components. The vascular smooth muscle layer, encircling the 
endothelium, is derived from mesenchymal precursors. In the great vessels, the 
smooth muscle cells develop, in part, from the neural crest whereas in smaller 
vessels, these cells arise from the differentiation of the surrounding mesoderm 
(Harvey, Rosenthal 1998). Pulmonary vascular development continues 
postnatally and involves both the vasculogenic differentiation of endothelial cells 
from gut mesoderm and angiogenic outgrowth of the six pharyngeal arches to 
form sections of the pulmonary arteries. Among the genetic factors known to 
regulate vessel formation are the vascular endothelial growth factor, fibroblast 
growth factor, transforming growth factor p and angiopoietin-1/2 along with 
several growth factor receptors. However, there is a paucity of information 
available about the mechanisms that regulate early vascular remodelling and the 
generation of endothelial cell diversity in various vascular beds (Towbin, Casey 
et al. 1999). 
 
1.1.1 GENERAL MORPHOLOGY OF NORMAL PULMONARY 
VASCULATURE 
 
All blood vessels, with the exception of capillaries, share the same structural 
basis. The vessel cell wall is sub-divided into three discrete layers or tunics. The 
innermost layer is described as the tunica intima It is composed of a simple 
squamous lining of endothelial cells and associated connective tissue. This layer 
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delineates the wall from the lumen of the cell. Encircling the tunica intima is the 
internal elastic lamina. The tunica media is the central section of the cell wall; it 
is derived from a layer of circumferential smooth muscle cells and varying 
amounts of connective tissue. The tunica media is enclosed by the external 
elastic lamina. The outermost layer of the blood vessel, or the tunica adventitia, 
is less clearly circumscribed than the other wall sections as it merges with the 
connective tissue of the extracellular matrix. It is primarily composed of 
connective tissue fibres (Figure 1-1) (Wagenvoort, Wagenvoort 1977). 
 
1.1.1.1 MORPHOLOGY OF SPECIALISED PULMONARY BLOOD VESSELS 
 
1.1.1.2 THE ARTERY 
 
The blood supply of the human organism originates from aorta, a large artery that 
protrubes from left ventricle. Blood from the periphery of the body is send to the 
lungs via the right ventricle and the pulmonary artery. Further arterial 
specialisation is dependent upon two principal factors: pressure pulses produced 
by contractions of the heart and blood supply regulation to target tissues of the 
artery. Specialisation centres on arterial wall variation within, principally, the 
tunica media. 
 
1.1.1.3 MUSCULAR ARTERIES 
 
The tunica intima of muscular pulmonary arteries is a simple layer of endothelial 
cells, sometimes with interspersed collagen fibres. The tunica media is 
predominantly composed of concentric smooth muscle fibres interwoven with 
scant amounts of collagen and reticulum. The media is clearly enclosed in internal 
and external elastic laminae. The tunica adventitia, consisting of dense collagen 
and elastic fibres, varies in thickness. This vessel type is demarcated by a size 
range of between 500 pm and 70 pm in external diameter (Wagenvoort, 
Wagenvoort 1977). 
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Figure 1-1 Basic structure of a blood vessel  
The three structural layers (tunics) of blood vessels.  (Adopted and modified from Human 
Cardiovascular System – Shuik Yin-blogspot.gr) 
 
 
 
1.1.1.4 ELASTIC ARTERIES 
 
In elastic arteries, the tunica intima is composed of endothelial cells and a sheet 
of underlying loose connective tissue. The tunica media contains concentric 
fenestrated lamellae of elastic fibres to aid distensibility. Smooth muscle and 
collagen fibres lie between the elastic layers. Both the intima and the media are 
thicker than those of muscular arteries. The external elastic lamina is difficult to 
discern from the other elastic layers. The adventitia is thinner than the media and 
contains deposits of collagen (Wagenvoort, Wagenvoort 1977). 
 
 
1.1.1.4 ELASTIC ARTERIES 
 
In elastic arteries the tunica intima is composed of endothelial cells and a sheet 
of underlying loose connective tissue. The tunica media contains concentric 
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fenestrated lamellae of elastic fibres to aid distensibility. Smooth muscle and 
collagen fibres lie between the elastic layers. Both the intima and the media are 
thicker than those of muscular arteries. The external elastic lamina is difficult to 
discern from the other elastic layers. The adventitia is thinner than the media and 
contains deposits of collagen (Wagenvoort, Wagenvoort 1977). 
 
 
1.1.1.5 ARTERIOLES 
 
Vessels with an external diameter in the size range of 70 pm and without smooth 
muscle tissue are arterioles. The tunica intima comprises a single endothelial 
layer resting on a clearly defined internal elastic lamina. The external elastic 
lamina and tunica adventitia are difficult to distinguish from the extracellular 
matrix (Wagenvoort, Wagenvoort 1977). 
 
1.1.1.6 CAPILLARIES 
 
The external diameter of these vessels extends from 4-15 pm. The organisation 
of the cell wall is very simple, with only the tunica intima being present. In 
capillaries, the intima typically consists of the endothelium, basal lamina and a 
discontinuous external layer of cells called pericytes (Wagenvoort, Wagenvoort 
1977). 
 
1.1.1.7 VEINS AND VENULES 
 
By comparison to arteries, cell wall definition in veins and venules is indistinct. 
The venous wall is thinner with a clear internal elastic lamina. In the tunica intima, 
an endothelial sheet overlies the internal lamina. The media, which blends into 
the adventitia, contains small, irregular bundles of smooth muscle as well as 
varying amounts of collagen. The adventitia is marked by dense collagen clusters 
with interspersed elastic fibres. Venules are smaller than veins and are 
muscularized in correlation to size of vessel. In the smallest venules, the 
muscular layer may be absent (Wagenvoort, Wagenvoort 1977). 
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1.1.2 THE NORMAL PULMONARY CIRCULATION 
 
The heart contains four chambers: two atria, which receive venous blood, and 
two ventricles, which eject blood into arteries. Blood whose oxygen content has 
become partially depleted and whose carbon dioxide content has increased as a 
result of tissue metabolism returns to the right atrium. This blood then enters the 
right ventricle, which pumps it into the pulmonary trunk and pulmonary arteries.  
The pulmonary arteries branch to transport blood to the lungs, where gas 
exchange occurs between the lung capillaries and the air sacks (alveoli) of the 
lungs. Oxygen diffuses from the air to the capillary blood, while carbon dioxide 
diffuses in the opposite direction. 
The blood that returns to the left atrium by way of the pulmonary veins is therefore 
enriched in oxygen and partially depleted of carbon dioxide. The path of blood 
from the heart (right ventricle), through the lungs, and back to the heart (left 
atrium) completes one circuit: the pulmonary circulation (Figure 1-2). 
 
Figure 1-2 The pulmonary circulation route  
(Adopted and modified from NewHealthAdvisor.com) 
 
Oxygen-rich blood in the left atrium enters the left ventricle and is pumped into a 
very large, elastic artery – the aorta. The aorta ascends for a short distance, 
makes a U-turn, and then descends through the thoracic and abdominal cavities. 
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Arterial brances from the aorta supply oxygen-rich blood to all of the organ 
systems and are thus part of the systemic circulation (Fox 2008). Any part of the 
heart-lung blood circuit can become damaged or blocked, leading to PVD. 
 
1.1.2.1 HAEMODVNAMIC AND STRUCTURAL ADAPTATION IN FOETAL 
AND NEONATAL PULMONARY CIRCULATION 
 
The placenta is the site of blood oxygenation for the foetus early developmental 
stages. At this phase of life, the patent foramen ovale and the patent ductus 
arteriosis are open. The blood flow from the placenta is, consequently, 
coordinated far from the foetal lungs. The high resistance of foetal pulmonary 
vasculature energizes redirection through the ductus arteriosis. The resistance 
identifies with the morphology of the muscular arteries and arterioles, in which 
the smooth muscle layer is thick and the lumen narrow. Upon birth, the lungs are 
utilized in blood oxygenation. A fall in pulmonary vascular resistance soon takes 
after as an outcome of pulmonary artery and arteriole dilatation. At this point, the 
difference in resistance is not accompanied by a morphological modification in 
the vasculature (Wagenvoort, Wagenvoort 1977). 
 
1.1.2.2 HAEMODVNAMIC AND STRUCTURAL FEATURES OF POSTNATAL 
AND ADULT CIRCULATION 
 
The closure of the ductus arteriosis and, subsequently, the foramen ovale 
produces a significant increment of blood flow through the lungs. During the first 
three weeks of post-natal stages, the muscular arteries and arterioles undergo 
significant structural stages. Significant luminal widening with associated medial 
thinning is exhibited. The pulmonary vasculature reaches a steady adult stage 
only after one year and a half, a period which characterized by graded decrease 
in media width. Finally, the adult pulmonary circulation utilizes its structural 
features to a low-pressure system of between 7 and 15 mmHg with an average 
of approximately 9 mmHg (Wagenvoort, Wagenvoort 1977). 
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1.2 CARDIOVASCULAR DISEASE 
 
Cardiovascular diseases (CVD) comprise a large spectrum of pathophysiological 
alterations that affect the heart and the vessels. The main manifestations of CVDs 
in the heart include a broad range of diseases such as cardiomyopathy, 
hypertensive heart disease, heart failure, pulmonary heart disease, cardiac 
dysrhythmias, inflammatory, valvular, rheumatic and congenital heart disease 
(Mendis, Puska et al. 2011). CVD manifestations also can be found in the arterial 
and venous system and include but not limited the blood vessels. They are known 
as vascular diseases. Typical examples are coronary artery disease, peripheral 
arterial disease, pulmonary vascular disease (PVD), cerebrovascular disease, 
renal artery stenosis and aortic aneurysm (Mendis, Puska et al. 2011).  
CVD is the leading cause of death globally, except the African region. Together 
they resulted in 17.9 million deaths (32.1%) in 2015 up from 12.3 million (25.8%) 
in 1990. (Mendis, Puska et al. 2011, GBD 2015 Mortality and Causes of Death 
Collaborators 2016). Although the advancement of new diagnostic and imaging 
modalities are promising, CVD morbidity and mortality is increasing steadily in 
the developed world (Moran, Forouzanfar et al. 2014). Coronary artery disease 
and stroke account for 80% of CVD deaths in males and 75% of CVD deaths in 
females (Mendis, Puska et al. 2011). Typically, the broad range of CVDs affects 
older adults. In the United States 11% of people between 20 and 40 have CVD, 
while the figure is 37% between 40 and 60, 71%  between 60 and 80, and 85% 
of people over 80 have CVD (Go, Mozaffarian et al. 2013) The average age of 
death from coronary artery disease in the developed world is around 80 while it 
is around 68 in the developing world. Disease onset is typically seven to ten years 
earlier in men as compared to women (Moran, Forouzanfar et al. 2014).  
The underlying pathophysiological mechanisms vary depending on the disease 
in question. However, a major component that triggers the pathophysiological 
alterations are risk factors that span throughout the lifespan of an individual. Risk 
factors such as gender, age, tobacco use, physical inactivity, excessive alcohol 
consumption, obesity, genetic predisposition and family history of cardiovascular 
disease, high blood pressure (hypertension), high blood sugar (diabetes 
mellitus), high blood cholesterol (hyperlipidaemia), psychosocial factors, poverty 
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and low educational status, and air pollution (GBD 2015 Mortality and Causes of 
Death Collaborators 2016). Epidemiological studies reveal the magnitude of high 
blood pressure resulting in 13% of CVD deaths, while tobacco resulting in 9%, 
diabetes 6%, lack of exercise 6% and obesity 5% (Mendis, Puska et al. 2011). 
It is estimated that 90% of CVD is preventable if established risk factors are 
avoided. Currently practiced measures to prevent cardiovascular disease include 
tobacco cessation, a low-fat, low-sugar high-fiber diet, systematic physical 
exercise per week, limit alcohol consumption, lower blood pressure if elevated, 
decrease body fat if overweight or obese and decrease of psychological stress 
(McGill, McMahan et al. 2008).  
 
1.3 PULMONARY VASCULAR DISEASE 
 
1.3.1 DEFINITION OF PULMONARY VASCULAR DISEASE 
 
Vascular disease is a subgroup of CVD and is the other end of the manifestation 
of CVD involving a wide array of diseases of the blood vessels; the arteries and 
veins of the circulatory system of the body. Many disorders in this vast network 
of vessels can cause a range of medical issues which can be serious or 
demonstrate lethality. A distinctive subtype of vascular disease is pulmonary 
vascular disease (PVD). PVD is the medical term for disease affecting the blood 
vessels leading to or from the lungs. Any kind of insulting stimulus that can cause 
blockage of the vessel or direct damage to the endothelial surface lead to 
pathophysiological alterations and at end PVD. 
 Characteristically, there are two main types of PVD: pulmonary embolism and 
pulmonary hypertension. In Europe, cases of pulmonary embolism range from 6 
to 20 per 10,000 people per year, which 7-11% of people do not survive, and 
there are 1.5-5.2 cases of pulmonary arterial hypertension per 100,000 people in 
Europe, who have a median survival rate of 2.8 years [(WHO Hospital Morbidity 
Database (Oct 2011) and Eurostat (Mar 2012)].  
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1.3.2 CAUSES, SYMPTOMS AND TREATMENTS OF PULMONARY 
VASCULAR DISEASE 
 
Up to date, there are several clinical tests for the diagnosis of PVD, based on a 
person’s symptoms, signs and clinical history. Computed tomography (CT scan), 
ventilation/perfusion scan (V/Q scan), echocardiography, right heart 
catheterization, chest x-ray film and pulmonary angiography are the main test for 
PVD identification. Also, the causes and treatments of PVD vary according to 
which of the lungs' blood vessels are affected. Pulmonary vascular disease is 
divided into four main categories: 
Pulmonary Arterial Hypertension (PAH): There are several causes for PAH which 
can be summarized as lung disease, autoimmune disease or heart failure. It is 
characterized by increased blood pressure in the pulmonary arteries (carrying 
blood away from the heart to the lungs). When there is no apparent cause, it's 
called idiopathic pulmonary arterial hypertension. This disease most often causes 
slow progressive shortness of breath. As the condition worsens, chest pain or 
fainting (syncope) with exertion can occur. Several medicinal approaches can 
lower blood pressure in the pulmonary arteries. Supplemental oxygen, specific 
vasodilators: a) endothelin receptor antagonists like Ambrisentan (Letairis), 
bosentan (Tracleer) and macitentan (Opsumit), b) prostacycline or prostacycline 
analogs like epoprostenol (Flolan), iloprost (Ventavis) and treprostenil 
(Orenitram, Remodulin, Tyvaso), c) prostacyclin receptor agonist selexipag 
(Uptravi), d) stimulator of soluble guanylate cyclase riociguat (Adempas), and e) 
phosphodiesterase type 5 inhibitors like sildenafil (Revatio), tadalafil (Adcirca) are 
some of the main drugs that are currently used.  
Pulmonary Venous Hypertension (PVH): It is mainly characterized by increased 
blood pressure in the pulmonary veins (carrying blood away from the lungs, to 
the heart). PVH is most often caused by congestive heart failure. A damaged 
mitral valve in the heart (mitral stenosis or mitral regurgitation) may contribute to 
PVH. This form of pulmonary vascular disease also causes shortness of breath, 
due to the congestive heart failure that's usually present. Shortness of breath may 
be worse while lying flat, when blood pressure is uncontrolled, or when extra fluid 
is present (edema). Because this form of pulmonary vascular disease is usually 
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caused by congestive heart failure, treatments for heart failure are usually 
appropriate: Diuretics, like furosemide (Lasix) and spironolactone (Aldactone), 
Angiotensin-converting enzyme (ACE) inhibitors, like Lisinopril, Beta-blockers, 
like carvedilol (Coreg) and metoprolol (Lopressor) and vasodilators that reduce 
blood pressure, like amlodipine (Norvasc), hydralazine (Apresoline) and 
isosorbide mononitrate (Imdur). 
Pulmonary Embolism: A blood clot breaks off from a deep vein (usually in the 
leg), travels into the right heart, and is pumped into the lungs. Rarely, the 
embolism can be a large bubble of air, or ball of fat, rather than a blood clot. A 
blood clot to the lungs typically occurs suddenly. Typical symptoms are shortness 
of breath, chest pain (often worse with deep breaths), and a rapid heart rate are 
common symptoms. Also, pulmonary embolism symptoms range from barely 
noticeable to severe, based on the size of the blood clot(s). Blood clots to the 
lungs are treated with blood thinners (anticoagulation). Treatments include the 
medicines are betrixaban (BEVYXXA), enoxaparin (Lovenox), heparin, and 
warfarin (Coumadin). 
Chronic Thromboembolic Disease: In rare cases, a blood clot to the lungs 
(pulmonary embolism) is never reabsorbed by the body. Instead, a reaction 
occurs in which multiple small blood vessels in the lungs also become diseased. 
The process occurs slowly, and gradually affects a large part of the pulmonary 
arterial system. Serious cases of thromboembolic disease may be treated with 
surgery to clear out the pulmonary arteries (thromboendoarterectomy). Blood 
thinners are also used. Riociguat (Adempas) is a drug approved for use after 
surgery or in those who can't have surgery, to improve the ability to exercise. 
If PVD is the underlying condition of another syndrome or clinical condition, 
treating that condition might improve the former disease. For example, 
autoimmune diseases as lupus, scleroderma or Sjogren’s syndrome are usually 
treated with immunosuppressant drugs like Prednisone, azathioprine (Imuran), 
and cyclophosphamide (Cytoxan) or steroids to reduce inflammation. Also, 
inhaled oxygen administration or FDA-approved medication such as nintedanib 
(Ofev) and pirfenidone (Esbriet), can slow the progression of PVD in cases of 
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lung diseases with low blood oxygen levels (chronic obstructive pulmonary 
disease, idiopathic pulmonary fibrosis and interstitial lung disease).  
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1.4 CLINICAL FEATURES OF PULMONARY ARTERIAL 
HYPERTENSION  
 
Pulmonary arterial hypertension (PAH) is a rare form of PVD, which is clinically 
characterized by sustained elevation in mean pulmonary artery pressure leading 
to vascular remodelling with luminal obliteration of small vessels and increased 
vascular resistance ultimately resulting to right ventricular failure and death 
(Figure 1-3) (Simonneau, Gatzoulis et al. 2013). The annual incidence rate of this 
particular disorder is 1-2 cases per 1 million in the general population (Shintani, 
Yagi et al. 2009) and it is often fatal. PAH is characterized by sustained mean 
pulmonary arterial pressure (mPAP) of >25 mmHg at rest and >30 mmHg during 
exercise. The pathobiology behind the vascular remodeling in PAH cases (Figure 
1-4) primarily corresponds to clonal proliferation of pulmonary artery endothelial 
cells (PAECs) and uncontrolled growth of smooth muscle cells (PASMCs) in the 
pulmonary arterioles, resulting in intima lesions (PASMC intima thickening, 
extracellular matrix fibrotic lesions, PAEC plexiform, concentric, and 
dilation/angiomatoid lesions) and reduction of the small pulmonary arteries 
luminal area (Tuder, Stacher et al. 2013). The monoclonal growth of PAECs in 
combination with abnormal glycolysis and mitochondrial dysfunction (Warburg 
phenomenon), indicates a link to pre-proliferating states and cancer progression 
(Ryan, Dasgupta et al. 2015). 
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Figure 1-3 Chest x-ray of patient with PAH  
A – posteroanterior, B – lateral view. Hypertrophy of right ventricle and pulmonary artery 
can be observed, caused by PAH (McLaughlin, McGoon 2006). 
 
 
 
Figure 1-4 Pathogenesis of Pulmonary Arterial Hypertension  
PAH occurs in susceptible patients as a result of an insult to the pulmonary vascular bed 
resulting in an injury that progresses to produce the characteristic pathological features. 
HIV, human immunodeficiency virus; BMPR2, bone morphogenetic protein receptor II 
gene [Image adopted and modified from (Gaine 2000)] 
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Despite the fact that in theory PAH can be present at any age, it is usually 
diagnosed in the fourth decade of life with an interesting gender bias towards 
female patients. Women are more prone to develop PAH than men with an 
estimated 1.7:1 ratio. Recent human and rodent data have suggested that altered 
levels of estrogen, differential signalling and altered metabolism of estrogens in 
PAH may underlie the gender difference in this disease (Pugh, Hemnes 2010). 
For adults, the mean representation age of the disease ranges from 36 to 50 
years, although individuals of any age may be affected (Soubrier, Chung et al. 
2013).  
If the disease is not clinically diagnosed at the time of appearance and treated 
accordingly, the outcome is usually fatal within 3 years (Shintani, Yagi et al. 
2009). The most vital screening tool which is widely used is echocardiography, 
but unfortunately is not suitable for clinical diagnosis. The reason is that an 
elevated right-ventricular systolic pressure that can be identified (i.e. 46mmHg 
without or <31 with additional signs of right heart strain), but is only indicative of 
PAH high probability. In order to distinguish pre-and post-capillary forms, the 
diagnosis of PAH is made by means of right heart catheterization. The severity is 
determined by the feasibility, for example a cardiac arrest volume (Sommer, 
Hecker et al. 2016).  
 
1.4.1 CLASSIFICATION OF PULMONARY ARTERIAL HYPERTENSION 
 
The World Health Organization (WHO) has endorsed many international 
conferences and world symposiums in order to review and classify different forms 
of pulmonary hypertension (PH) under a clinical and pathobiological context. The 
5th World Symposium on PH, which was held in Nice 2013 (Simonneau, 
Gatzoulis et al. 2013), revised previously established classification criteria to take 
into consideration the recent clinical and non-clinical published data of the various 
research groups globally (Table 1-1). The most common underlying causes 
include PAH from congenital heart disease (CHD), persistent PH of the newborn, 
connective tissue disease, chronic lung diseases and hypoxemia, PH due to left-
sided heart disease, and chronic thromboembolic pulmonary disease (George, 
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Schieb et al. 2014). Demographic data from UK and France report a PH incident 
rate of 1.1 to 2.4 cases per million population per year, with PAH cases to reach 
a prevalence range of 6.6 to 15.0 cases per million population per year and a 5-
year mortality of approximately 40%. PAH may be heritable (HPAH), Idiopathic 
(IPAH), or associated with drug or toxins, or other medical conditions such as 
previously mentioned connective tissue disease, human immunodeficiency virus 
infection (HIV), congenital heart disease and portal hypertension.  
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Table 1-1 Updated clinical classification of pulmonary hypertension, Nice 2013 
(Simonneau, Gatzoulis et al. 2013) 
1. Pulmonary arterial hypertension 
 1.1 Idiopathic PAH 
 1.2 Heritable PAH 
 1.2.1 BMPR2 
 1.2.2 ALK-1, ENG, SMAD9, CAV1, KCNK3 
 1.2.3 Unknown 
 1.3 Drug and toxin induced 
 1.4 Associated with: 
 1.4.1 Connective tissue disease 
 1.4.2 HIV infection 
 1.4.3 Portal hypertension 
 1.4.4 Congenital heart diseases 
 1.4.5 Schistosomiasis 
1′ Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis 
1′′. Persistent pulmonary hypertension of the newborn (PPHN) 
 
2. Pulmonary hypertension due to left heart disease 
 2.1 Left ventricular systolic dysfunction 
 2.2 Left ventricular diastolic dysfunction 
 2.3 Valvular disease 
 2.4 Congenital/acquired left heart inflow/outflow tract obstruction and 
congenital cardiomyopathies 
 
3. Pulmonary hypertension due to lung diseases and/or hypoxia 
 3.1 Chronic obstructive pulmonary disease 
 3.2 Interstitial lung disease 
 3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
 3.4 Sleep-disordered breathing 
 3.5 Alveolar hypoventilation disorders 
 3.6 Chronic exposure to high altitude 
 3.7 Developmental lung diseases 
 
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
 5.1 Hematologic disorders: chronic hemolytic anemia, myeloproliferative 
disorders, splenectomy 
 5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, 
lymphangioleiomyomatosis 
 5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid 
disorders 
 5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal 
failure, segmental PH 
 
Key: ALK-1 = activin receptor-like kinase 1 gene; APAH = associated pulmonary arterial 
hypertension; BMPR2 = bone morphogenetic protein receptor, type 2; CAV1 = caveolin-
1; ENG = endoglin; HIV = human immunodeficiency virus; PAH = pulmonary arterial 
hypertension. 
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1.4.2 GENETICS OF PAH  
 
Microsatellite linkage analysis in a significant number of autosomal dominant 
families with PAH by 2 distinct groups in 2000 (Deng, Morse et al. 2000, 
International PPH Consortium, Lane et al. 2000) (35 and 6 accordingly), 
highlighted that PAH has a genetic aetiology, which corresponds to mutations of 
a type II receptor of the transforming growth factor beta (TGF-β) superfamily, 
known as bone morphogenetic protein receptor II (BMPR-II) on chromosome 
2q33. More specifically, over 70% of HPAH and approximately 25% IPAH cases 
harbour deleterious BMPR2 mutations (Machado, Eickelberg et al. 2009). The 
majority of these mutations (70%) are frameshifts and nonsense mutations, that 
likely lead to elimination of BMPR2 mRNA via nonsense-mediated decay (NMD), 
the remainder comprise missense mutations identified across all BMPR2 regions 
(Machado, Eickelberg et al. 2009, Machado, Aldred et al. 2006) (Figure 1-5). 
 
 
Figure 1-5 BMPR-II receptor structure illustrating the key functional domains 
 
HPAH is inherited as an autosomal dominant trait with incomplete penetrance 
and an estimated life risk of 10-20%; while taking into account the recent Nice 
classification and the alteration of familial PAH term to hereditary, a distinctive 
20% of patients that harbour identifiable BMPR2 mutations and previously 
thought to be IPAH, pose hereditary risk to other family members (Machado, 
Southgate et al. 2015). It is rational to infer that in the majority of HPAH cases, 
and due to high prevalence of truncating mutations that would likely be subject to 
NMD, the inherited molecular mechanism of the disease is BMPR2 
haploinsufficiency (Machado, Pauciulo et al. 2001). Other mutations that much 
less commonly contribute to PAH phenotype are mutations in the TGF-β 
superfamily, Activin-like Kinase-Type I (ALK1) and Endoglin (ENG), which are 
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associated with hereditary hemorrhagic telangiectasia (HHT) that may lead 
directly to the development of PAH. In addition, rare nonsense mutations of 
SMAD9 gene, the intracellular partner of the BMP signalling pathway, also 
highlight key role to the dysregulation of the canonical signalling cascade and 
further implication to the disease pathogenesis (Shintani, Yagi et al. 2009, Nasim, 
Ogo et al. 2011).   
 
1.4.3 PATHOPHYSIOLOGY OF PAH 
 
1.4.3.1 PULMONARY COMPENSATORY MECHANISM 
 
Pulmonary vascular resistance (PVR) is observed in the cardio-vasculature when 
the pulmonary circulation responds to moderate hypoxia (∼20–60 mmHg PO2) 
via vasoconstriction (Aaronson, Robertson et al. 2006). This effect is known as 
hypoxic pulmonary vasoconstriction (HPV) and is exclusive to the pulmonary 
vasculature; vasodilation is normally observed in systemic circulation during 
periods of hypoxia (Ward, Aaronson 1999). In cases of HPV there is a particular 
mechanism in which efficient ventilation-perfusion ratio is maintained by directing 
blood from the lungs to the systemic circulation. (Mark Evans and Ward, 2009). 
However, this homeostatic mechanism is insufficient in sustained exposure to 
hypoxia and PVR increase lead to a rise in pulmonary artery pressure, causing 
vascular remodelling and sustained PH, even after hypoxia recedes to normoxic 
conditions (Ward, Aaronson 1999). 
 
1.4.3.2 HISTOPATHOLOGY 
 
Despite the numerous disease aetiologies, common characteristic 
pathophysiology and clinical manifestations are observed in each PH 
classification, through the use of histological examination. The proliferation of 
smooth muscle cells of tunica media and/or endothelial cells of tunica intima 
provide explanation for the occurred vascular remodelling. A certain homeostatic 
imbalance and dysregulation of vasodilators and vasoconstrictors lead to 
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increased cell proliferation, intimal hyperplasia and medial thickening and 
adventitial proliferation (McLaughlin, McGoon 2006). 
The histopathologic classification criteria that pulmonary arteries are subjected 
for evaluation are: a) muscularization of arterioles, b) concentric laminar intimal 
proliferation and fibrosis, eccentric intimal proliferation and fibrosis, plexiform and 
dilatation lesions, active and healed arteritis and fresh and recanalized thrombi 
(Pietra, Edwards et al. 1989). It is of special interest a pathological PAH hallmark 
which depicts a collection of disorganised and dysregulated endothelial cells as 
a form of plexiform lesion, and is highly associated with idiopathic PAH (IPAH) 
(Figure 1-6) (Jonigk, Golpon et al. 2011). Plexiform legion development is 
believed to occur in response to the up regulation of growth factors, smooth 
muscle cell proliferation and endothelial proliferation (Wideman, Hamal 2011, 
Yang, Long et al. 2011). However, the mechanism of this up regulation and 
initiation event is currently not known (Machado 2012). Plexiform lesions are an 
important histological marker of PAH, however are not specific to PAH; and are 
observed in additional PH-associated diseases (Jonigk, Golpon et al. 2011). 
Hypertension and occlusion of the pulmonary arterial vessels, further complicates 
and promotes remodelling and hypertrophy; this is observed due to an increased 
right-ventricle afterload, as a compensatory mechanism to increase ventilation-
perfusion ratio (Crosswhite, Sun 2014, Li, Qiu et al. 2014). 
The up to date most reliable identification of endothelial plexiform lesions is 
trichrome immunohistochemical assays usually probing for factor VIII antigen 
present on endothelial cells. 
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Figure 1-6 Histopathology of IPAH endothelial plexiform lesions  
A. Pulmonary artery displaying medial hypertrophy. C. Cross-section of plexiform 
lesions. D. Increased magnification of plexiform lesion E. Low-magnification of 
revasculariased plexiform lesion, using factor VIII related immunohistochemistry F. High-
magnification of cellular plexiform lesion. 
 
1.4.4 MOLECULAR PATHOLOGY OF PAH 
 
Pulmonary artery smooth muscle cells (PASMC) from patients with PAH not only 
exhibit attenuated growth suppression by BMPs, but an abnormal mitogenic 
response to transforming growth factor-β1 (TGF-β1) (Davies, Holmes et al. 
2012). Also, TGF-β ligands are regulating the endothelium (PAECs) via the 
BMP/TGF-β signalling pathways (Goumans, Valdimarsdottir et al. 2003). 
The transforming growth factor-β (TGF-β) superfamily is well characterised with 
associated pathways and ligands. However, the largest group of cytokines 
belonging to the TGF-β, bone morphogenetic proteins and their downstream 
affects are not as well characterised (Machado, Eickelberg et al. 2009). The key 
receptors in the TGF-β superfamily are endoglin-1, ALK1 and BMPR-II, all of 
which are receptors for the BMP ligand (Dyer, Pi et al. 2014). This superfamily of 
receptors is highly conserved throughout species, and mutations within this 
superfamily of receptors play a crucial role in the onset and pathogenesis of PAH 
(Machado, Eickelberg et al. 2009). The primary function of the TGF-beta 
signalling pathway is tumour suppression, through mechanisms that inhibit 
cellular proliferation, induce apoptosis, activate autophagy, inhibit growth factor 
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effects, suppress immune response and inhibit progression of angiogenesis 
(Demagny, Araki et al. 2014) 
 
1.4.4.1 BMP/TGF-β SIGNALLING PATHWAY 
 
The BMP/TGF-β superfamily comprises over 30 members in humans and many 
orthologues are found in most primitive metazoan linage sequenced. BMP/TGF-
β signalling plays key roles in the regulation of cell growth, differentiation and 
development in a wide and highly conserved range of biological systems. In 
general, the signalling cascade is initiated with ligand-induced oligomerization of 
serine/threonine receptor kinases. Initially, ligand stimulation assembles two 
type-I and two type-II serine/threonine membrane receptors consisting of short 
cytoplasmic segments followed by the kinase domain and a carboxy-terminal tail, 
which in case of BMPR-II receptor is extended. The signal is propagated after 
phosphorylation of type-I components by type-II receptors. The complexity of 
ligand-receptor combinations and the differential stages of the BMP/TGF-β 
signalling pathway is demonstrated in Figure 1-7.  
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Figure 1-7 TGF-β signal transduction 
TGF-β ligands bind to a range of type-II receptors to form complexes that interact with 
type-I receptors. Consequently, the receptors form heteroteramers, which phosphorylate 
and activate R-SMADs, that subsequently form complexes with common SMAD4. The 
complexes translocate to the nucleus for direct or indirect regulation of gene 
transcription. Endoglin is a co-receptor for TGF-β1, 2 and 3.  
 
Key: Act, activin; ActR, activin receptor; ALK, activin-like kinase; BMP, bone 
morphogenetic protein; BMPR, BMP receptor; TGF-βR, TGF-β receptor. 
 
Subsequently, type-I receptors phosphorylate the cytoplasmic receptor regulated 
SMADs (R-SMAD). This sub-set of the SMAD family, orthologues of the 
Drosophila protein, mothers against decapentaplegic (MAD) and the 
Caenorhabditis elegans protein SMA (from gene sma for small body size), 
function as transcriptional regulators. Consequently, the carboxy-terminal 
phosphorylated SMAD dimers bind to the common-SMAD4 (co-SMAD4 – 
chaperone molecule) and this complex translocates to the nucleus, where it acts 
as transcription factor and regulator of gene expression. The N- and C- terminals 
of SMADs are highly conserved and termed as Mad homology (MH) 1 and MH2 
domains, which are bridged by a linker region of variable amino acid sequences. 
INTRODUCTION CHAPTER 1 
 
24 
 
The MH2 domain is highly conserved in all SMADs, in contrast of MH1 where is 
conserved in R-SMADs and SMAD4, but not in other SMAD members as 
inhibitory SMADs (I-SMADs). The characteristic Ser-Ser-Val/Met-Ser sequence 
(SSXS motif) of R-SMADs at their C- terminal end is phosphorylated by the type-
I receptors. More specifically and in case of TGF-β signalling, the R-SMADs that 
transduce the signal are SMAD2 and SMAD3, whereas in BMP signalling are 
SMAD1, SMAD5 and SMAD accordingly. The regulation of the signalling cascade 
is orchestrated by I-SMADs 6 and 7, as part of a negative feedback loop.  
Furthermore, the stability of the superfamily receptors and /or the SMADs are 
tightly regulated by SMURF E3 ubiquitin ligases and USP4/11/14 
deubiquitinases. In addition, the BMP/TGF-β signalling pathway is modulated by 
MAPK signalling at a number of levels. Moreover, there are other SMAD-
independent signalling cascades that affect BMP/TGF-β signalling, including 
ERK, SAPK/JNK and p38 MAPK pathways. Despite numerous reports of 
dysregulated MAPK signalling in PAH, the role of altered MAPK and Raf/ERK1/2 
activation remains to be extensively investigated. Ultimately, the phosphorylated 
R-SMAD/SMAD4 complex enters the nucleus where it binds transcription 
promoters/cofactors to initiate DNA transcription. SMAD3 and 4 directly bind to 
SMAD-binding elements (SBEs), which include AGAC or GTCT sequences. 
SMAD2 indirectly binds DNA as it forms complexes with SMAD3 and 4. In 
contrast, SMAD1, 5 and 8 have a weak affinity for AGAC/GTCT sequences and 
instead they bind strongly to GCCGnCGC sequences of other target genes. The 
wide range of transcription factors that are activated from the BMP/TGF-β 
signalling consists of members of the basic helix-loop-helix (bHLH) and Fox 
proteins, activator-protein 1 (AP-1), inhibitor of DNA-binding proteins (IDs), Runx 
family of transcription factors, targets of other signalling cascades as Wnt 
signalling and epithelial-mesenchymal transition mechanisms (i.e. corepressor 
SIP1) and several coactivators like CBP/p300 which enhance Runx-dependent 
transcription. A characteristic overview of the whole BMP/TGF-β signalling 
pathway is summarized in Figure 1-8. 
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Figure 1-8 BMP/TGF-β Signalling Pathway  
(Illustration reproduced courtesy of Cell Signaling Technology, Inc. 
(www.cellsignal.com))  
 
1.4.4.2 SIGNAL TRANSDUCTION ROUTED THROUGH BMPR-II 
 
The BMPR2 gene is 13 exons in length, encoding an extracellular ligand binding 
domain, a transmembrane domain, a highly conserved catalytic kinase domain 
and an extended cytoplasmic tail (Machado, Aldred et al. 2006) (Figure 1-5). The 
translated protein, BMPR-II, functions as a serine-threonine receptor kinase 
which binds bone morphogenetic proteins (BMPs), members of the TGF-β 
superfamily of ligands that are involved in paracrine signalling. BMPR-II has a 
molecular weight of 115 kiloDaltons (kDa) and forms heteroterameric complexes 
with the type I receptors (ALK3, ALK6, and ACVR1) (50-55 kDa) in order to 
transduce the BMP signal. In general, type II receptors are capable of binding 
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various BMP ligands (BMP7, BMP4, BMP2) in the absence of type I receptors; 
when the binding occurs, type I receptors are recruited and phosphorylated. In 
turn, the type I receptors phosphorylate the receptor regulated R-SMAD1,5 or 8. 
Consequently, the SMAD dimers bind to the common SMAD4 and this complex 
translocates to the nucleus, where it acts as transcription factor and regulator of 
gene expression.  
This canonical SMAD signalling cascade is involved in many cellular processes 
in both embryo development and the adult organism, including cell growth, cell 
differentiation, osteogenesis, apoptosis, cellular homeostasis and other cellular 
functions relative to anti-proliferating effects (Miyazono, Maeda et al. 2005). In 
contrast, there are also non-canonical BMP cascades that result in increased cell 
proliferation, through activation of the Mitogen-activated protein kinase (MAPK) 
cascades (Rudarakanchana, Flanagan et al. 2002, Nishihara, Watabe et al. 
2002)  (Figure 1-9). Recent protein-protein interaction studies have revealed that 
there are several other interacting partners of BMPR-II, including LIMK1 and 
Tctex-1 (Foletta, Lim et al. 2003, Machado, Rudarakanchana et al. 2003), that 
are involved in PAH pathogenesis, through activation of the mitogenic p38MAPK. 
BMPR-II target genes of particular importance are the ID proteins, which almost 
certainly are activated by BMP stimulation in a variety of cell types (Miyazono, 
Maeda et al. 2005). They have two main roles as they function as negative 
regulators of cell differentiation and positive regulators of cell proliferation (Yang, 
Li et al. 2013). The group consists of 4 members (ID1, 2, 3 and 4) that exhibit 
similar biological activities, and they are part of the family of HLH transcription 
factors. They basically interact with other tissue-specific bHLH transcription 
factors activating genes (like MyoD/myogenin in muscle and 
NuroD/Mash1/neurogenin in neurons) that contain enhancer E-box sequences 
(CANNTG, with a palindromic canonical sequence of CACGTG) (Lopez-Rovira, 
Chalaux et al. 2002). In the context of vascular remodelling, they are important 
regulators of vascular cell function, as they are widely involved in vasculogenesis 
and angiogenesis and cardiovascular diseases as PH and atherosclerosis (Yang, 
Li et al. 2014).  For example, ID proteins stimulate the migration and proliferation 
of endothelial cells and promote survival and vessel regeneration after BMP/TGF-
β and VEGF stimulation, while they suppress the de-differentiation and 
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proliferation of smooth muscle cells and limit tunica-media thickness as they are 
involved in the cell proliferative responses to thrombin, angiotensin II and oxidized 
low-density lipoprotein (ox-LDL) (Yang, Li et al. 2014). Of interest, ID proteins are 
also down or up-regulated by BMP/TGF-β-independent signalling cascades as 
ERK1/2 and intracellular signalling mediators like XIAP and TAK1 respectively 
(Augeri, Langenfeld et al. 2016, Nasim, Ogo et al. 2012). 
 
 
Figure 1-9 BMP signalling pathway  
Upon BMP4/7/9/10 ligand binding, the BMPR-II receptor activates and phosphorylates 
through its kinase domain, type-I receptors such as BMPR1A/B. In turn, type-I receptors 
phosphorylate R-Smads 1/5/8, or independently activate the p38MAPK pathway. Smad4 
acts as a chaperone molecule and makes a trimer with receptor-activated Smads, which 
translocate to the nucleus and form complexes with other transcription cofactors, 
regulating targeted gene expression (Machado, Eickelberg et al. 2009). 
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1.4.4.3 FUNCTIONAL CONSEQUENCES OF BMPR-II MUTATION 
 
Mutations predicting premature truncation is likely to result in NMD of BMPR-II 
transcript. The majority of amino-acid substitutions outside the cytoplasmic tail 
lead to a diminution of SMAD activation as indicated by in vitro luciferase assays 
(Rudarakanchana, Flanagan et al. 2002, Nishihara, Watabe et al. 2002). A 
common outcome of mutation is activation of the mitogen p38MAPK.  Of interest, 
immunohistochemical analysis of lung sections with PAH denote further loss of 
BMPR-II, than is expected by haploinsufficiency by as yet unknown mechanisms 
(Atkinson, Stewart et al. 2002).  
The BMPR-II tail has several poorly understood functions, including regulation of 
p38 and p42/44 MAPK and interaction with LIMK, c-Src, and Tctex (West, Harral 
et al. 2008). 
In order to identify the extent of key pathways in regulation of the pulmonary 
circulation, Machado et al. conducted a yeast-two hybrid system, using the 
catalytic kinase domain of BMPR-II as bait in a lung cDNA library which was 
assembled in order to identify potential interacting partners of the wild-type 
receptor (unpublished data refer to chapter 3). The preliminary results identified 
Jun activation domain-binding protein 1 (JAB1) as an interacting partner of 
BMPR-II. 
 
1.5 CHARACTERIZATION OF THE NOVEL BMPR-II 
INTERACTING PROTEIN JAB1 
 
JAB1 is a subunit of the COP9 signalosome (CSN), which is a protein complex, 
highly conserved across species, with crucial functions in the ubiquitin-
proteasome pathway (Wei, Serino et al. 2008). The last two decades of research 
have revealed that the CSN consists of 8 distinct subunits, each named CSN1-
CSN8, which appears to have co-evolved with the 26S proteasomal lid, it displays 
proteasomal activity reliant on deneddylation of the cullin- RING ligases (CRL) of 
ubiquitin E3 complexes. Neddylation is the process by the ubiquitin-like protein 
NEDD8 is conjugated to its target proteins. These eight subunits harbour different 
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domains and as a result illicit different functions in vivo. The two key domains 
within the CSN are the proteasome-COP9 signalosome-initiation factor 3 (PCI) 
and MPR1-PAD1-N-terminal (MPN) domain (Pan, Wang et al. 2014). 
Interestingly, these two domains have been identified as components of the ‘lid’ 
sub-complex of the 26S proteasome and the eukaryotic translation initiation 
complex (eIF3); meaning these structural and functional homologies may predict 
that the PCI and MPN domain have additional roles (Shackleford, Claret 2010).  
CSN5/JAB1 contains the catalytic centre of the CSN isopeptidase activity; 
Interestingly, can also stably exist and act independently of the complex, 
promoting a diverse range of protein-protein interactions with its targets. Of note, 
overexpression or down-regulation of JAB1 protein levels have little effect in its 
presence in the CSN holo-complex, an observation that led to conclusion that 
JAB1 is an active mediator of crucial biological functions, both as part of the CSN-
complex or independently (Yoshida, Yoneda-Kato et al. 2010). 
It is of note that JAB1 is the CSN subunit with the vastest number of protein 
interactions with significant cellular regulators and the resulting down-steam 
effects are largely dependent on the target (Chun, Lee et al. 2013).  In general, 
JAB1 stabilizes or de-stabilizes the target protein. For example, key regulatory 
proteins like C-JUN, AP-1, HIF1-α and Mdm2 are stabilised by JAB1, whereas 
p27Kip, p53, 9-1-1 (Rad9-Rad1-Hus1) DNA repair complex, Cyclin E and 
oestrogen receptor alpha (ERalpha) are destabilised (Shackleford, Claret 2010). 
In case of protein de-stabilization, JAB1 and through a CRM1-dependent 
pathway is nuclear exporting its target to the cytoplasm and more specifically in 
the peri-nuclear region for degradation (Wei, Serino et al. 2008). Therefore, a way 
to prevent JAB1-mediated degradation is prevention of the nuclear export. 
However, the specific mechanism in which JAB1 drives nuclear export of its 
binding partners is not yet known.  
JAB1 is closely associated with both apoptotic and cellular proliferative 
mechanisms, and JAB1 knockdown animal models displayed a more severe 
apoptosis than knockdowns of other CSN subunits like CSN2, 3 and 8 
(Shackleford, Claret 2010). Furthermore, apoptosis in JAB1-deleted thymocytes 
is correlated with increased expression of proapoptotic protein BCL2-associated 
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X protein (BAX) and a decrease in expression of the anti-apoptotic protein family 
B-cell CLL lymphoma 2 (Bcl-2), most notably Bcl-xL (Wei, Serino et al. 2008). In 
case of cell cycle and in particular its tight regulation by cyclin-dependent kinases 
(CDK) inhibitors, JAB1 notably interacts with p27Kip, a crucially important CDK 
inhibitor (Shackleford, Claret 2010). Increased JAB1 expression correlates with 
reduced p27Kip levels, driving cell proliferation (Wei, Serino et al. 2008). 
Recent studies through pathological investigation of JAB1 expression in several 
types of human cancer, suggest that JAB1 is up-regulated in breast, colon, 
pancreatic and lung carcinomas (Fukumoto et al. 2006, Hsu et al. 2008). Of note, 
JAB1 antagonises TGF-β signalling by inducing targeting the chaperone SMAD4 
and SMAD5 and 7 for proteolytic degradation (Wan, Cao et al. 2002, Haag, 
Aigner 2006, Kim, Lee et al. 2004) and also controls multiple events in the 
mammalian cell cycle, mainly by inhibition of tumour suppressor genes as p53 
and p27Kip1 (Tomoda, Kubota et al. 2002). In regards to BMPR-II, there is no 
published research that indicates a potential interaction of JAB1 with the BMP 
type-II receptor, a fact that makes the initial experimental yeast-two hybrid system 
results unique, and further drives this particular investigation of verifying the 
interaction and its signalling consequences.  
P27Kip1 interactions and metalloproteinase activity of JAB1 have been associated 
with specific domains of the mature protein (Figure 1-10). The direct binding of 
JAB1 with P27Kip1 is facilitated by the p27-binding domain (PBD) of JAB1, which 
is closely located to the nuclear export signal (NES) domain of the protein. NES 
domain is responsible for the CRM1-dependent shuttling of P27Kip1 between the 
nucleus and the cytoplasm. Also, JAB1 contains a Mpr1-Pad1-N (MPN) domain 
with a metalloenzyme (JAMM) motif. The JAMM motif is accountable for the 
deneddylation activity of the JAB1/CSN5 subunit within the context of the CSN 
holo-complex and further loss of any CSN subunit will result into reduced JAMM 
activity (Wei, Serino et al. 2008). On the other hand, it has been postulated that 
the MPN domain is serves as a protein-protein platform, and the adjacent to the 
N- terminal JNK binding domain (JBD) is reported to have a centromeric 
component CENP-T binding activity of the CENP-T/CENP-W complex regulating 
its degradation (Chun, Lee et al. 2013). Further studies are required to fully 
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elucidate the functions of the above mentioned JAB1 domains, regarding their 
roles within or outside the JAB1/CSN5/COP9 complex. 
 
Figure 1-10 Structure of the JAB1 gene and the JAB1 protein domains  
(A) The 33kb long JAB1 gene, localized at chromosome 8Q13.2. (B) The FASTA 
sequence of the 8 exons within the 334-amino acid sequence are high lightened. (C) 
Schematic of JAB1 protein with a JAMM mottif-containing MPN domain, and an NES 
domain close to the PBD domain at the C-terminal end. (Adopted and modified from 
Shackleford and Claret, 2010) 
 
Key: JBD, JNK binding domain; MPN, Mpr1-Pad1-N domain; JAMM, JAB1/MPN/Mov34 
metalloenzyme motif; NES, nuclear export signal; PDB,  p27-binding domain 
 
1.5.1 JAB1 AND THE UBIQUITINATION PATHWAY 
 
The ubiquitin pathway is a mechanism of post-translational modification, that 
affects proteins in varying ways, most importantly by degradation through the 
ubiquitin-proteasome pathway. It is mediated via ubiquitin, a 8.5 kDa regulatory 
protein which is found in most tissues of eukaryotic organisms, that apart 
degradation of the tagged target may also contribute to cellular relocation or 
prevent protein-protein interactions (Glickman, Ciechanover 2002, Chao 2015).  
The ubiquitination process requires three types of enzymes: ubiquitin-activating 
enzymes (E1), ubiquitin-conjugating enzymes (E2) and ubiquitin ligases (E3). 
These three types of enzymes form a three-stages of a reaction cascade, a) an 
ATP-dependent activation of ubiquitin by E1 enzymes, b) conjugation of ubiquitin 
from E1 to the cysteine active site of E2 via a trans(thio)esterification reaction, 
and c) ligation of ubiquitin to the target protein, through an isopeptide bond 
between a lysine of the protein and the C-terminal glycine of ubiquitin. For the 
last stage, numerous classes of E3 enzymes act as an enzymatic scaffold 
between E2 enzymes, ubiquitin and the E3-recognised substrate protein. The 
largest class of ubiquitin E3 ligases is represented by cullin-RING ligases (CRL) 
that are widely involved in the formation of multi-subunit E3sm like the anaphase-
1 334 aa JBD 
MPN 
JAMM Motif NES PDB 
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promoting complex (APC) and the Skp1-Cullin-F-box protein complex (SCF), 
which main role is to recognise and ubiquitinate specific target proteins for 
degradation via the proteasome. However, a large number of ubiquitin-like 
proteins (UBL) exist that clearly modify target proteins in pathways akin, but 
distinct from ubiquitination (Welchman, Gordon et al. 2005). The most notable 
UBL up to date is is neuronalprecursor-cell-expressed developmentally down-
regulated protein 8 (NEDD8). The conjugation of NEDD8 to the SCF scaffold or 
its removal are termed neddylation and deneddylation respectively, and 
represent a distinct mechanism of CRL-SCF regulation (den Besten, Verma et al. 
2012).  
The COP9-CSN proteasome mediates the dennedylation process by cleavage of 
the NEDD8 moiety by the metalloisopeptidase activity of the JAMM motif, 
apparent in the JAB1/CSN5 subunit. However, the dennedylation activity is a 
property of the CSN holo-complex and not the JAB1/CSN5 itself (Cope, Suh et 
al. 2002). Instead, JAB1 protein it is widely reported that is tagging other 
processes for ubiquitination through the proteasomal pathway. Up to date, 
verified JAB1 targets for ubiquitination are p27Kip, Lutropin/choriogonadotropin 
receptor (LHR), p53, estrogen receptor α (ΕRα), West nile virus capsid, Cyclin E, 
Rad9-Rad1-Hus complex, RUNX-3, DNA topoisomerase II alpha, Endothelin 
type A and B receptrors (ET(A) and ET(B)) and SMAD4, 5 and 7. Of interest, 
ET(A) and (B) overexpression is associated with chronic heart failure and in 
infiltrating cells of atherosclerotic lesions, whereas SMAD4, 5 and the I-SMAD7 
are positive and negative regulators respectively of the previously described 
BMP/TGF-β signalling (Yoshida, Yoneda-Kato et al. 2010). Therefore, since 
novel data (extensively described in Chapter 3) reveal JAB1 and BMPR-II 
interaction, it is only rational to hypothesise that JAB1 binds BMPR-II as a target 
for degradation via the 26S proteasome pathway. As previously described, PAH 
has been associated with BMPR2 mutations; however, this is a potential for wild-
type BMPR-II to be down-regulated by specific intracellular JAB1-BMPR-II 
interactions. Ultimately, researching this potential BMPR-II down-regulation, and 
other down-stream effects of such interaction, may help to elucidate the portions 
of HPAH and IPAH cases, where BMPR2 mutations are absent, and/or further 
decrease of the receptor’s expression that is observed in clinical 
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immunohistochemical samples which cannot be explained by BMPR2 loss of 
function mutations and haploinsufficincy (Machado, Pauciulo et al. 2001, Pietra, 
Edwards et al. 1989, Atkinson, Stewart et al. 2002, Rajkumar, Konishi et al. 
2010).  
 
1.6 ASSOCIATED FORMS OF PAH  
 
As determined in the Evian-Venice and later in Nice PH classification 
(Simonneau, Gatzoulis et al. 2013, van Albada, Berger 2008) it is of critical 
importance to state that PAH can be clinically associated in patients suffering 
from vascular diseases such as hereditary hemorrhagic telangiectasia (HHT) 
(Harrison, Flanagan et al. 2003) and Adams-Oliver syndrome (AOS) (Patel, 
Taylor et al. 2004, Piazza, Blackston et al. 2004, Snape, Ruddy et al. 2009). HHT 
is clinically characterized by epistaxis, mucocutaneous telengiectases and 
visceral arteriovenous malformations (AVMs), particularly in the brain (CAVMs), 
lungs (PAVMs), liver (HAVMs), and gastrointestinal tract (GI) (Sabba, Pasculli et 
al. 2007). Of interest, the predominant causes of HHT, demonstrated at both the  
molecular and functional level, are diverse heterozygous mutations in endoglin 
(ENG) and activin receptor-like kinase 1 (ALK1), encoding type III and type I 
receptor members of the TGF-β superfamily, both are known to form 
heterotetramers with BMPR-II (Harrison, Flanagan et al. 2003). By contrast, AOS 
is a developmental disorder, predominantly characterised by the combination of 
aplasia cutis congenita (ACC) and terminal transverse limb defects (TTLD). 
However, a number of neurological and cardiovascular features, including 
pulmonary hypertension, are also seen in conjunction with the limb and scalp 
defects, suggesting that this condition represents an aggregation of clinical 
findings resulting from a vasculopathy during embryogenesis (Swartz, Sanatani 
et al. 1999). The recent identification of pathogenic mutations in the NOTCH1 
receptor add significant weight to this hypothesis and support a 
genotype/phenotype correlation between Notch pathway mutations and AOS-
related cardiovascular disease (Stittrich, Lehman et al. 2014). 
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1.6.1 ADAMS-OLIVER SYNDROME AND PAH 
 
Adams-Oliver syndrome (AOS) is a rare congenital disorder with highly variable 
prevalence (Martinez-Frias, Arroyo Carrera et al. 1996), with an estimated 
incidence of 1 in 225,000 live births. Its primary features are a specific 
abnormality in skin development (aplasia cutis congenita, ACC) and several 
malformations of the limbs and digits (terminal transverse limb defects, TTLD). 
ACC, a condition characterized by localized areas of missing skin typically 
occurring on the top of the head, is the second most common condition, affecting 
75% of people that are suffering from AOS; abnormalities involving abnormal 
development of the hands and feet (syndactyly, brachydactyly or oligodactyly) 
are the major feature in AOS, manifesting in 86% of cases (Figure 1-11). In 
approximately 20% of AOS cases, AOS patients can develop cardiovascular 
conditions like cutis marmorata telangiectatica congenita, hepatoportal sclerosis, 
arterio-venous malformations and PAH (Patel, Taylor et al. 2004, Snape, Ruddy 
et al. 2009). Moreover, congenital heart defects (CHDs) affect approximately 13-
20% of cases with ACC and TTLD (Digilio, Marino et al. 2008). These include 
Tetralogy of Fallot, aortic coarctation and valvular defects. AOS is also associated 
with neurological problems, such as developmental delay, learning disabilities, or 
abnormalities in the structure of the brain. 
Early clinical investigations (Zapata, Sletten et al. 1995), report that 13.4% cases 
of AOS have been associated with congenital heart defects and Swartz et al., 
1999 identified a case of a young girl diagnosed with AOS and PH associated 
with double outlet right ventricle and portal hypertension. They suggested that the 
development of PAH in patients suffering from AOS may have a shared genetic 
aetiology, especially in cases where no thromboembolic episodes in large 
vessels are recorded, and generalized abnormalities in small vessels are likely to 
be causing a disruption of blood flow. A more recent clinical review (Snape, 
Ruddy et al. 2009) reports several identified cases of AOS associated with 
pulmonary vascular anomalies including PAH, implicating a common aetiology to 
pulmonary vascular disease and AOS. 
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A) Aplasia cutis congenita (ACC): 
 
 
 
Genetics of Adams-Oliver syndrome 
 
B) Terminal transverse limb defects (TTLD): 
 
 
 
 
 
 
 
Figure 1-11 The primary features of AOS  
A) aplasia cutis congenita (ACC) and B) terminal transverse limb defects (TTLD). 
 
1.7 GENETICS OF ADAMS-OLIVER SYNDROME 
 
AOS may be inherited as an autosomal dominant or autosomal recessive trait, 
as well as occurring in isolated cases. Mutations in four genes so far have been 
identified as key players in the appearance of AOS phenotypes in all forms of 
inheritance. ARHGAP31, DOCK6, EOGT and/or RBPJ genes play important 
roles during embryonic development and functional changes in their transcripts 
and expression underlie different types of AOS (Table 1-2) (Shaheen, Faqeih et 
al. 2011, Southgate, Machado et al. 2011, Hassed, Wiley et al. 2012, Shaheen, 
Aglan et al. 2013, Cohen, Silberstein et al. 2014).  
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Table 1-2: AOS candidate genes 
Locus AOS1 AOS3 AOS2 AOS4 
 
Inheritance 
 
 
Autosomal 
dominant 
 
 
Autosomal 
dominant 
 
 
Autosomal 
recessive 
 
 
Autosomal 
recessive 
 
 
Gene 
 
 
ARHGAP31 
 
 
RBPJ 
 
DOCK6 EOGT 
Description 
 
Rho GTPase-
activating 
protein 31 
 
 
Recombination 
signal binding 
protein for 
immuno-
globulin kappa J 
region 
 
 
Dedicator of 
cytokinesis 6 
 
EGF domain-
specific O-
linked N-
acetylglucosami
ne transferase 
 
Chromosome 
 
3q13.33 
 
4p15.2 19p13.2 3p14.1 
 
  Gene span 
 
 
126.34 Kb 
 
 
111.95 Kb 
 
 
63.16 Kb 
 
 
38.41 Kb 
 
 
# of exons 
 
 
12 
 
 
12 
 
48 
 
15 
 
 
  CDS length 
 
 
4,335 bp 
 
 
1,503 bp 
 
 
6,144 bp 
 
 
1,332 bp 
 
 
Protein 
length 
 
 
1,444 aa 
 
 
500 aa 
 
 
 
2,047 aa 
 
 
 
 
443 aa 
 
 
Mutations 
identified 
p.Gln683X 
p.Lys1087Serfs
X4 
 
p.Glu63Gly 
p.Lys169Glu 
 
 
p.Thr455SerfsX24 
p.Asp416X 
p.Arg841SerfsX6 
p.Thr1370MetfsX19 
 
p.Trp207Ser 
*p.Gly359Aspfs
X28 
p.Arg377Gln 
[*recurrent 
mutation: n=9] 
 
  References 
 
Southgate et al., 
2011 
 
 
Hassed et al., 
2012 
 
 
Shaheen et al., 
2011 
Shaheen et al., 
2013 
 
 
Shaheen et al., 
2013 
Cohen et al., 
2014 
 
 
 
INTRODUCTION CHAPTER 1 
 
37 
 
Heterozygous mutations in the ARHGAP31 (AOS1) or RBPJ (AOS3) genes 
cause an autosomal dominant pattern of inheritance. Conversely, mutations in 
both copies of DOCK6 (AOS2) or EOGT (AOS4) lead to AOS development in an 
autosomal recessive manner. The ARHGAP31 and DOCK6 proteins are both 
involved in the regulation of proteins called GTPases (i.e. Cdc42 and RAC1) 
which cycle between an inactive form bound to GDP and an active form bound to 
GTP, and are critical for several aspects of embryonic development. On the other 
hand, both RBPJ and EOGT proteins are associated with the NOTCH signalling 
pathway. More specifically, RBPJ is an internal part of the signalling pathway, 
acting downstream as the major transcription factor of NOTCH target genes (e.g. 
HEY1, HES1). The role of EOGT is less clear but it is believed to act by 
transferring a molecule called N-acetylglucosamine to the NOTCH extracellular 
domain. Recently, a novel report by Stittrich et al., 2014, identified mutations of 
the NOTCH1 gene in a proportion of a AOS cohort, only to be rapidly followed by 
Southgate et al in order to provide solid evidence of haploinsufficiency of 
NOTCH1 receptor as a cause of AOS with variable cardiac abnormalities 
(Southgate, Sukalo et al. 2015). 
 
1.7.1 OVERVIEW OF THE NOTCH1 SIGNALLING PATHWAY 
 
1.7.1.1 DOMAIN ARCHITECTURE OF NOTCH1 RECEPTOR 
 
The NOTCH1 receptor is a single-pass transmembrane protein of 2555 amino 
acids length in human pre-protein isotype (Figure 1-12A), which may be 
subjected to further cleavage and modification in the trans-Golgi to form non-
covalent heterodimers on the cell surface. The extracellular domain (ECD) of the 
receptor varies in length from species to species; for example mammalian ECDs 
spanning a much larger length than of Caenorabditis  elegans  counterparts. Both 
Drosophila and human NOTCH1 contain a distinct 36 EGF-like domains at the 
N- terminal part, a subset of which contain calcium binding sites (cbEGF). 
Adjacent to the EGF-like repeats, there are 3 Lin-12-Notch (LNR) repeats, and 
hydrophobic region which mediates heterodimerization of the receptor (HD). 
Together, LNR and HD regions form the negative regulatory region (NRR), next 
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to the cell membrane. There are 3 main cleavage sites for NOTCH1 proteins 
termed S1, S2 and S3. S1 is target for proteolysis of the receptor and along with 
the S2, they are lying in the NRR area, which is responsible for protecting the 
cleavage sites from post-translational modifications. The final S3 cleavage site 
lies within the transmembrane segment to liberate Notch intracellular domain 
(NICD). NICD consists of a RAM domain (RBPjk associated molecule), followed 
by seven ankyrin repeats (ANK), a transcription activation domain (TAD) and a 
C- terminal OPA/proline/glutamic acid/serine/threonine-rich (PEST) domain 
which is involved in NICD degradation by proteolysis. 
 
1.7.1.2 NOTCH1 CANONICAL SIGNALLING PATHWAY 
Canonical NOTCH1 signalling is initiated on the binding of the receptor to 
Delta/Serrate/LAG-2 (DSL) ligands, which are predominantly expressed on 
opposing cell-surfaces. Upon DSL-NOTCH1 interaction, a series of proteolytic 
cleavages take place in the extracellular NOCH1 compartment at S2 site by 
ADAM metalloproteases, and within the transmembrane counterpart at S3 site by 
γ-secretase respectively. Finally, the cleaved NICD domain translocates to the 
nucleus and interact with the RBPJκ/CSL transcription repressor, which in turn is 
being converted to a transcriptional activator. A simplified schematic of the 
canonical pathway is illustrated in Figure 1-12B. This active transcription complex 
induces the expression of bHLH family of genes such as Hairy and ebhancer of 
split (Hes) family genes (HES1, 3, 5 and 7), and Hes-related with YRPF motif 
(Hey) family genes (HEY1, 2 and HEYL) (Zanotti, Canalis 2016). 
Hey and Hes genes are the main transducers of NOTCH1 signalling in mammals, 
during vast diverse developmental stages, like somitogenesis and neurogenesis, 
coordinated spatiotemporal patterning of the mesoderm, and embryonic heart 
and vascular development (Fischer, Schumacher et al. 2004). Of note, HEY1 is 
well known to have a prominent role in cardiovascular development, along with 
HES1 at a lesser extend (Southgate, Sukalo et al. 2015). Finally, there are also 
highly conserved non-canonical Notch signalling pathways that are exert their 
biological functions by targeting the Wnt/β-catenin signalling pathway, inducing 
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arterial fate in vascular progenitors and play key suppressor roles in human 
cancers (Andersen, Uosaki et al. 2012).  
Up to date, there are well characterized interactions of Notch signalling with also 
other signalling pathways. These signalling cross-talks are generating the notion 
that signalling mechanisms do not operate in isolation, rather than being 
implemented in to far greater signalling networks. In the context of the greater 
BMP/TGF-β superfamily or receptors and intermediately signal transduction 
molecules, Notch signalling directly converges with BMP/TGF-β signalling after 
interaction of NICD with SMAD3 for TGF-β and SMAD1 for BMP (Andersson, 
Sandberg et al. 2011). The result of this cross-talk is enhancement of the 
canonical Notch signalling whereas the effect of Notch on TGF-β signalling is 
more complicated. For example, Notch/TGF-β mediated induction of HEY1, 
occurs only after ID1 mediated induction by TGF-β signalling. In cases of 
epithelial-to-mesenchymal transition (EMT), active TGF-β signalling requires 
active Notch signalling in the developing heart, and in endothelial-to-
mesenchymal transition (EndMT) programming the cardiac cushion 
morphogenesis, Notch signalling represses SMAD1, 2, but enhances SMAD3 
mRNA expression (Fu, Chang et al. 2009). Interestingly, CSL co-
immunoprecipitated with SMADs, an evidence of SMAD recruitment in the Notch 
transcription complex (Tang, Urs et al. 2010). Finally, TGF-β down-regulates the 
expression of Notch3, but up-regulates HES1 expression, during smooth muscle 
differentiation. Taken all into account, Notch signalling acts in certain cases 
synergistically with BMP/TGF-β signalling, whereas in other cases antagonises 
the down-stream effects of the later in the context of vascular development and 
remodelling in disease states (Itoh, Itoh et al. 2004).  
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Figure 1-12 The NOTCH1 protein and the canonical NOTCH1 signalling pathway  
A) Schematic of the human NOTCH1 protein highlighting all the critical functional 
domains. B) Simplified schematic of the canonical NOTCH1 signalling cascade. EGF-
repeat domain is glycosylated by EOGT in mammalian cells. The signal transduction is 
initiated by 1 of 5 ligands through direct contact of adjacent cells. Following ligand 
activation, the intracellular domain NICD is cleaved and further translocates to the 
nucleus to form an active transcriptional complex with RBPJ, MAML and CoA. In the 
absence of Notch activation, RBPJ complexes with CoR to repress the transcription of 
down-stream genes.  
 
Key: EGF, epidermal growth factor-like repeat domain; LNR, Lin-12 NOTCH repeat 
domain; TM, transmembrane domain; RAM, RBPJ-associated molecule; ANK, ankyrin 
repeat domain; TAD, transcription activation domain; PEST, OPA/proline/glutamic 
acid/serine/threonine-rich domain; EOGT, EGF Domain-Specific O-Linked N-
Acetylglucosamine Transferase; NICD, Notch intracellular domain; MAML, mastermind-
like transcriptional co-activator (CoA); CoR, transcriptional co-repressor; RBPJ, 
Recombining Binding Protein Suppressor Of Hairless transcriptional regulator 
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1.7.2 THE NOTCH1 GENE IN AOS 
 
Despite the identification of four causal genes, each of these genes only accounts 
for a small proportion of AOS cases, collectively explaining around 10% of 
affected individuals. To further define the molecular genetic factors involved in 
AOS pathogenesis, Southgate et al., 2015 performed whole-exome sequencing 
of 12 probands with a clinical diagnosis of AOS and identified 2 novel truncating 
mutations (c.1649dupA; p.Y550* and c.6049_6050delTC; p.S2017Tfs*9) in the 
NOTCH1 gene. Further mutation screening of a patient cohort comprising of 50 
unrelated AOS subjects (Appendix D – Table D-1) detected NOTCH1 mutations 
in an additional 7 individuals, including two de novo variants (Table 1-3). All 
mutations were predicted to be pathogenic by bioinformatic software (Appendix 
D – Table D-2). Of note, 47% of mutation carriers also had a congenital heart or 
vascular abnormality, highlighting a genotype/phenotype correlation between 
NOTCH1 mutation and cardiovascular defects. These findings are highly 
correlated with existing vast literature reviews that linking NOTCH1 mutations 
with cardiovascular and lung conditions (Zong, Ouyang et al. 2016, Rusanescu, 
Weissleder et al. 2008, Kerstjens-Frederikse, van de Laar et al. 2016, Zhou, Liu 
2014); (Southgate, Sukalo et al. 2015)  
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Table 1-3: Summary of identified NOTCH1 variants 
Exon Coding variant Protein 
variant 
Variant 
type 
Protein 
domain 
7 c.1220C>G p.P407R Missense EGF 10 
8 c.1343G>A p.R448Q Missense EGF 11 
8 c.1345T>C p.C449R Missense EGF 11 
10 c.1649dupA p.Y550* Frameshift EGF 14 
25 c.4120T>C p.C1374R Missense EGF 35 
26 c.4663G>T p.E1555* Nonsense LNR 3 
26  
c.4739dupT 
 
p.M1580Ifs*30 
 
Frameshift 
 
- 
28 c.5218G>T p.A1740S Missense TM 
32 c.6049_6050delT
C 
p.S2017Tfs*9 Frameshift ANK 4 
 
It is of particular interest to establish how the novel AOS-related NOTCH1 
missense mutations affect the regulation of NOTCH1 signalling. Specifically, 
c.1220C>G, c.1343G>A and c.1345T>C affect amino acids that are located in or 
adjacent to the NOTCH1 ligand-binding domain, specified by EGF repeats 11-13 
(Figure 5A, B). Similarly, the c.4120T>C (p.C1374R) mutation affects a cysteine 
residue within an EGF domain which is likely to adversely affect the protein 
structure. By comparison, the c.5218G>T mutation is located in the 
transmembrane domain and its significance on the structural integrity of the 
molecule has to be assessed. Thus, quantitative studies will be undertaken to 
assess the NOTCH1 potential down-regulation in AOS-affected individuals, along 
with its implication in the signalling cascade.   
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1.8 AIMS AND OBJECTIVES 
 
Hypothesis: The primary hypothesis to be tested in this thesis is that JAB1 and 
NOTCH1 are involved in the development of CVD, in the regulation of BMPR-II 
expression and key intracellular pathways including BMP/TGF-β and NOTCH1 
canonical signalling. In order to test this hypothesis, the following areas will be 
investigated: 
 
1. Hypothesis: JAB1 functions as the first identified proteasomal-associated 
inhibitor of BMPR-II. 
 
Aims and Objectives: The interaction of JAB1 and BMPR-II will be 
analysed in vitro and in vivo in a panel of cancer cell lines followed by the 
confirmation of down-regulation of BMPR-II by JAB1 through proteasomal 
ubiquitination.  
 
2. Hypothesis: Dysregulation of JAB1 leads to abnormal BMPR-II receptor 
loss and PAH progression by disruption of the homeostatic BMP/TGF-β 
signalling balance. 
 
Aims and Objectives: Through the use of transient transfections of JAB1 
into cancer cell lines and pulmonary artery smooth muscle cells, the 
potential BMP/TGF-β stochiometric imbalance will be investigated along 
with alterations in the phenotypic proliferation rates of the cells. 
Additionally, transient RNA interference will be employed to reverse 
abnormal proliferation of cells in PAH.    
 
3. Hypothesis: NOTCH1 mutations are significantly associated with AOS and 
cardiac abnormalities via a loss of structural integrity of the receptor. 
 
Aims and Objectives: NOTCH1 expression and signalling will be assessed 
for novel missense and nonsense mutations identified in AOS patients, 
through the use of quantitative RT-PCR and ectopic protein expression. 
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Finally, a potential cross-talk between NOTCH1 and BMP signalling will 
be investigated.  
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2.1 CHEMICALS AND REAGENTS 
 
Unless otherwise stated below, reagents were purchased from Sigma-Aldrich, 
Gibco, life-technologies, Lonza and BIO-RAD. 
     Table 2-1 Reagents 
Reagent/ Kit Company Catalogue Number 
ΧL1-Blue Competent Cells Agilent Technologies 
(Santa Clara, 
California, USA) 
200249 
High Capacity cDNA reverse 
transcription kit 
Applied Biosystems 
(Foster City, 
California, USA) 
4368814 
DC Protein Assay Kit II  
 
Bio-Rad 
(Hertfordshire, UK) 
5000112 
Cell Counting Slides for TC20 Cell 
Counter 
1450015 
30% Acrylamide/Bis Solution 1610154 
Precision plus protein prestained 
standards, dual colour 
161-0374 
Fluoromount G Cambridge Bioscience 
(Cambridge, UK) 
0100-01 
Glycerol (Laboratory reagent grade) Fisher Scientific 
(Hampton, New 
Hampshire, USA) 
G/0600/08 
Methanol (HPLC grade) 67-56-1 
Ethanol (HPLC grade) 64-17-5 
2-Propanol (HPLC grade) 67-63-0 
HighRanger 1kb DNA Ladder Geneflow 
(Staffordshire, UK) 
L3-0020-S 
Heat inactivated fetal bovine serum 
(FBS) 
 
Gibco 
(Thermo Fisher 
Scientific) 
10082147 
DBPS, no calcium, no magnesium 14190169 
Penicillin-Streptomycin (PS) (100X) 15140122 
Trypsin-EDTA (0.25%), phenol red 25200056 
Trypan Blue Solution, 0.4% 15250061 
Lipofectamine™ 2000  
 
Invitrogen (Paisley, 
UK) 
11668-027 
Miller’s LB Broth Base® (Luria Broth 
Base) 
12795-027 
Ultra-pure water 10977-049 
Neon Transfection System 10 & 
100ul Kit 
MPK1096 & 
MPK10096 
LB Agar, powder (Lennox L Agar) 22700-025 
SmGM-2 Smooth Muscle Growth 
Medium-2 
Lonza (Slough, UK) CC-3182 
HEPES >99.5%, Free Acid  Melford (Ipswich, UK) B2001 
Purified BSA 100X New England Biolabs 
(Ipswich, 
Massachusetts, USA) 
B90015 
COPS5-Human, 4 unique 29mer 
shRNA constructs in pRS 
OriGene Technologies 
(Rockville, Maryland, 
USA) 
TR313776 
Protein G Sepharose beads TP790005 
Marvel Dried Skimmed Milk Powder Premier brans N/A 
Custom designed real-time PCR 
assay kit with Double-Dye probe 
(Taqman-style, 2x PrecisionPLUS 
Mastermix) 
Primerdesign Ltd 
(Southampton, UK) 
DD-hu-300 
FuFENE HD Transfection Reagent Promega  E2311 
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CellTiter 96® Non-Radioactive Cell 
Proliferation Assay (MTT) 
(Madison, Wisconsin, 
USA) 
G4000 
HiSpeed Plasmid Maxi Kit QIAGEN (West 
Sussex, UK) 
12662 
RNeasy Plus Mini Kit 74134 
Recombinant Human BMP-4 Protein R&D Systems 
(Minneapolis, 
Minnesota, United 
States) 
314-BP-050 
cOmplete, mini EDTA-free protease 
inhibitor cocktail tablets 
Roche Applied 
Science (West 
Sussex, UK) 
11 836 153 001 
Dulbecco’s modified eagle media 
(DMEM) high glucose with L-
Glutamine, Sodium Pyruvate and 
Sodium Bicarbonate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SIGMA-ALDRICH 
(GmbH, Hannover, 
Germany) 
D6429 
2-Mercaptoethanol >99% M6250 
Ammonium persulphate A3678 
Lactacystin >90% (HPLC) L6785 
Sodium Dodecyl Sulphate (SDS) 
(Molecular Biology Grade) 
71725 
N,N,N′,N′-
Tetramethylethylenediamine 
T9281 
Tris base 000000010708976001 
Bromophenol Blue B0126 
Ampicillin sodium salt A9518 
Kanamycin sulfate 60615 
Sodium Chloride (Molecular Biology 
Grade) 
S3014 
Sodium hydroxide solution 
(Molecular Biology Grade) 
72068 
Hydrochloric acid (Molecular Biology 
Grade) 
H1758 
Potassium Chloride (Molecular 
Biology Grade) 
P9541 
Ponceau S solution P7170 
Dimethyl sulfoxide (Molecular 
Biology Grade) 
D8418 
Ethidium bromide solution (Molecular 
Biology Grade) 
E1510 
Triton X-100 (Molecular Biology 
Grade) 
T8787 
Tween-20 (Molecular Biology Grade) P9416 
Glycine >99% G8898 
Sodium orthovanadate 99.98% 450243 
Sodium fluoride (Molecular Biology 
Grade) 
S7920 
Magnesium chloride anhydrous 
>98% 
M8266 
Phenylmethanesulfonyl fluoride 
(Molecular Biology Grade) 
78830 
Phosphate buffered saline tablets P4417 
Hoechst Stain solution H6024 
Pierce ECL Western Blotting 
Substrate 
Thermo Scientific 
(Waltham, 
Massachusetts, USA) 
32106 
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    Table 2-2 Buffers 
Reagent Name Components 
DNA loading dye (6X) 
 
0.25% (w/v) xylene cyanol or bromophenol 
blue; 30% glycerol (v/v) (25 mg xylene 
cyanol or bromophenol blue; 3 ml glycerol; 
6.7 ml water) 
Glycerol dye 0.5 mg/ml bromophenol blue; 50% (v/v) 
glycerol 
Laemmli lysis buffer (cell lysis buffer) (4X) 
 
200  mM Tris-HCl (pH 6.8), 8% SDS, 40% 
(v/v) glycerol 
Lysis buffer 50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 
1mM EDTA; 1 mM EGTA; 50 mM NaF; 5 
mM sodium pyrophosphate; 10% v/v 
glycerol; 1% v/v triton X-100; 1 mM NaVO4; 
1 cOmplete mini protease inhibitor tablet per 
10 mL of lysis buffer added immediately 
prior to use 
Phosphate buffered saline (PBS) (g/L:- 8.0 
sodium chloride; 0.2 potassium chloride; 
1.15 di-odium hydrogen phosphate; 0.2 
potassium dihydrogen phosphate; pH 7.3± 
0.2 at 25 oC) 
Dissolve 10 PBS tablets/1 litre  
 
Ponceau S staining solution 0.1% (w/v) Ponceau S; 5% (v/v) acetic acid 
Protein loading buffer 
 
0.2% (w/v) bromophenol blue; 1% (v/v) 2-
mercaptoethanol 
Protein running buffer 25 mM Tris-HCl; 192 mM glycine; 0.1% 
(w/v) SDS 
Protein transfer buffer 
 
25 mM Tris, 192 mM glycine, 20% (v/v) 
methanol; pH 8.3 
RNA gel loading buffer 50 % (v/v) formamide; 20 % (v/v) 
formaldehyde; 10 % (v/v) 10x MOPS buffer; 
20% (v/v) glycerol dye 
Stripping Buffer 100 mM 2-mercaptoethanol, 2% SDS, 
62.5mM tris-HCL pH 6.7 
Tris-acetic acid ethylenediaminetetraacetic 
acid (EDTA) buffer (TAE) 
40 mM Tris; 20 mM acetic acid; 1 mM EDTA 
 
Tris-borate EDTA buffer (TBE) (1X) 89 mM Tris; 89 mM boric acid; 2 mM 
EDTA 
Tris-buffered saline with Tween (TBS-T) 
 
50mM Tris-HCl (pH 8.0); 150 mM NaCl; 
0.1% (v/v) Tween-20 
TBS-T with bovine serum albumin (BSA) TBS-T; 5% BSA 
TBS-T with milk TBS-T; 5% (w/v) Marvel dried milk powder 
Tris-EDTA (TE) buffer  10 mM Tris-HCl (pH 7.5); 1 mM EDTA (pH 
8.0) 
Tris-SDS buffer 0.05 M Tris (pH 8); 0.1% SDS 
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Table 2-3 Primary antibodies 
Antibody Product number Company Isotype Migration in 
SDS/PAGE 
(kDa) 
Immunogen Dilution 
α-tubulin Ab7291 Abcam Mouse 
monoclonal 
IgG1 [DM1A] 
50 Raised against amino acids 426-450 
of chicken α-tubulin 
1:8000 WB 
Jab1 GTX70203 GeneTex Mouse 
monoclonal 
IgG2b 
38 Raised against the full-length mouse 
JAB-1 gene (expressed in E.coli) 
1:3000 WB 
 
2 μg for 107 
 cells IP 
BMPR-II AF811 R&D 
SYSTEMS 
Goat polyclonal 
IgG 
115 Raised against the mouse myeloma 
cell line NS0-derived recombinant 
human BMPR-II 
0.05 μg/ml WB 
Smad 5 12534S Cell Signalling Rabbit 
monoclonal IgG 
[D4G2] 
60 Raised against a synthetic peptide 
corresponding 
to residues surrounding Pro249 of 
human Smad5 
1:1000 WB 
phospho-Smad1/5 
(Ser463/465) 
9516S Cell Signalling Rabbit 
monoclonal IgG 
[41D10] 
60 Raised against a synthetic 
phosphopeptide corresponding to 
residues surrounding Ser463/465 of 
human Smad5 
1:1000 WB 
p38 MAPK 9212S Cell Signalling Rabbit 
polyclonal IgG 
43 Raised against a synthetic peptide 
corresponding 
to the sequence of human p38 
MAPK 
1:1000 WB 
phospho-p38 MAPK 
(Thr180/Tyr182) 
9215S Cell Signalling Rabbit 
monoclonal IgG 
[3D7] 
43 Raised against a synthetic 
phosphopeptide corresponding to 
residues surrounding Thr180/Tyr182 
of human p38 MAPK 
1:1000 WB 
Smad2/3 3102S Cell Signalling Rabbit 
polyclonal IgG 
52, 60 Raised against a synthetic peptide 
corresponding 
to residues in the amino-terminal 
region of Smad2/3 
1:1000 WB 
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phospho-Smad2 
(Ser465/467)/ 
Smad3(Ser423/425)  
8828S Cell Signalling Rabbit 
monoclonal IgG 
[D27F4] 
52, 60 Raised against a synthetic peptide 
corresponding to residues 
surrounding Ser465/467 of human 
Smad2 
1:1000 WB 
TAK1 5206S Cell Signalling Rabbit 
monoclonal IgG 
[D94D7] 
78 to 82 Raised against a synthetic peptide 
corresponding 
to residues surrounding Gln600 of 
human TAK1 
1:1000 WB 
phospho-TAK1 
(Thr184/187) 
4508S Cell Signalling Rabbit 
monoclonal IgG 
[90C7] 
82 Raised against a phosphopeptide 
(KLH-coupled) corresponding to 
residues surrounding 
Thr184 and Thr187 of human TAK1 
1:1000 WB 
RAC1 Ab33186 Abcam Mouse 
monoclonal 
IgG2b [0.T.127] 
21 Raised against recombinant full 
length protein corresponding to 
Human Rac1 
1 μg/ml WB 
 
2 μg for 107 
 cells IP 
c-Myc M4439 SIGMA-
ALDRICH 
Mouse 
monoclonal 
IgG1 [9E10] 
- Raised against a synthetic peptide 
corresponding to residues 408-439 
of the human p62c-Myc 
1:5000 WB 
 
2.5 μg for for 
107 
 cells IP 
FLAG M2 F3165-.2MG SIGMA-
ALDRICH 
Mouse 
monoclonal 
IgG1 
- Raised against FLAG sequence at 
the 
N-terminus, Met-N-terminus, C-
terminus, or at an 
internal site of FLAG fusion proteins 
1:5000 WB 
 
1 μg for for 107 
 cells IP 
HA H6908 SIGMA-
ALDRICH 
Rabbit 
polyclonal IgG 
- Raised against a synthetic peptide 
corresponding to amino acid 
residues 98-106 (Tyr-Pro- 
Tyr-Asp-Val-Pro-Asp-Tyr-Ala) of the 
human Influenza 
hemagglutinin (HA), conjugated to 
KLH. 
1:1000 WB 
 
5 μg for for 107 
 cells IP 
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Table 2-4 Secondary antibodies 
Antibody Product number Company Type Dilution 
Anti-Mouse 
Immunoglobulins/HRP 
Ab97023 Abcam Polyclonal Goat 1:3000 WB 
Anti-Rabbit 
Immunoglobulins/HRP 
Ab16284 Abcam Polyclonal 
Donkey 
1:1000 WB 
Anti-Goat 
Immunoglobulins/HRP 
Ab97100 Abcam Polyclonal  
Rabbit 
1:5000 WB 
 
 
Table 2-5  4 unique 29mer shRNA constructs sequences in pRS (retroviral untagged vector) for silencing Human COPS5  
Oligo Name  Sense sequence 5’-3’ Anti-sense sequence 5’-3’ References 
Scrambled Negative 
Control (TR30012) 
GCACTACCAGAGCTAACTCAGATAGTACT AGTACTATCTGAGTTAGCTCTGGTAGTGC - 
TR313776A (TI355097) GCCAACAACATGCAGGAAGCTCAGAGTAT ATACTCTGAGCTTCCTGCATGTTGTTGGC  
(Okoh et al., 2015) TR313776B (TI355098) TACTCAGATGCTCAATCAGCAGTTCCAGG CCTGGAACTGCTGATTGAGCATCTGAGTA 
TR313776C (TI355099) TCTGCTGAAGATGGTGATGCATGCCAGAT ATCTGGCATGCATCACCATCTTCAGCAGA 
TR313776D (TI355100) AGAAGCTATCCATGGATTGATGTCTCAGG CCTGAGACATCAATCCATGGATAGCTTCT 
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2.2 CELL CULTURE 
 
2.2.1 ROUTINE CELL MAINTAINANCE  
 
All cell culture procedures were performed in a class II laminar flow cabinet, with 
cell lines maintained in an incubator at 37 oC, 5% CO2 and 100% humidity. The 
range of cell lines used can be found in Table 2.5, including guidance on the type 
of cell culture media used. All media was stored at 4 oC and warmed to 37 oC 
prior to use. Tissue culture flasks, T25, T75 and T175, were purchased from 
SARSTEDT. Cells were maintained in culture and passaged at approximately 
80% confluency.  Cells were not passaged more than 20 times. All cultures 
consisted of adherent cell types, and the cells were sub-cultured with two washes 
of phosphate-buffered saline (PBS), prior to trypsinization with 1X trypsin-EDTA.  
Cells were returned to the incubator at 37 oC for 3 to 5 minutes, after which the 
flask was gently tapped to detach cells.  The 1X trypsin-EDTA was neutralised 
with the addition of cell culture media.  Cells were transferred to a 50 ml centrifuge 
tube (CLS430829 SIGMA) and pelleted via centrifugation at 200 ×g for 5 minutes, 
and the pellet re-suspended in 1 ml of media.  The cells were seeded at the 
required cellular density in the correct sized flask and media added.  Cells were 
immediately returned to the incubator.  
 
2.2.2 CELL COUNTING 
 
Cells were counted using a TC20 Automated Cell Counter (1450102 BIO-RAD).  
Cells were washed, detached, pelleted and re-suspended in 1 ml of PBS. Ten µl 
of the cellular suspension were added to the counting slides (1450011 BIO-RAD), 
and the cell viability was defined by the trypan-blue method, when mixed in 1:2 
dilution with the chemical.  Cells were counted with a lower limit for detection of 
6 µm and an upper limit of 20 µm and a dilution factor of 1000. The number of 
cells required was determined using the following formula, where V is the volume 
of cells required in µl, REQ is the required number of cells, DET is the detected 
cell count and DIL is the dilution factor: 
V = (REQ/DET) × DIL 
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The volume of cells required was then placed in a suitable tissue culture flask 
and re-suspended in tissue culture media. 
For proliferation assay studies, cells were counted manually using Neubaouer 
haemocytometers (1127884 camlab).  
 
2.2.3 FREEZING AND THAWING CELL LINES 
 
Cells were washed, trypsinized and pelleted. Cells were subsequently counted, 
with 2 × 106 cells re-pelleted and re-suspended in 1 mL of freezing media (70% 
cell culture media with glutamine; 20 % FBS; 10 % DMSO) and aliquoted into 
Cryo.s™ Freezing Tubes from Greiner Bio-One (123263). These tubes were 
placed in a Cryo tube freezing container, containing isopropanol, and stored at -
80 oC overnight. Cells were then transferred into the liquid nitrogen container for 
long-term storage.  
Cells removed from liquid nitrogen were immediately placed in a 37 oC water bath 
to thaw. Cells were then mixed with 10 ml of cell culture media and pelleted by 
centrifugation. The pellet was re-suspended in 5 mL of complete media, 
transferred to a T25 tissue culture flask and placed in the incubator. 
 
Table 2-6 Cell lines 
Cell line Culture media Cellular origin BMPR2 status References 
HeLa DMEM; 10% 
FBS; 1% P/S 
Human cervix 
epithelial; 
adherent cells 
WT Supplied by 
ATCC 
HEK293T DMEM; 10% 
FBS; 1% P/S 
Human 
embryonic kidney 
epithelial; 
adherent cells  
WT Supplied by 
ATCC 
hTERT PASMC SmGM-2 
Smooth Muscle 
Growth Medium-
2 
Human 
immortalized 
smooth muscle 
cells  
WT / 
BMPR2+/R899X 
 
In lab 
pPASMC SmGM-2 
Smooth Muscle 
Growth Medium-
2 
Human primary 
smooth muscle 
cells  
WT /  
BMPR2+/W9X 
 
Supplied by 
Lonza 
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2.2.4 TRANSIENT TRANSFECTIONS 
 
Appropriate high quality Plasmid DNA (Table 2-7) and shRNA (Table 2-5) 
amounts at the required concentration were transiently transfected into cells 
using the Neon® Resuspension Buffer R in combination with the Neon® 
Transfection System-electroporator from ThermoFisher Scientific (MPK5000), 
which was set at optimised settings for every used cell line (Table). 
Cells were washed in PBS (without Ca2+ and Mg2+), trypsinized, pelleted and 
counted, and 2.5 × 105 cells per each 10 µl Neon® Tip or 1.5 × 106 cells per each 
100 µl Neon® Tip were electroporated for most optimised protocols. Afterwards, 
the cells were aliquoted in desired densities and plated in 24 or 12 well plates 
with pre-warmed media for proliferation studies, or 10cm dishes for protein-based 
analysis, and returned to the incubator. For each set of transfections, a negative 
control for transfection was included, which consisted of transfection with the 
pCMV-Tag3-empty plasmid (Table 2-7). Cell viability was determined the 
following day and cell culture media replaced.   
In preliminary studies, HeLa and HEK293T cell lines were transiently transfected 
at 80% confluence with plasmid DNA using liposomal reagent Lipofectamine 
2000 (Life Technologies) or with the non-liposomal reagent Fugene HD 
(Promega) at 3:1 ratio of transfection reagent (μl) to plasmid DNA (μg), and cells 
were incubated for 48h, prior to fluorescent imaging or Western blotting. The 
above reagents were selected after comparison of transfection efficiency against 
the other commercial liposomal reagents Metafectane PRO, K2 (Biontex), and 
Lipofectamine 3000 (life technologies) (Appendix C). After the 48h incubation the 
cells were fixed with 4% para-formaldehyde and nuclei stained with Hoechst 
(1:20000 dilution).  
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Table 2-7 Plasmids constructs and vectors 
Plasmid name Plasmid Insert Use Provided by 
pCMV-Tag 3 
(empty) 
pCMV-Tag 3 - negative control Stratagene 
pCMV-Tag 3 
Myc-JAB1 
pCMV-Tag 3 mouse JAB1 
with N-terminal 
Myc-tag 
JAB1 expression 
in transient 
transfections 
Stratagene 
pCMV-Tag 2 
FLAG-JAB1 
pCMV-Tag 2 mouse JAB1 
with N-terminal 
FLAG-tag 
JAB1 expression 
in transient 
transfections 
Stratagene 
pCMV-Tag 5 
Myc-BMPR2 
pCMV-Tag 5 human BMPR2 
with N-terminal 
Myc-tag 
BMPR-II 
expression in 
transient 
transfections 
Stratagene 
pcDNA 3.0 
BMPR2 
pcDNA 3.0 human BMPR2 
 
BMPR-II 
expression in 
transient 
transfections 
Invitrogen 
pFN21A-Notch1 
WT 
pFN21A  human 
NOTCH1 WT 
NOTCH1 WT 
expression in 
transient 
transfections 
Promega 
pFN21A-Notch1 
c.1345T>C 
pFN21A human 
NOTCH1 
c.1345T>C 
NOTCH1 c.1345 
expression in 
transient 
transfections 
Promega 
pFN21A-Notch1 
c.1649dupA 
pFN21A human 
NOTCH1 c.1649 
dupA 
NOTCH1 c.1649 
expression in 
transient 
transfections 
Promega 
pRK5-HA-
Ubiquitin-WT 
pRK5-HA human ubiquitin 
with with N-
terminal HA-tag 
Full length 
ubiquitin 
expression in 
transient 
transfections 
addgene 
 
 
2.2.5 CHEMICAL TREATMENTS 
 
For hBMP4 treatment, the cells were left in transfection media for 24 hours 
following a starvation period of 12 hours with 0.5% FBS in DMEM. Afterwards, 
10ml of cell culture were treated with 10ng/ml of hBMP4 (from a stock solution of 
100μg/ml in sterile 4 Mm HCl containing 0.1% bovine serum albumin) for 1 hour 
for Smad phosphorylation or 4 hours for ID1 transcription (cite that).  
For lactacystin-based studies, 24 hours after transfection with Jab1, the cells 
were incubated for 6 hours with or without the proteasome inhibitor lactacystin at 
20μΜ and were further subjected to SDS-PAGE and western blotting.  
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2.2.6 CELL PROLIFERATION ASSASYS AND GROWTH CURVES 
 
HeLa cells were transfected with JAB1-pCMVTag3 or pCMV-Tag 3 empty vector 
(control) and seeded in triplicate in 6 well plates at a density of 25,000 cells per 
well (day 0). On days 1, 2, 3, 4 and 5, the cells were harvested by trypsinization 
and counted by haemocytometer.  
A 7-day SMC proliferation assay was conducted to independently assess the 
proliferation of the PAH-associated human p.R899X PASMCs against WT 
PASMCs. The cells were seeded in technical triplicates in 12 well plates at a 
density of 50,000 cells/well and counted by haemocytometer. 
HeLa, HEK293T and hTERT-SMC WT growth curves were constructed by 
maintaining the cells in 6 well plates for 7 days and counting every 24 hours by 
haemocytometer (Appendix B).  
For each proliferation assay, the cell media was replaced every second two days 
and the cell viability was determined by using 0.4% filtered Trypan Blue solution. 
  
MTT ASSAY 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)  conversion 
to insoluble formazan as colorimetric assay to assess cells viability and 
proliferation, was employed to verify manual cell counts. The MTT method was 
used in 96 well plate experiments at a final concentration of 1mg/ml in DMEM 
with 10% FBS. MTT-treated cells were incubated for 3.5 hours, MTT media 
removed and DMSO added. Absorbance of the viable cells was read by 
SpectraMax Plus 384 Microplate Reader at 540 nm. 
 
 
2.2.7 LIVE CELL AND FLUORESCENT IMAGING 
Adherent cell morphology and confluence was observed using a Nikon Eclipse 
TE2000-S inverted microscope, equipped with Dn100 digital net camera and 
Nikon Dn100 web interface software. The expression of fluorescent proteins and 
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4',6-diamidino-2-phenylindole (DAPI) staining of cell nuclei were visualized by 
use of Nikon Eclipse 80i fluorescent microscope. 
 
 
2.3 MANIPULATION OF NUCLEIC ACIDS 
 
2.3.1 RNA EXTRACTION 
 
RNA extraction was performed with RNeasy Plus Mini kit (74134 QIAGEN). The 
cells were washed twice with PBS, trypsinized and re-suspended in media. The 
cell suspension was transferred to RNase-free tube and pelleted by 
centrifugation. Lysis of cells (1-10 million) was accomplished by addition of 600μl 
of RLT Plus buffer (with 1% β-mercaptoethanol) and vortexing. QIAshredder spin 
column homogenized cell lysates were transferred in gDNA eliminator spin 
columns and the flow-through were subjected in 70% ethanol prior RNA 
precipitation in RNeasy spin column. 3 wash steps of the column were performed 
and the finally the total RNA eluted in Elution Solution (30ul) and stored for short-
term storage at -80 oC. 
 
2.3.2 NUCLEIC ACID QUANTIFICATION 
 
Nucleic acid concentration and the total yield were determined using the 
NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, USA).  At the 
beginning and in between samples the pedestal and lid were cleaned with optical 
instrument cleaner.  The program was initialized with ultra-pure water and 
blanked with the buffer used to dissolve the nucleic acid.  Samples were applied 
onto the pedestal in 1.2 µl volumes. Samples were measured in duplicate. 
Sample purity was determined by monitoring the absorbance readings at 260 and 
280 nm, with DNA and RNA having an optimal A260/280 ratio of 1.8 and 2.1 
respectively.   
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2.3.3 VISUALISATION OF RNA 
 
The quality of extracted RNA was determined by visualising the 18S and 28S 
rRNA subunits. A formaldehyde-agarose gel (1% agarose) was produced by 
dissolving 1 g of agarose in 74 ml of water by boiling. This was allowed to cool to 
approximately 55 oC and 16 ml of 37% formaldehyde, 10 ml of 10X MOPS buffer 
(200 mM MOPS, pH 7.0, 80 mM Sodium Acetate, and 10 mM EDTA, pH 8.0) and 
ethidium bromide to a final concentration of 2 µg/ml were added, the gel cast into 
the Rio-Rad gel equipment and allowed to set, all within a fume hood. RNA 
totalling 2 µg was resuspended to a total of 25 µl with RNA loading buffer. This 
was heated to 65 oC for 15 minutes and then allowed to cool on ice. The RNA 
was electrophoresed in 1X MOPS buffer for 40 minutes at 60 volts. The RNA was 
visualised using a BIO-RAD ChemiDoc XRS+ transilluminator and gel images 
taken.   
 
2.3.4 TWO STEP REVERSE TRANSCRIPTASE QUANTITATIVE PCR (RT-
qPCR)  
 
2.3.4.1 cDNA SYNTHESIS 
 
Generation of cDNA from total RNA was performed with the High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems). All components, including the 
RNA, were stored on ice throughout. 
The 20 μl reactions were synthesized by 10 μl MasterMix (Table 2-8) and 10 μl 
of 1000 ng/μl RNA. The optimised thermal cycler conditions for first strand cDNA 
synthesis, RNA denaturation, cDNA synthesis and termination of reaction are 
described in Table 7.  
Samples containing the resulting cDNA were stored at -80 oC prior to further use. 
In order to monitor for the presence of genomic DNA contamination and reagent 
contamination within the cDNA samples, a reverse transcriptase-minus reaction 
and a no template reaction were performed with each experiment. 
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  Table 2-8 2x RT Master Mix Composition (Adopted and Modified from AB High   
Capacity cDNA Reverse Transcription Kit - Life Technologies) 
 
 
Table 2-9 Thermal Cycler Conditions for cDNA synthesis 
 Step 1 Step 2 Step 3 Step 4 
Temperature (℃) 25 37 85 4 
Time 10 min 120 min 5 min ∞ 
 
 
2.3.4.2 QUANTITATIVE PCR (qPCR) 
 
Quantitative real-time PCR was performed on a StepOne Plus real-time PCR 
machine (Applied Biosystems) using double-dye Taqman-style detection 
chemistry with the PrimerDesign 2x PrecisionPLUS MasterMix (Table 2-10) and 
custom-designed probe sets for JAB1, NOTCH1, HEY1 and HES1 mRNAs 
(PrimerDesign). GAPDH and ACTB house-keeping genes were used for 
normalization in mRNA relative quantifications. The qPCR total volume reaction 
was 10 ul (5ul of master mix + 2.5ul of diluted 1:10 cDNA template) and the qPCR 
amplification conditions profile is provided in Table 2-11 
Gene of interest expression levels for patient and mutagenized samples were 
calculated by the 2-ΔΔCt method relative to the wild-type baseline.  
 
 
 
 
 
 
Component Volume/Reaction (μL) 
10x RT Buffer 1.0 
25x dNTP Mix (100mM) 0.4 
10x RT Random Primers 1.0 
MultiScribe Reverse 
Transcriptase 
1.0 
Nuclease-free H2O 6.6 
Total per Reaction 10 
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  Table 2-10 PrimerDesign 2x PrecisionPLUS qPCR MasterMix composition. 
Component 1 Reaction 
Resuspended primer/probe mix 0.5 μl* 
PrimerDesign 2x PrecisionPLUSTM Mastermix 5 μl 
RNAse/DNAse free water 2μl 
Final volume 
 
7.5 μl 
*Working Concentration of primers = 150nM in a 10μl reaction 
 
 
Table 2-11 Amplification Conditions using PrimerDesign 2x PrecisionPLUS qPCR 
MasterMix. 
 Step Time Temperature (℃) 
Cycling x40 
Enzyme Activation 2 min 95 
Denaturation 15 sec 95 
Extension/Data Collection* 60 sec 60 
*Fluorogenic data should be collected during this step through the FAM channel. 
 
 
2.3.5 STATISTICAL ANALYSIS 
 
The statistical analysis and graphs of the dCT, fold change and RQ values were 
calculated using One-Way Analysis of Variance (ANOVA) and paired student-t-
tests. In case of proliferation studies, Two-Way Analysis of Variance was used 
and the Holm’s-Sidak Multiple Comparison test (more powerful) was chosen for 
P values calculation between the cell lines or the various treatments. For 
densitometric analysis of immunoblots and further analysis of significance (P-
values) between controls and protein over-expression or in vivo measurements 
in cell lines or primary cells, unpaired student-t-tests and One-Way ANOVA were 
used as per respective experimentation. The software which used for the entire 
statistical analysis was GraphPad Prism Version 6.02. 
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2.4 BACTERIAL PRODUCTION OF PLASMID DNA 
 
2.4.1 CHEMICAL TRANSFORMATION OF E.COLI 
 
Plasmid DNA was chemically transformed into XL-1 blue Competent Cells, of 
gold efficiency. Prior to use, cells were stored at -80 oC and thawed on ice. Cells 
were mixed by gentle flicking of the tube and 50 µl of thawed competent cells 
were aliquoted into pre-chilled 1.5 ml microcentrifuge tubes. 2 µl of plasmid DNA 
was added to the competent cells, gently flicked and incubated on ice for 30 
minutes. Cells were then heat shocked in a water bath at 42 oC for 45 seconds. 
Samples were returned to ice for 2 minutes. 500 µl of SOC medium (2% (w/v) 
tryptone; 0.5% (w/v) yeast extract, 8.6 mM NaCl, 2.5 mM KCl, 20 mM MgSO4, 
20 mM glucose) was added to the transformation reaction and orbitally shaken 
for 1 hour at 37 oC. As a positive control for transformation, pUC19 DNA was 
provided with the competent cells and used in a separate reaction. Additionally, 
a negative control for transformation was included, which lacked plasmid DNA 
and so was antibiotic sensitive.   
Previously dissolved and autoclaved LB agar (10g Bacto-tryptone; 5 g yeast 
extract; 10 g sodium chloride; 15 g agar per litre) was melted by heating and 
allowed to cool prior to the addition of either ampicillin or kanamycin to a final 
concentration of 100 µg/ml or 50 µg/ml, respectively. This was then poured into 
culture dishes and allowed to set. 50 µl of the transformation reaction was then 
spread onto the culture dish and incubated overnight at 37 oC. Single colonies 
were then picked from the plate using a sterile pipette tip and the bacterial 
population expanded following the steps for small scale production of plasmid 
DNA. 
 
2.4.2 PURIFICATION OF PLASMID DNA 
 
Colonies were directly picked from the agar plate and added to 3 ml of LB broth 
(10 g Bacto-tryptone; 5 g yeast extract; 10 g sodium chloride per litre) 
containing antibiotic at the previously mentioned concentrations and incubated 
at 37 oC for approximately 8 hours with orbital shaking. This was classed as the 
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starter culture. In order to generate high quantities of purified plasmid DNA, the 
QIAGEN Plasmid Maxi kit (12162) was used, following the protocol for maxi 
high-copy plasmid purification. This advised recovery of up to 500 µg of plasmid 
DNA. A large overnight culture was prepared using 500 ml of LB Broth with 
antibiotic and diluting the starter culture 1:1000. This culture was grown for 16 
hours at 37 oC with orbital shaking. The culture was then pelleted by 
centrifugation at 6,000 x g for 20 minutes at 4 oC. After re-suspension of the 
bacteria pellet in lysis buffer, the plasmid DNA in the clarified lysate was bound 
in the silica resin column by gravity flow. The column was washed and then 1 ml 
DNA was eluted in Buffer QC and further precipitated by iso-propanol in a QIA 
precipitator. The DNA pellet was washed by 70% ethanol, air-dried and 
subsequently eluted in nuclease-free water. The quantity and quality of the 
purified plasmid DNA was check using the Nanodrop and was then ready for 
use in downstream process, such as in transient transfections. 
 
2.5 MANIPULATION OF PROTEINS 
 
2.5.1 PROTEIN ISOLATION 
 
Cells were obtained from the cell culture incubator and washed two times with 
PBS. The cell lysates were prepared from cell monolayers growing in 10 cm 
dishes and harvested after trypsinization and re-suspension in assay-dependent 
Extraction Buffer (Appendix A). Lysis buffer containing detached cells was 
pipetted into a 1.5 ml microcentrifuge tube and then left on ice for 30 minutes with 
occasional vortexing. The samples were sonicated on a Soniprep 150 from MSE 
for 10 seconds to fragment DNA, and subsequently centrifuged at 15000g for 
20min at 4 OC. The supernatant was boiled on a heat block at 94oC for 5 minutes. 
Protein concentration was then determined or samples were stored at -20oC for 
future use.    
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2.5.2 PROTEIN QUANTIFICATION 
 
Protein quantification was performed using the DC Protein Assay Kit (5000112 
BIO-RAD), which is compatible with the SDS detergent present within 
Extraction buffer. This was a colorimetric detection method for total protein 
quantification, based on the reaction of protein with an alkaline copper tartrate 
solution and Folin reagent. As with the Lowry assay, there are 2 steps which 
lead to colour development. The reaction between protein and copper in an 
alkaline medium, and the subsequent reduction of Folin reagent by the copper-
treated protein. Quantification occurred in a 96-well format (Greniner, 655180), 
with 25 µl of Reagent A required for each sample, and 200 μl of Reagent B. 
Additionally, a series of protein standards was included, ranging from 1.4 µg/µl 
to 25 ng/µl of bovine serum albumin (BSA). The colorimetric reaction 
commenced with the addition of 5 µl of pre-boiled protein sample or protein 
standard. A blank sample was also included, whereby the protein sample was 
replaced with Laemmli buffer. The 96-well plate was placed on a shaker for 10 
seconds, then at room temperature for 30 minutes.  An absorbance reading at 
750 nm was taken on a BioTek ELx808 Absorbance Microplate Reader 
(BTELX808).  The absorbance value obtained for the blank sample was 
subtracted from the absorbance readings for the protein samples and 
standards. A standard curve was generated for the protein standards, allowing 
the concentration of the unknown protein samples to be determined. Protein 
samples were diluted with the addition of 1X Laemmli buffer to a concentration 
of 1 µg/µl.   
 
2.5.3 SODIUM DODECYL SULPHATE-POLYACRYLAMIDE GEL 
ELECTROPHORESIS (SDS-PAGE) 
 
The Mini-PROTEAN Tetra Electrophoresis System from Bio-Rad (165-8006) was 
used to cast 1.5 mm vertical gels. Varying percentages of resolving gel were 
produced, comprised of 0.375 M Tris-HCl pH 8.8, 8.0-12% (v/v) 37.5:1 
acrylamide:bisacrylamide and 0.1% (w/v) SDS.  Polymerisation of the resolving 
gel was initiated by the addition of 0.1% (w/v) ammonium persulphate and 0.1% 
TEMED. The gel was poured between two vertical glass plates and water 
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saturated isobutanol applied to the top to remove air bubbles. The gel was 
allowed to set for 30 minutes. The isobutanol was subsequently removed and the 
top of the gel flushed with water and dried. A 5% stacking gel was then applied, 
consisted of 0.125 M Tris-HCl pH 6.8, 5.0% (v/v) 37.5:1 acrylamide:bisacrylamide 
and 0.1% (w/v) SDS. Polymerisation of the stacking gel was initiated by the 
addition of 0.1% (w/v) ammonium persulphate and 0.1% TEMED. The stacking 
gel was poured between the glass plates and a 16 well comb placed in the top. 
The gel was allowed to set for an additional 30 minutes. 
Meanwhile, proteins samples at 1 µg/µl were combined with protein loading buffer 
and samples heated to 96 oC for 5 minutes and centrifuged. 20 µl of each sample 
were loaded into the cast wells, including a protein standard, and electrophoresis 
performed in protein running buffer at 125 volts for approximately 70 minutes. 
The bromophenol blue dye front was monitored to check for efficient 
electrophoresis.  
 
2.5.4 PROTEIN TRANSFER TO NITROCELLULOSE MEMBRANE 
 
After electrophoresis, the gel was equilibrated in transfer buffer for 5 minutes for 
removal of electrophoresis buffer salts and detergents. The nitrocellulose 
membrane that was used was Amersham Protran Premium (10600003 GE), with 
pore size of 0.45 μm. For the purposes of protein transfer to the membrane, the 
Trans-Blot® SD Semi-Dry Transfer Cell (1703940 BIO-RAD) was used, 
employing the philosophy of semi-dry blotting; the platinum-coated titanium and 
stainless steel electron pair provides efficient and background-free blotting. 
Before the assembly of the unit for standard transfer, the membrane and the filter 
papers were soaked into transfer buffer and all components along with the gel 
were fit together, according to the manufacturer’s instructions. Mini-gels of 0.75 
mm thickness were transferred for 15-30 minutes at 15 V. After transfer, the 
membrane was stained with Ponceau S to confirm successful protein transfer 
and then washed with water to remove the staining.   
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2.5.5 IMMUNOLOGICAL DETECTION OF MEMBRANE BOUND PROTEIN 
 
Membranes containing the transferred proteins were incubated in a TBS-T-milk 
or TBS-T-BSA solution for 1 hour at room temperature with shaking. Primary 
antibody at the appropriate concentration in TBS-T-BSA (Table 2-3) was applied 
to the membrane and incubated overnight at 4 oC with agitation. Membranes were 
then washed 4 times for 5 minutes in TBS-T with shaking. The appropriate 
horseradish peroxidase conjugated secondary antibody (Table 2-4) was then 
applied to the membrane and incubated for 45 minutes in RT. The membrane 
wash step was then repeated. The peroxidase activity of the secondary antibody 
was then detected using the luminal-based Pierce® enhanced 
chemiluminescence (ECL) Western Blotting Substrate. Equal volumes of 
Detection Reagents 1 and 2 were combined and 1 ml incubated on the membrane 
for 1 minute. The presence of chemiluminescence was detected using the CL-
XPosure Film from Fisher Scientific (PN34089), in the dark room with the AGFA 
Curix 60 film developer (Figure 2-1). The duration of film exposure was specific 
for each cell line and antibody used. Presented images represent the optimal 
exposure for the experimental conditions. Samples were processed in duplicate 
or triplicate.  
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Figure 2-1 Protein detection of enhanced chemiluminescence (ECL) 
The schematic represents the luminescence reaction that occurs in the detection of 
protein following the ECL reaction. The primary antibody, specific to the protein of 
interest, is bound by a species-specific secondary antibody, which was conjugated to 
horse radish peroxidase (HRP). HRP is able to catalyze the oxidation of luminal in the 
presence of H2O2, generating light, allowing the immobilised protein to be visualised. 
This reaction occurs in the presence of enhancers, such as modified phenols, which 
prolong and increase the intensity of the light emitted (Marquette & Blum, 2006).  
 
The resulting CL-XPosure Film, with visualised protein bands, were scanned 
using a Canon CanoScan LiDE 35 and the density of the bands determined 
using the Image Studio Lite Ver 5.2 software. This allowed the area covered 
and the intensity of each protein band to be determined and compared to the 
control sample. When required, a one-way ANOVA (analysis of variance) was 
performed on the data to test for significant variation between sample types 
using the GraphPrism 6 for Windows, Version 6.01, with statistical significance 
identified when the P-value was ≤ 0.05. 
 
2.6 CO-IMMUNOPRECIPITATION 
 
Prior to the immunoprecipitation (IP), the required cells were transfected (Section 
2.2.4) with the approximately plasmids (table).  
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Transfected cells in tissue culture dishes were placed on top of ice and media 
removed. The cells were washed twice with ice-cold PBS, PBS removed and 500 
µl of ice-cold lysis buffer added and cells removed by scrapping. Cells were 
transferred into a 1.5 ml microcentrifuge tube and stored on ice. Cell lysates were 
sonicated for 10 seconds, vortexed and centrifuged at 16,000 xg for 10 minutes 
at 4 oC to sediment any insoluble material. The protein concentration of the 
samples was determined by the DC Protein Assay Kit. 
Protein lysates were pre-cleared with Protein A or G sepharose beads alone, and 
1 mg of protein extract was incubated with 2.5 μg of anti-c-myc antibody, 1μg of 
anti-flag antibody, 2 μg of anti-JAB1 antibody or 2 μg of anti-RAC1 antibody as 
negative control by rotation overnight at +4oC. The antibody-lysate mixture was 
incubated with 50 μl of Protein A or G sepharose beads, pre-equilibrated with co-
ΙP lysis buffer, for 5 hours at +4oC. The beads were washed 4 times with 1 ml co-
IP buffer without protease inhibitors, followed by centrifugation for 5 min at 500 
g. The pellet was resuspended in 50ul 2X Laemmli Buffer (2%w/v SDS, 10%w/v 
glycerol, 50mM Tris pH 6.8, 0.025% w/v bromophenol blue, 1% v/v 2-
mercaptoethanol), incubated at 96oC for 10 min and centrifuged at 2500g for 3 
min. The supernatant containing the immunoprecipitated proteins was then 
analyzed by Western blotting (see section 2.2.1) looking for protein-protein 
interactions. Samples were processed in duplicate.   
 
2.7 UBIQUITINATION ASSAY 
 
HeLa cells were transfected with Myc-tagged BMPR-II, Flag-tagged JAB1 and 
HA-tagged Ubiquitinin in the presence or absence of lactacystin. Forty eight hours 
after transfection, cell lysates were immunoprecipitated using antibody against 
Myc (SIGMA), boiled in SDS and then re-precipitated prior to immunoblotting. To 
detect ubiquitylation of precipitated BMPR-II, western blotting was performed 
using anti-HA (SIGMA) antibody. The expression levels of Myc-BMPR-II or Flag-
Jab1 in cell lysates were detected by antibodies against Myc or Flag, respectively. 
Degradation of BMPR-II was analysed by western blotting.  
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*** All the mentioned project experimentation has been conducted in triplicates 
and repeated thrice. The wide range of powerful and reproducible techniques 
described above have been established by myself under the supervision and 
guidance of Dr R.D. Machado and Dr L. Southgate, in the available facilities of 
the University of Lincoln and King’s College London, UK. 
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3.1 INTRODUCTION 
 
To interrogate the extent and nature of pathways key in regulation of the 
pulmonary circulation, a yeast two-hybrid screening experiment was conducted 
by Dr R.D. Machado (unpublished data), using the catalytic kinase domain of 
BMPR-II as bait in a lung cDNA library. This approach facilitated the identification 
of JAB1 as a novel interacting protein partner, providing insight and potentiating 
the explanation of BMPR-II degradation via the proteasomal pathway in the 
normal circulation and, further, the currently unexplained elevated receptor loss 
in disease progression (Atkinson, Stewart et al. 2002). Of note, the biological 
relevance of JAB1 to TGF-β and BMP signalling is well established as it has been 
demonstrated to bind to and promote degradation via the proteasomal pathway 
of SMADs, 4, 5 and 7 (Wan, Cao et al. 2002, Haag, Aigner 2006, Kim, Lee et al. 
2004). Through the yeast two-hybrid experiment, 5 clones of different lengths, 
were identified, encoding the JAB1 cDNA. GST pull-down assays utilising the 
tagged BMPR-II kinase domain have confirmed the interaction in vitro (Figure 3-
1A). Immunofluorescence studies have demonstrated clear subcellular co-
localization of the two proteins. Of interest, over-expression of JAB1 in HeLa cells 
alters the normal membrane-bound appearance of BMPR-II and, instead, 
appears to sequester the receptor adjacent to the nucleus analogous to co-
localization between JAB1 and SMADs 5 and 7, a physical interaction culminating 
in degradation of both SMADs (Haag, Aigner 2006, Kim, Lee et al. 2004). 
Magnification of the co-localization indicates a significant and reproducible 
enrichment of both proteins in the peri-nuclear region (Figure 3-1B). 
Immunofluorescence of JAB1 with the non-interacting protein SMAD1 
demonstrates a markedly different localization pattern with JAB1 predominantly 
dispersed in the cytoplasm and no evidence of co-aggregation (preliminary 
studies - data not shown).  Further, JAB1 protein is overexpressed in a plethora 
of tumour types with implication in initiation and progression of several types of 
cancer by promoting cell proliferation, angiogenesis, stabilization of certain 
oncogenes and promoting degradation of tumour suppressor genes 
(Shackleford, Claret 2010, Fukumoto, Tomoda et al. 2006, Tsujimoto, Yoshida et 
al. 2012, Hsu, Huang et al. 2008, Augeri, Langenfeld et al. 2016, Jumpertz, 
Hennes et al. 2014). Here, data is presented examining whether BMPR-II and 
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JAB1 interact, whether JAB1 is overexpressed in BMPR2 mutant PASMC cells, 
the impact of JAB1 overexpression in a cancerous cell line, and finally assessing 
whether JAB1 down-regulation of BMPR-II is dependent on its ability to target 
BMPR-II for ubiquitin conjugation. 
 
 
Figure 3-1 Validation of the interaction between BMPR-II and JAB1 
A) Autoradiographs of the in vitro translated BMPR-II kinase domain (KD) used in GST 
pull-downs with GST alone and GST-JAB1. B) Subcellular localization of BMPR-II and 
JAB1 singly transfected (upper panels) and co-localisation of both proteins following co-
transfection (lower panels). Data provided by Dr Rajiv D. Machado. 
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3.2 AIMS 
 
• To verify the interaction of JAB1 with BMPR-II in vitro and in vivo by co-
immunoprecipitation and Western blotting analysis. 
• To examine how ectopic expression of JAB1 affects BMPR-II intracellular 
levels, by transient transfection studies and Western blotting in cancerous 
generic cell line. 
• To assess JAB1 expression in WT and mutant PASMC cells by Western 
blotting analysis. 
• To validate enhanced proliferation rates of JAB1 transfected cells, by use 
of manual and MTT proliferation assays. 
• To test the hypothesis that JAB1 down-regulation of BMPR-II is mediated 
via the proteasomal pathway, by Ubiquitination assay and further blockage 
of ubiquitination process by lactacystin, a well-studied inhibitor of the 
proteasomal pathway. 
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3.3 RESULTS 
 
3.3.1 INTERACTION OF JAB1 WITH BMPR-II 
 
3.3.1.1 CONFIRMATION IN VITRO 
 
To verify the preliminary indication of potent JAB1 and BMPR-II interaction in 
mammalian cells, in vitro co-immunoprecipitations were conducted in a HeLa cell 
line. Myc-BMPR-II together with Flag-JAB1 constructs were co-electroporated in 
HeLa cells. Following a 48hours incubation period, the whole cell-lysates were 
immunoprecipitated by either anti-Flag (Figure 3-2A) or anti-Myc (Figure 3-2B) 
and then separated on an SDS-polyacrilamide gel and blotted to nitrocellulose. 
Immobilized Flag-JAB1 was incubated with either anti-Myc or anti-RAC1 
(negative control) respectively. Reciprocally, immobilized Myc-BMPR-II was 
incubated with either anti-Flag or anti-RAC1 respectively. Thus, BMPR-II 
associated with JAB1 in HeLa cells when both proteins were overexpressed. The 
endogenous small GTPase protein RAC1 of the Rho family of GTPases was used 
as a negative control of the experiment, as there is no known, suspected or 
confirmed interaction with the BMP receptors. 
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Figure 3-2   Interaction of Jab1 with BMPR-II in vitro  
HeLa cells were transfected with 8μg Myc-BMPR-II, 6μg Flag-JAB1 and/or 6μg RAC1 
(negative control) per 10-cm dish. Immunoprecipitation assays were performed using 
anti-Flag and anti-RAC1 (A) or anti-Myc and anti-RAC1 (B) antibody, and the 
immunocomplex was detected by western blotting using anti-Myc or anti-Flag antibody, 
respectively. The immunoblots revealed no interaction for the negative control RAC1. 
The expression levels of Myc, Flag fusion proteins and RAC1 in cells were also detected, 
as indicated in the lower panels.  
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3.3.1.2 CONFIRMATION IN VIVO 
 
Most importantly, it has been also demonstrated that endogenous BMPR-II 
interacts with JAB1 in HeLa and HEK293T cancer cell lines. This has been 
validated by in vivo co-immunoprecipitation experimentation in the mentioned cell 
lines. Whole-cell lysates of cell monolayers in 80% confluence were 
immunoprecipitated with anti-JAB1 antibody and then separated on an SDS-
polyacrylamide gel. The interaction of JAB1 with BMPR-II was analysed and 
confirmed in both cell lines, by Western blotting using an anti-BMPR-II antibody 
(Figure 3-3). Again, RAC1 was used as a negative control of the experiment. 
 
 
Figure 3-3 In vivo interaction of endogenous JAB1 with BMPR-II in HeLa and HEK293T 
cell lines  
A) Immunoblots of endogenous BMPR-II, JAB1, and RAC1 in HeLa and HEK293T cell 
lines. B) Immunoprecipitation and Western Blotting of JAB1 and RAC1 in the above cell 
lines; anti-JAB1 and anti-RAC1 antibodies were used for both experiments to 
immunoprecipitate the endogenous proteins. C) Co-Immunoprecipitation of RAC1 and 
JAB1 probing for BMPR-II. The immunoblots revealed no interaction for the negative 
control RAC1 and strong interaction of JAB1 with BMPR-II in both cell lines. 
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3.3.2 DOWN-REGULATION OF BMPR-II BY JAB1 
 
Since ectopic expression of JAB1 induces degradation of p53, p27Kip, and 
SMADs 4, 5 and 7, it has been investigated whether JAB1 expression also affects 
the steady-state level of BMPR-II protein in HeLa cells. Titrated expression of 
increasing amounts of Myc-JAB1 resulted in a dose-depended significant 
decrease of BMPR-II in HeLa cells (Figure 3-4). Interestingly, JAB1 titrated over-
expression decreased also the endogenous levels of SMAD5, a finding which 
correlates with previous evidence of JAB1 and SMAD5 protein-protein interaction 
and inhibition of BMP signalling (Haag, Aigner 2006). However, JAB1 expression 
did not decrease SMAD1 protein level, consistent with its inability to bind this 
SMAD, along with SMADs 2, 3 or SMAD6 (Kim, Lee et al. 2004). Densitometric 
and further statistical analysis was employed to show significant differences of 
BMPR-II and SMAD5 down-regulation (Figure 3-4B) after JAB1 over-expression, 
compared with control groups (electroporated with empty vectors). These data 
suggest that JAB1 specifically targets BMPR-II protein for degradation, while 
having no effect on other highly homologous SMADs, apart SMAD5.  
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Figure 3-4   Down-regulation of BMPR-II and SMAD5 after ectopic expression of JAB1 
A. Immunoblots of endogenous BMPR-II, SMAD5 and SMAD1 following ectopic titrated 
expression of JAB1 vector or control plasmid in HeLa cell line. Ectopic expression of 
JAB1 decreases endogenous BMPR-II and SMAD5 steady-state levels, while SMAD1 
remains unaffected. α-Tubulin was used as a loading control. B. Densitometric analysis 
in arbitrary units (%) from the immunoblots for BMPR-II and SMAD5. Data are means 
±SD of 3 independent experiments; *P < 0.05 and **P< 0.01 vs the control group, RM 
one-way ANOVA. 
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3.3.3 JAB1 EXPRESSION IN WILD TYPE AND MUTANT PASMC 
 
3.3.3.1 JAB1 PROTEIN EXPRESSION IS UP-REGULATED IN BMPR2-
MUTANT CELLS IN VIVO 
 
To elucidate the molecular consequence of JAB1 up-regulation and further 
impairment of the BMP signalling cascade, preliminary experimentation on 
primary PASMC cells, harbouring the HPAH-associated BMPR-II kinase domain 
missense mutation p.D485G, revealed enhanced JAB-1 expression when 
compared with healthy control cells (Figure 3-5A,B). Notably, the endogenous 
levels of the COP9 component CSN6 did not alter (Figure 3-5A, B), suggestive 
of a complex independent role of JAB1 in PAH progression. Furthermore, JAB1 
expression mirrors BMPR-II expression in pulmonary arterioles (Figure 3-5C), 
only to enhance of its key role in BMPR-II regulation and disruption of the 
pulmonary vascular architecture resulting in perturbation of arterial tone and 
muscularization. 
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Figure 3-5 Endogenous JAB1 overexpression in Primary PASMCS harbouring 
p.D485G mutation 
A. Preliminary experimentation revealed significant upregulation of endogenous JAB1 
expression in primary PASMC-BMPR2+/D485G cells, while CSN6 levels remained 
A. Immunoblot 
B. Densitometry 
Smooth muscle 
cells
Endothelial 
cells
C. Immunohistochemistry 
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unaffected. B. Densitometric Analysis of JAB1 and CSN6. Data are means ±SD; ***P < 
0.001 vs the control group, paired student-t-test. C. Immunohistochemistry of JAB1 in 
pulmonary arterioles demonstrating localisation to key sites of disease in PAH. Data 
provided by Dr Rajiv D. Machado. 
 
3.3.3.2 BMPR2-MUTANTS STIMULATE JAB1 UP-REGULATION IN PASMC 
 
Further in vitro studies were employed to investigate the potentiality of JAB1 up-
regulation in the presence of PAH-associated BMPR-II mutations, as the 
previously described aspartate mutation p.D486G and the p.R899X, an arginine 
to termination tail mutation, which is a HPAH-associated recurrent dysfunction. 
Transfection studies with BMPR2 constructs harbouring the missense p.D485G 
and the truncating p.R899X mutation accordingly,  in primary WT PASMC cells, 
revealed significant JAB1 up-regulation in both cases (Figure 3-6). This finding 
comes in agreement with the preliminary in vivo observation, enhancing the novel 
regime hypothesis of dysregulated JAB1 expression in PAH cases harbouring 
BMPR-II specific mutations.  
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Figure 3-6 Transfection of mutant BMPR-II stimulates JAB1 up-regulation in Primary 
PASMCs  
A. Over-expression (10ug/transfection) of p.D485G and p.R899X mutations of BMPR-II 
revealed significant upregulation of endogenous JAB1 protein expression in primary 
PASMC-BMPR2+/+ cells; JAB1 levels remained unaffected when the cells were 
transfected with WT BMPR-II. Control cells were transfected with empty vector. B. 
Densitometric Analysis of BMPR-II and JAB1. Data are means ±SD of 3 independent 
experiments; **P < 0.01 and ***P<0.001 vs the control group, RM one-way ANOVA. 
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3.3.4 JAB1 PROMOTES PROLIFERATION IN JAB1-TRANSFECTED HELA 
CELLS 
 
Since one of the many roles of JAB1 outside the CSN holo-complex is oncogenic 
through its contribution to dysregulation of the suppression mechanisms of cell 
proliferation, it was only rational to interconnect the down-regulation of BMPR-II 
due to enhanced JAB1 up-regulation in PASMC cells with their enhanced 
proliferation rates in PAH. For the purposes of proving the significantly increased 
proliferation rates of cells after over-expression of JAB1, a 5-day proliferation 
assay by manual counting was conducted in order to verify the suggested tumour 
inducer potential of JAB1, after transfection into HeLa cells. An increased pattern 
of cell proliferation was visible from day 3 onwards and significant differences in 
proliferation between control and JAB1 transfected cells were observed on day 4 
and day 5 (adjusted P values < 0.0001) (Figure 3-7). The experiment was 
repeated in triplicate and the transfection efficiency of each experiment was 
evaluated through Western blotting analysis. Further MTT assay studies 
independently verified the same trend of increased proliferation in HeLa cells that 
were overexpressing JAB1. 4 day assays showed significant differences 
comparing control and JAB1 transfected cells (Figure 3-7B). 
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Figure 3-7 HeLa cells proliferation assays 
A) A significant difference in proliferation between JΑΒ1 transfected cells and control at 
days 4 and 5 was identified. B) MTT Proliferation Assays. A 4-day time-course revealed 
significantly increased proliferation of myc-JAB1 transfected cells at days 2, 3 and day 4 
by comparison to control cells. All p values were calculated by Sidak’s multiple 
comparison test in a 2 way Analysis of Variance (ANOVA). 
Key: ****p<0.0001; ***p=0.0002; *p≤0.015 
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3.3.5 JAB1 DRIVES BMPR-II UBIQUITINATION AND THE PROCESS IS 
REVERSED BY PROTEOLYTIC INHIBITION 
 
Since ectopic expression of JAB1 induces degradation of BMPR-II, it is possible 
that JAB1 regulates BMP activity by also inducing degradation of BMPR-II in the 
BMP pathway. The interaction between JAB1 and BMPR-II suggests a 
mechanism of BMPR-II degradation. However, JAB1 is a component of COP9 
signalosome in the nucleus, which is a multifunctional protein complex associated 
with regulation of protein stability, transcription, protein phosphorylation and 
intracellular distribution. Based on the initial preliminary findings of JAB1 and 
BMPR-II interaction and co-localization at the perinuclear region (Figure 3-1), all 
the above raised the question of whether COP9 signalosome complex is required 
for BMPR-II degradation. To ensure whether JAB1-dependent degradation of 
BMPR-II occurred through the 26S proteasome pathway, the turnover of BMPR-
II in the presence and absence of lactacystin was assessed. Lactacystin inhibits 
protein degradation by the proteasome and JAB1-induced down-regulation of 
BMPR-II protein level was blocked by 20μΜ of lactacystin administration in HeLa 
cells that were over-expressing JAB1 (Figure 3-8B). Taking that into account, a 
ubiquitination assay was designed to assess whether the degradation of BMPR-
II is mediated by the 26S proteasome. Proteins destined for degradation by the 
26S proteasome are marked by covalent attachment of ubiquitin chains, which 
mediate recognition by the 26S proteasome. Thus, to investigate the 
ubiquitination of BMPR-II, an HA epitope-tagged version of ubiquitin was 
expressed along with Myc-BMPR-II and Flag-JAB1, and the levels of BMPR-II 
and ubiquitin conjugates were evaluated by immunoprecipitation with Myc 
antiserum followed by immunoblotting with anti-HA antibody (Figure 3-8). As 
shown in Figure 3-8, no BMPR-II ubiquitination was observed when HeLa cells 
over-expressed the HA-ubiquitin and the Myc-tagged version of BMPR-II. On the 
contrary, a fairly strong ladder of high-molecular-weight ubiquitin-conjugated 
BMPR-II products was observed when both Flag-JAB1 and HA-ubiquitin were 
ectopically expressed, alongside Myc-BMPR-II. This finding is a novel verified 
indication that JAB1 functions as the first identified proteasomal-associated 
inhibitor of BMPR-II.  
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Figure 3-8 JAB1 induces degradation of BMPR-II through ubiquitination 
A) Ubiquitynation of BMPR-II mediated by JAB1. HeLa cells were transfected with Myc-
BMPR-II together with Flag-Jab1 or/and HA-Ubiquitin as indicated. Cell lysates were 
subjected to immunoprecipitation with Myc antiserum, boiled in SDS, and then re-
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precipitated prior to immunoblotting. Protein expression was confirmed by 
immunoblotting total cell lysates. B) Degradation of BMPR-II is sensitive to 26S 
proteasome inhibitors. HeLa cells transfected with JAB1 were incubated with or without 
the proteasome inhibitor lactacystin (20 μM), and expression of endogenous BMPR-II 
was analyzed by immunoblotting and desitometry.  Data are means ±SD of 3 
independent experiments; **P< 0.01 vs the control group, RM one-way ANOVA. 
 
 
3.4 DISCUSSION 
 
3.4.1 INTERACTION OF JAB1 WITH BMPR-II 
 
It is widely accepted that a primary initiating factor for arterial tunica media/intima 
disorganization and PAH progression is loss of BMPR-II signalling (Long, 
Ormiston et al. 2015). BMPR2 heterozygous mutations underlie more than 70% 
of HPAH and 25% of IPAH cases. Specifically, BMPR2 nonsense mutations are 
likely to follow NMD pathway, and recurrent PAH-associated missense mutations 
of extracellular BMPR-II compartment or the kinase domain may never allow the 
receptor to reach the cell surface. Thus, BMPR-II haploinsufficiency is the main 
inherited mechanism of disease progression, contributing in the formation of 
pulmonary vascular lesions in PPH and vascular obliteration in severe PH 
(Atkinson, Stewart et al. 2002, Machado, Pauciulo et al. 2001). BMPR-II is 
expressed predominantly in endothelium and in a lesser extend in vascular 
smooth muscle cells. However, BMPR-II expression in respiratory system is 
highly reduced in patients with severe PH, either harbouring heterozygous 
germline BMPR2 mutations or in other mutation negative cases of primary PH 
(Atkinson, Stewart et al. 2002). Specifically, immunohistochemistry of PAH 
patient lung sections displayed a profound loss of BMPR-II beyond that which 
may be explained by haploinsufficiency. For that reason and to further investigate 
the unexplained receptor loss in PAH disease progression state, preliminary 
experimentation undertaken by Machado et al., identified JAB1 as a novel 
interacting protein partner of BMPR-II receptor, validating the interaction in vitro 
(Figure 3-1). Preliminary transient transfection and co-localization studies of 
JAB1 and BMPR-II, also undertaken by Machado et al., demonstrated the 
subcellular co-localization of both proteins at the perinuclear region of HeLa cells 
(Figure 3-1), a sequestration analogous to co-localization between JAB1 and 
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other verified interacting proteins as p53, p27Kip and SMADs 4, 5 and 7 (Wan, 
Cao et al. 2002, Haag, Aigner 2006, Kim, Lee et al. 2004, Tomoda, Kubota et al. 
2002, Chao 2015).  
As a first aim of this study and to confirm the interaction of JAB1 with BMPR-II, 
co-immunoprecipitation studies were employed to validate the interaction in vivo 
and in vitro (Figures 3-2 and 3-3). The results indicated that JAB1 was vice versa 
immunoprecipitated with BMPR-II in both cases, thus this novel interaction was 
confirmed and opened the investigation of the potential down-regulation of the 
receptor by JAB1. Since ectopic expression of JAB1 is inducing the degradation 
of its targets in a plethora of cases (Shackleford, Claret 2010), it was also 
examined if JAB1 also affects the endogenous levels of BMPR-II in HeLa cell 
line. Figure 3-4 demonstrates that the expression of JAB1 reduced BMPR-II 
steady-state levels in a dose dependant manner, whereas SMAD1 levels 
remained unaffected as it is not a known target of JAB1. As expected, SMAD5 
protein levels were also decreased verifying Haag et al., 2006 results and fulfilling 
the second aim of this project.  
 
3.4.2 JAB1 EXPRESSION IN WT AND MUTANT PASMC 
 
For the purposes of this study, it was vital to investigate if JAB1 was over-
expressed in BMPR2 mutant PASMC cells, in order to correlate the molecular 
consequence of the potential JAB1 up-regulation during disease progression with 
BMPR-II signalling impairment and further loss of the receptor. The BMPR2 
p.D485G KD mutation and p.R899X TD mutation were selected for screening of 
the JAB1 protein expression in primary PASMC cells, both in vivo and in vitro 
cases. The selection of the above mentioned mutations was made mainly 
because they are recurrent mutations in HPAH, allowing the receptor to reach the 
surface (no detected NMD in vitro), disrupting the SMAD1/5/8 signalling in the 
first case (p.D485G), while retaining it unaffected in the other (p.R899X) (Foletta, 
Lim et al. 2003, Machado, Aldred et al. 2006). Furthermore, the p.R899X tail 
mutation is causing disruptions to tail functions, including regulation of p38 and 
p42/44 MAPK (Rudarakanchana, Flanagan et al. 2002, Yang, Long et al. 2005) 
and interaction with LIMK (Foletta, Lim et al. 2003), c-Src (Yang, Long et al. 2005) 
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and Tctex-1 (Machado, Rudarakanchana et al. 2003). Also, the PASMC cells was 
the model cells of choice because of their abnormal proliferation, de-
diferentiation, EC matrix production and significant contribution to the vascular 
lesions in PAH disease state (Morrell, Yang et al. 2001). Indeed, JAB1 protein 
expression in primary cells was upregulated in vivo and in vitro, comparing with 
healthy WT controls (Figure 3-5 and 3-6), whereas CSN6 protein levels remained 
unaffected, implying that the COP9 holo-complex is not participating in PAH 
progression, also suggesting a JAB1 independent role in disease state. This 
experimentation fulfilled the third aim of the project providing novel information 
about JAB1 dysregulation in PAH. A further final indication that JAB1 is up-
regulated in primary endothelial and smooth muscle cells of pulmonary arteries 
in PAH is depicted in Figure 3C. This up-regulation mirrors BMPR-II expression 
and may contribute to disease progression by impairing the BMP signal and 
possibly by promoting the cells in a pro-proliferating or even hyper-proliferating 
state.  
 
3.4.3 JAB1 CONTRIBUTION IN CELL PROLIFERATION 
 
JAB1 as a monomer or a small complex outside the CSN holo-complex, 
specifically stabilizes via phosphorylation oncoprotein complexes of JNK, c-Jun 
or JunD with AP-1 sites contributing to cell proliferation, inhibits p53 and p27Kip 
function to induce G1 cell cycle arrest thus acting as positive regulator of cell 
cycle progression, acts as modulator of intracellular signalling by inducing 
degradation of key down-stream molecules as SMAD4, 5 and I-SMAD7 or 
stabilizing HIF-1α, and it is also involved in DNA damage-repair mechanisms by 
degrading 9-1-1 damage sensing complex or by promoting Rad51-mediated 
repair mechanism (Shackleford, Claret 2010, Chamovitz, Segal 2001, Tian, Peng 
et al. 2010). Thus, it is rational to characterize JAB1 as an onco-protein, which 
contributes to tumour cell proliferation and is over-expressed in many human 
cancers including breast, colon, pancreatic and lung carcinomas (Yoshida, 
Yoneda-Kato et al. 2010). Interestingly, the vascular proliferation in PPH is 
monoclonal, which is evocative of neoplastic proliferation, in contrast to the 
polyclonal cell proliferation in secondary PP (Waite, Eng 2003). It is also believed 
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that the PAH-associated vascular proliferation is monoclonal due to the BMPR2 
haploinsufficiency model that leads to early neoplastic-like vascular proliferation 
(Waite, Eng 2003, Machado 2012). For the purposes of the forth aim of the project 
and in order to validate the tumorigenic potential of JAB1 protein, the proliferation 
of HeLa cells after human JAB1 ectopic expression was monitored in by manual 
cell counting or MTT assays (Figure 3-7). Indeed, the transfected cells exhibited 
enhanced proliferation as expected. Taken together, the observation that JAB1 
protein is over-expressed during PAH progression and the fact that JAB1 
promotes uncontrolled cell proliferation and survival, underlines the significance 
of this molecule in the vasculature and sets it as a potential novel target in cancer 
therapy, and for drugs against PASMC cells in pro-proliferating state harbouring 
or not BMPR2 PAH-associated mutations.   
 
3.4.4 UBIQUITINATION AND DEGRADATION OF BMPR-II BY JAB1 
 
To interrogate the hypothesised proteolytic mechanism of identified BMPR-II 
down-regulation, by JAB1 protein-protein interaction and subsequent 
proteasomal degradation, it was vital to ensure that the decrease in BMPR-II 
steady-state levels is mediated by the 26S proteasome. Thus, the proteasomal 
inhibitor lactacystin was added to HeLa cells transfected with human JAB1. 
Interestingly, JAB1-induced down-regulation of BMPR-II protein level was 
blocked by lactacystin (Figure 3-8B). Proteins destined for degradation by the 
26S proteasome are marked by covalent attachment of ubiquitin chains. 
Obviously, the degradation of BMPR-II is mediated by the 26S proteasome. 
Subsequently, an in vitro ubiquitination assay was designed in order to be 
evidenced whether enhanced BMPR-II turn-over by JAB1 is through its ability to 
promote the ubiquitination of BMPR-II. As expected, JAB1 down-regulation of 
BMPR-II and its subsequent degradation was mediated via the proteasomal 
pathway in case of JAB1 over-expression (Figure 3-8), fulfilling the last aim of the 
project and verifying the initial hypothesis.  
This novel identified mechanism in which BMPR-II is targeted by JAB1 for 
proteasomal degradation is the second indication of the proteolytic degradation 
of BMP receptors, as it has also been identified that Smurf1 ubiquitin ligase 
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causes down-regulation of BMPR-II and interestingly, its degradation is induced 
in cases of monocrotaline and hypoxia models of PAH (Murakami, Mathew et al. 
2010). This finding correlates with a report that identifies Tribbles-like protein 3 
(Trb3) as a BMPR-II TD-interacting protein, in which upon BMP stimulation its 
dissociation from the TD triggers Smurf1 degradation, thus resulting in 
stabilization of the BMPR-II receptor (Chan, Nguyen et al. 2007). In contrast of 
the above observations and against the verified BMPR-II proteasomal 
degradation, it has also been proposed that a lysosomal degrative pathway is 
regulating BMPR-II expression (Durrington, Upton et al. 2010). Further studies 
showed that the lysosomal inhibitor chloroquine increased cell surface BMPR-II 
levels and restored BMP9 signalling in EC cells harbouring BMPR2 mutations 
(Dunmore, Drake et al. 2013). In comparison to this study, it has been also shown 
that BMPR-II could be degraded by the proteasomal pathway. This post-
translational modification of the WT receptor, driven by JAB1 protein, is a finding 
which also explains its further loss in PAH progression, in cases whether BMPR-
II is mutated or not.    
 
3.5 CONCLUSION AND FURTHER WORK 
 
This report facilitated the identification of a BMPR-II novel interacting protein 
partner, namely JAB1, which though association with the kinase domain of the 
receptor, functions as the first identified proteasomal-associated inhibitor of 
BMPR-II. Dysregulation of JAB1 is a major factor in disruption of the pulmonary 
vasculature architecture, resulting in perturbation of arterial tone and 
muscularization. Furthermore, the linked experimental data of this report are 
indicative of BMPR-II degradation via the proteasomal pathway in the normal 
circulation and, finally, the up to date unsolved elevated receptor loss in disease 
progression could be explained through the identified protein-protein interaction 
with JAB1.  
The proposed future directions, based on these findings, include the 
determination of the minimal JAB1 interacting regions, by domain, with the 
BMPR-II receptor and the definition of the real-time interaction of BMPR-II with 
JAB1 by fluorescence resonance energy transfer (FRET) analysis. Given the fact 
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that PAEC cells are the primary site of disease in PAH (Long, Ormiston et al. 
2015), blood outgrowth endothelial cells (BOEC) harbouring mutation specific 
classes (i.e. missense/truncating) could be utilised to determine JAB1 status 
across the BMPR2 mutation spectrum, and further JAB1 expression and 
localization. BOEC cells could be also utilised to analyse proliferation, migration 
and adhesion in the context of JAB1 down-regulation in HPAH, and also to extend 
this analysis in idiopathic disease (mutation-negative) to assess ubiquity of JAB1 
down-regulation (Atkinson, Stewart et al. 2002). Finally, co-immunoprecipitation 
studies could be undertaken in order to assess the JAB1 potential interactions 
with BMP type I receptors, such as BMPR1A, -1B and ALK1, and if detected, 
repeat the experiments described above with these additional molecules. If to 
continue working in the field, a recommended allowing suitable time for the 
above-mentioned experimentation, would be a 2-year study, as this was the time 
frame for the evolution of the research described in the current chapter.   
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4.1 INTRODUCTION 
 
Following the proven down-regulation of BMPR-II by JAB1 via the proteasomal 
pathway, a more comprehensive analysis was undertaken to assess the 
dysregulation of BMP canonical signalling, after the verified loss of the receptor. 
To underline the fact that this effect belongs to a model post-translational 
modification of BMPR-II, a HeLa generic cell line was selected to impact the 
severity of BMP signal loss and more specifically of its signalling intermediaries.  
Based on the initial findings of JAB1 up-regulation in primary PASMC cells 
harbouring the p.D485G KD of BMPR-II and the concomitant in vitro work of 
inserting the p.D458G mutation and the p.R899X TD mutation in primary PASMC 
cells following observation of the increased levels of JAB1 protein expression, the 
p.W9X nonsense mutation of the extra-cellular ligand-binding domain of BMPR-
II was selected and investigated in terms of proliferation, defective BMP signalling 
(intermediaries and down-stream target), endogenous JAB1 protein expression 
and TGF-β signalling. The p.W9X mutation is related to HPAH and is frequently 
recurrent in patients with PAH (Machado, Aldred et al. 2006). In addition, a first 
approach to reverse the proliferation potential of p.W9X mutants was also 
addressed by enhancing the BMP pathway with BMP4-ligand stimulation. While 
the reduced antiproliferative effect of BMP-ligand stimulation of BMP pathway in 
PAH-associated mutant PASMC and PAEC cells has already been demonstrated 
alone or with reference to various drug approaches like iloprost (Yang, Li et al. 
2010, Yang, Li et al. 2013, Waite, Eng 2003), herein a manual proliferation assay 
on patient p.W9X PASMC cells treated specifically with BMP4 alone, was 
employed to verify the potential BMP signalling enhancement and reversal of 
PAH phenotype.  
Recent evidence suggests that alternate pathways, independent of BMP-related 
SMADs, are critical to the context-specific nature of TGF-β superfamily signalling. 
These alternative SMAD-independent signalling cascades include kinases such 
as ERK1/2, JNK, TAK1 and p38 MAPK (Awad, Elinoff et al. 2016). Therefore, it 
is crucial to investigate the potential dysregulation of p38 MAPK, which has been 
shown to be up-regulated after functional loss of the BMPR-II receptor in PAH 
cases following PAH-associated BMPR2 mutations (Rudarakanchana, Flanagan 
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et al. 2002). For the purposes of this investigation, the model cell line which was 
selected for experimentation was again the same cancerous cell line, in order to 
potentiate the activation of p38 MAPK signalling, a SMAD-independed signalling 
cascade after JAB1 mediated down-regulation of BMPR-II.  Subsequently, p38 
MAPK potential induction was investigated in PAH p.W9X mutant PASCM cells 
in order to correlate the results with the cancer cell line. Furthermore, previous 
studies have addressed the activation of canonical TGF-β signalling cascade, in 
cells where JAB1 targets the inhibitory SMAD7 for degradation, or the regulation 
of TGF-β and the BMP signalling, because of the common-SMAD4 and SMAD5 
degradation after JAB1 over-expression (Haag, Aigner 2006, Wan, Cao et al. 
2002, Kim, Lee et al. 2004). Putting that into context, a full expression profile 
analysis of endogenous levels of BMP/TGF-β intermediateries, p38 MAPK and 
TAK1, along with JAB1 and BMPR-II protein expression, was carried out in 
p.W9X PASMC cells, to determine potential activation of SMAD-dependent or 
SMAD-indepentent BMP/TGF-β signalling outcomes. To end this, a similar 
investigation in the BMP/TGF-β-dependent or independent signalling, after JAB1 
mediated down-regulation of BMPR-II, was undertaken in HeLa cell line.  
Finally, to investigate whether JAB1 down-regulation could effectively reverse the 
abnormal proliferation of primary PASMC-BMPR2+/W9X mutants, the RNA 
interference technique was employed to specifically deplete the JAB1 protein in 
both p.W9X and healthy human PASMCs. 
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4.2 AIMS 
 
• To assess BMP defecting signalling and p38 MAPK pathway activation in 
Hela cells after ectopic JAB1 overexpression, by transient transfection 
studies and Western blotting analysis. 
• To examine and validate the antiproliferative effect of BMP4-ligand 
stimulation on PASMC-BMPR2+/W9X cells, by manual counting assays. 
• To assess JAB1 mRNA and protein expression levels in PASMC-
BMPR2+/W9X mutants, by qPCR and Western blotting analysis 
respectively.  
• To profile BMP/TGF-Β signalling cascades in PASMC-BMPR2+/W9X cells, 
by Western blotting analysis 
• To investigate the potential differential regulation of BMP/TGF-Β signalling 
balance in a SMAD-dependent and SMAD-independent manner, by JAB1 
and BMPR-II interaction in HeLa cell line, by transfection studies and 
Western blotting analysis. 
• To reverse the abnormal proliferation of PASMC-BMPR2+/W9X mutants via 
JAB1 protein knock-down, by RNA interference and further MTT 
proliferation assay assessment.  
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4.3 RESULTS 
 
4.3.1 JAB1-MEDIATED SUPPRESSION OF THE BMP SIGNALLING 
PATHWAY 
 
4.3.1.1 JAB1 OVER-EXPRESSION LEADS TO REDUCED BMP SIGNALLING 
 
In order to assess the potential dysregulation of BMP signalling after the verified 
loss of expression of the BMPR-II receptor preceded by ectopic over-expression 
of JAB1, the protein levels of phosphorylated SMAD1/5 were assessed through 
Western blotting analysis in HeLa cells. The p-SMAD1/5 levels were significantly 
down-regulated in both titrated and non-titrated manners of JAB1 overexpression 
after BMP4 ligand stimulation (Figures 4-1 and 4-3). The down-regulation of 
SMAD5 was also observed, verifying the previous experimentation.  
 
4.3.1.2 JAB1 OVER-EXPRESSION PROMOTES DOWN-REGULATION OF 
P38 MAPK 
 
To define abnormalities in alternate pathways specific to down-regulation of 
BMPR-II after ectopic over-expression of JAB1, the expression of p38 MAPK, 
which is an important mediator of BMP non-canonical signalling, was analysed in 
HeLa cells. Interestingly, the levels of phosphorylated p38 MAPK protein were 
significantly down-regulated in the presence of excess JAB1 and the down-
regulated WT receptor (Figure 4-2). This finding was also consistent after 
stimulation with BMP4 ligand and activation of the BMP pathway in both titrated 
and non-titrated manners of JAB1 overexpression (Figures 4-1 and 4-3), which 
in this case was also disrupted due to down-regulated BMPR-II expression.  
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Figure 4-1 Down-regulation of BMPR-II, p-SMAD1/5, SMAD5 and p-p38 MAPK after 
ectopic expression of JAB1 stimulated with BMP4 
 
 
B. Densitometry 
A. Immunoblot 
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A) A. Immunoblots of endogenous BMPR-II, p-SMAD1/5, SMAD5, p-p38 MAPK and p-
38 MAPK following ectopic over expression of JAB1 vector or control plasmid in HeLa 
cell line. Ectopic expression of JAB1 decreases endogenous BMPR-II, p-SMAD1/5, 
SMAD5 and p-p38 MAPK steady-state levels, while p-38 MAPK remains unaffected. α-
Tubulin was used as a loading control. B. Densitometric analysis in arbitrary units (%) 
from the immunoblots for BMPR-II, p-SMAD1/5, SMAD5 and p-p38 MAPK. Data are 
means ±SD of 3 independent experiments; **P < 0.01 and ****P<0.0001 vs the control 
group, paired student-t-test. 
 
 
 
Figure 4-2 Down-regulation of BMPR-II and p-p38 MAPK after ectopic expression of 
JAB1 
A. Immunoblots of endogenous BMPR-II, p-p38 MAPK and p-38 MAPK following ectopic 
overexpression of JAB1 vector or control plasmid in HeLa cell line. Ectopic expression 
of JAB1 decreases endogenous BMPR-II and p-p38 MAPK steady-state levels, while p-
38 MAPK remains unaffected. α-Tubulin was used as a loading control. B. Densitometric 
analysis in arbitrary units (%) from the immunoblots for BMPR-II and p-p38 MAPK. Data 
are means ±SD of 3 independent experiments; **P< 0.01 and ***P < 0.001 vs the control 
group, paired student-t-test. 
B. Densitometry 
A. Immunoblot 
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Figure 4-3 Down-regulation of BMPR-II, p-SMAD1/5, SMAD5 and p-p38 MAPK after 
ectopic expression of JAB1 stimulated with BMP4 
A. Immunoblots of endogenous BMPR-II, p-SMAD1/5, SMAD5, p-p38 MAPK and p-38 
MAPK following ectopic titrated expression of JAB1 vector or control plasmid in HeLa 
A. Immunoblot 
B. Densitometry 
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cell line. Ectopic expression of JAB1 decreases endogenous BMPR-II, p-SMAD1/5, 
SMAD5 and p-p38 MAPK, steady-state levels, while p-38 MAPK remains unaffected. α-
Tubulin was used as a loading control. B. Densitometric analysis in arbitrary units (%) 
from the immunoblots for BMPR-II, p-SMAD1/5 and SMAD5. Data are means ±SD of 3 
independent experiments; **P < 0.01, ***P< 0.001 and ****P<0.0001 vs the control 
group, RM one-way ANOVA. 
 
 
4.3.2 JAB1 UP-REGULATION IS BMPR-II MUTATION SPECIFIC 
 
4.3.2.1 ABNORMAL PROLIFERATION OF PRIMARY PASMC-BMPR2+/W9X 
MUTANTS AND INHIBITION OF PROLIFERATION WITH SELECTIVE BMP4 
TREATMENT. 
 
The analysis of the rates of proliferation between healthy primary PASMC cells 
and PASMC cells harbouring the BMPR2 p.W9X mutation, was assessed after a 
4 days proliferation assay in 12-well plates (Figure 4-4). The enhanced 
proliferation rate of the BMPR2+/W9X cells when compared to WT cells, was visible 
even from the second day of the manual counting (adjusted P value <0.0001), 
maintaining the significant proliferation rate until the last day of the experiment. 
In a parallel experiment, primary PASMC-BMPR2+/W9X cells incubated with 
conditioned smooth muscle growth media (SmGM-2, Lonza) enhanced with 
10ng/ml of BMP4, exhibited no significant proliferation when compared with 
healthy primaries. (Figure 4-4).  
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Figure 4-4 Primary PASMC proliferation assay harbouring BMPR-II p.W9X mutation 
A significant difference in proliferation between PASMC BMPR2+/+ and BMPR2+/W9X 
cells at days 2 and 4 was identified. A 4-day time-course revealed no significantly 
increased proliferation of WT and mutant cells when treated with 10 ng/ml BMP4. P 
values were calculated by Sidak’s multiple comparison test in a 2-way Analysis of 
Variance (ANOVA). 
Key: ****p<0.0001 
 
4.3.2.2 DEFECTIVE BMP SIGNALLING AND JAB1 EXPRESSION PROFILE IN 
PRIMARY PASMC-BMPR2+/W9X MUTANTS 
 
As expected, primary PASMC-BMPR2+/W9X mutants exhibited a heavily 
impaired BMP signalling, as it was verified by both quantitative RT-PCR for the 
BMP-responsive element ID1 (Figure 4-5), a main target gene of BMP 
signalling, and Western blotting analysis for phosphorylated levels of SMAD1/5 
proteins (Figure 4-6), with or without BMP4 ligand stimulation. Surprisingly, the 
levels of JAB1 mRNA expression were significantly reduced in the p.W9X cells, 
regardless of BMP4 stimulation (Figure 4-5). On the contrary, the JAB1 protein 
levels remained unaffected in PASMC-BMPR2+/W9X mutants compared with WT 
healthy primary cells. 
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Figure 4-5 Real-time PCR of JAB1 and ID1 levels of expression in primary PASMC-
BMPR2+/W9X cells 
A) Graphs show in vivo levels of gene expression for Jab1 w/o BMP4 stimulation. 
Surprisingly, primary PASMC cells harbouring BMPR-II p.W9X mutation, reduce Jab1 
transcript levels. B) Graphs show in vivo levels of gene expression for ID1 w/o BMP4 
stimulation. Relative quantification (RQ) of mRNA transcripts are calculated relative to 
the WT baseline and normalised to ACTB levels.  Key:  **p≤0.01; ***p<0.001; 
****p<0.0001 
 
 
 
 
 
 
 
 
A 
B 
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4.3.3 BMPR-II HAPLOINSUFFICIENCY POTENTIATES TGF-Β SIGNALLING 
IN PRIMARY PASMC-BMPR2+/W9X MUTANTS 
 
Through Western blotting analysis, the endogenous levels of phosphorylated 
SMAD2/3 proteins for TGF-β signalling, along with the endogenous 
phosphorylated levels of SMAD1/5 proteins for BMP signalling in primary 
PASMC-BMPR2+/W9X cells (stimulated or not with BMP4-ligand), were assessed 
for whole cell lysates. In case of the untreated cells, the BMP signalling was found 
heavily impaired, with almost no p-SMAD1/5 protein expression, whereas the 
signalling was partially restored after BMP4 treatment (Figure 4-6). There was no 
difference in p-SMAD2/3 protein expression in the BMPR2 p.W9X PASMC cells. 
However, a significant sift of p-SMAD2/3 protein levels was observed after BMP4-
ligand stimulation. Utilizing the same method for protein analysis, the 
endogenous phosphorylated levels of the SMAD-independent molecules TAK1 
and p38 MAPK (with or without BMP4 stimulation) were also assessed in the 
diseased cells. Interestingly, p-TAK1 along with p-p38 MAPK protein levels were 
up-regulated in the diseased cells previously stimulated or not with BMP4-ligand 
(Figure 4-6). The down-regulated levels of endogenous BMPR-II protein 
expression and the unaltered levels of endogenous JAB1 for the mutant cells are 
also depicted in the Figure 4-6.   
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*(Continues at next page) 
 
A. Immunoblot 
B. Densitometry 
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Figure 4-6 TGF-β and BMP signalling in Primary PASMC- BMPR2+/W9X cells 
A. Immunoblots of endogenous BMPR-II, p-SMAD1/5, SMAD5, p-SMAD2/3, SMAD2/3, 
p-TAK1, TAK1, p-p38 MAPK, p-38 MAPK and JAB1, w/o BMP4 stimulation. α-Tubulin 
was used as a loading control. B. Densitometric analysis in arbitrary units (%) from the 
immunoblots for BMPR-II, p-SMAD1/5, p-SMAD2/3, p-TAK1 and p-p38 MAPK. Data are 
means ±SD of 3 independent experiments; *P<0.05, **P < 0.01, ***P< 0.001 and 
****P<0.0001 vs the control group, RM one-way ANOVA. 
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4.3.4 JAB1 OVER-EXPRESSION DRIVES SMAD-DEPENDENT AND SMAD-
INDEPENDENT TGF-Β SIGNALLING OUTCOMES 
 
To investigate whether SMAD-dependent and/or SMAD-independent TGF-β 
signalling is affected after JAB1 over-expression and impairment of BMP 
signalling, a JAB1 WT cDNA construct was transfected into HeLa cells and the 
phosphorylated levels of SMAD2/3 and TAK1 were taken into account by Western 
blotting analysis, with or without BMP4 stimulation. Interestingly, the excess of 
JAB1 protein and impairment of BMP signalling due to BMPR-II down-regulation, 
activated the TGF-β signalling in the cancer cell line, in a both SMAD-dependent 
and SMAD-independent manner (Figure 4-7). The p-SMAD2/3 protein levels 
were significantly up-regulated after JAB1 over-expression in the absence of 
BMP4 ligand stimulation, an alteration which was not observed after BMP4 
stimulation. In addition, significantly increased p-TAK1 expression was also 
observed in JAB1 transfected cells when compared with cells transfected with 
empty plasmid, with or without BMP4 stimulation (Figure 4-7), suggesting 
activation of SMAD-independent signalling and activation of TAK1-MAPK 
pathways in cells where defecting BMP signalling occurs after JAB1 over-
expression and down-regulation of the BMPR-II receptor. Furthermore, the levels 
of endogenous ID1 mRNA transcripts were quantified by qPCR analysis, after 
ectopic expression of JAB1 protein in both immortalized hTERT-PASMC and Hela 
cell lines. Interestingly, ID1 levels of expression were significantly up-regulated in 
both cell lines after JAB1 over-expression with or without BMP4-ligand 
stimulation (Figure 4-8). 
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Figure 4-7 Over-expression of JAB1 activated TGF-β signalling in HeLa cells 
A.  Immunoblots of endogenous p-TAK1, TAK1, p-SMAD2/3 and SMAD2/3 of HeLa cells 
transiently transfected with JAB1 construct, w/o BMP4 stimulation. B. The levels of p-
TAK1 were significantly up-regulated in the presence of JAB1 over-expression, 
regardless BMP4 stimulation. p-SMAD2/3 levels showed increased expression only in 
the case of absence of BMP4 stimulation, by comparison to cells transfected with empty 
plasmid (control). Data are means ±SD of 3 independent experiments; **P < 0.01, vs the 
control group, paired student-t-test
A. Immunoblot 
B. Densitometry 
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Figure 4-8 ID1 up-regulation in cell lines after ectopic over-expression of JAB1 
Real-time PCR of ID1 mRNA levels of expression in hTERT-PASMC (A) and HeLa (B) 
cells. A) Graph show in vitro levels of gene expression for ID1 in hTERT-PASMCs after 
JAB1 was transiently overexpressed (20ug/transfection), w/o BMP4 stimulation. B) 
Graph show in vitro levels of gene expression for ID1 in HeLa cell line after JAB1 was 
transiently overexpressed (20ug/transfection), w/o BMP4 stimulation. Surprisingly, all 
cases presented significant up-regulation of ID1, regardless the presence of BMP4. 
Relative quantification (RQ) of mRNA transcripts are calculated relative to the control 
(cells transfected with empty plasmid) baseline and normalised to ACTB levels. Data are 
means ±SD of 3 independent experiments; *P<0.05 and **P < 0.01 vs the control group, 
paired student-t-test. 
 
 
4.3.5 shRNA KNOCK-DOWN OF JAB1 REVERSES ABNORMAL 
PROLIFERATION IN PRIMARY PASMC-BMPR2+/W9X CELLS 
 
Two specific short hairpin (sh) RNA expression vectors specific to human JAB1 
(hJAB1-shRNA) were selected along with a Scramble shRNA vector for negative 
control, and the efficiency of transfection was tested prior the main 
experimentation (Appendix E). Importantly, the effect of JAB1-specific knock-
down was evident at 48h after transfection. After satisfying results on JAB1 
knock-down levels in HeLa cell line (Appendix E – Figure E-3), a 50-50 mix of the 
2 shRNA constructs was inserted though co-transfection in both mutant and 
healthy WT PASMCs and after 48h of incubation time, the cells were trypsinized, 
diluted and seeded into 96-well plates (4x103 cells/well). MTT assay studies were 
employed to verify the effect on proliferation of the JAB1-knock out cells in a 2-
days incubation time. At day 0 (6h after seeding of cells), there was no difference 
A B 
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in cell proliferation of p.W9X mutants transfected with Scramble shRNA or 
hJAB1-shRNA, compared to WT cells, giving an equal start on proliferation for 
both mutants and healthy PASMCs. As expected, the mutant cells transfected 
with Scramble shRNA showed significant difference in proliferation at day 2 (P < 
0.0001). Interestingly, the pathogenic phenotype of BMPR2 mutants and their 
enhanced proliferation rate was rescued at day 2, while transfected with hJAB1-
shRNA and compared with the healthy individuals, also depleted of JAB1 protein 
(Figure 4-9).  
 
 
 
Figure 4-9 MTT Proliferation Assay of Primary PASMC-BMPR2+/W9X cells transiently 
transfected with specific shRNA constructs for efficient knock-down of JAB1  
While transfected with Scramble shRNA, mutant cells showed significant difference in 
proliferation at day 2; Interestingly, the pathogenic phenotype rescued when JAB1 was 
knocked-out with combination of 2 anti-Jab1 specific shRNAs (5ug/transfection). All p 
values were calculated by Sidak’s multiple comparison test in a 2 way Analysis of 
Variance (ANOVA). 
Key: ****p<0.0001;  
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4.4 DISCUSSION 
 
4.4.1 JAB1-MEDIATED SUPPRESSION OF THE BMP SIGNALLING 
PATHWAY: RECEPTOR TO SIGNALLING INTERMEDIARIES 
 
As a first aim of this project and to determine whether JAB1-mediated down-
regulation of BMPR-II has an effect in BMP signalling, SMAD1/5 levels of protein 
expression have been analysed. As expected, SMAD1/5 protein expression was 
repressed, even after stimulation with BMP4 (Figures 4-1 and 4-3). While BMPs 
have not yet explored in clinical trials, both PAECs and PASMCs are responding 
to BMP2, 4, 6 and 9 in terms of BMPR-II signalling enhancement and restoration 
of the vascular integrity, aspects that are critically dysregulated in PAH (Long, 
Ormiston et al. 2015). While BMP9 exhibits enhanced selectivity for endothelium, 
thus preventing endothelium apoptosis and increasing the stability of tunica 
interna, BMP4 selectivity is concentrated in tunica media, thus controlling 
abnormal proliferation responses and dedifferentiation of PASMC cells in disease 
state (Long, Ormiston et al. 2015). Despite the fact that this analysis was made 
in a generic cell line, the reduced BMP signalling is indicative of the dysregulation 
of the SMAD1/5 canonical signalling after ectopic JAB1-overexpression. Further 
to that, the endogenous levels of SMAD5 were greatly reduced, validating the 
experimentation of the previous chapter. Surprisingly, JAB1 over-expression 
promoted the down-regulation of activated p38 MAPK in HeLa cells, a finding 
which contradicts with the notion of activation of p38 MAPK in the absence of 
exogenous ligand and defective BMP signalling, due to loss-of function of the 
BMPR-II receptor (Figure 4-2). BMP4 stimulation and subsequent BMP signalling 
activation did not alter the down-regulation of activated p38 MAPK in the cells 
(Figures 4-1 and 4-3). Rudarakanchana et al., 2002, reported that substitution of 
the cysteine residues in the ligand binding or kinase domain prevented trafficking 
of BMPR-II to the cell surface and reduced BMP4 binding; transfection of mutant 
constructs led to impairment of BMP SMAD-dependent mediated signalling and 
activation of p38MAPK. In addition, Gao, Zhu et al., 2010, indicated a positive 
correlation of JAB1 with p38 MAPK, as expression levels of both proteins were 
significantly higher in rats with PAH compared to control subjects, and after 
treatment with atorvastatin also both were down-regulated. These early findings 
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contradict with the results of the current study. This project novel data suggest a 
SMAD1/5/8 unrelated down-regulation of p-p38 MAPK in the presence of excess 
JAB1, which in turn triggers a) the association of p-p38 MAPK regulation with 
JAB1, b) the loss of BMPR-II expression with the loss of p38 MAPK activation, 
and c) the potentiation of activation of other SMAD-independent or SMAD-
depended signalling cascades, such as the TGF-β signalling pathway, in order to 
investigate the proliferation potential of cells with defective BMP signalling and 
type II receptor due to JAB1 over-expression. Taken all together, the BMP 
defective signalling and a further dysregulation of p38 MAPK signalling upon 
JAB1 over-expression were assessed in HeLa cell line fulfilling the first aim of this 
project.  
 
4.4.2 JAB1 DYSREGULATION IS BMPR-II MUTATION SPECIFIC IN PAH 
CELLS 
 
The BMPR2 p.W9X mutation which is associated with HPAH, was selected for 
assessment of JAB1 potential up-regulation and profiling of BMP/TGF-β 
signalling in primary PASMC patient cells. While this mutation has been reported 
as pathogenic in several studies (Nasim, Ghouri et al. 2008, Yang, Long et al. 
2011, Drake, Dunmore et al. 2013), there are no up to date data for further 
association with JAB1 expression nor SMAD-independent signalling activation. 
As expected, BMP signalling was heavily impaired in patient cells, as activated 
SMAD1/5 signalling was heavily down-regulated along with the expression of the 
down-stream target gene ID1 (Figures 4-5 and 4-6). Of note, BMP4-ligand 
stimulation significantly enhanced the activation of SMAD1/5 signalling. 
Surprisingly, JAB1 MRNA levels of expression were significantly down-regulated, 
a finding which comes in opposition with the steady-state levels of JAB1 protein 
expression in the mutants, when compared with the WT cells.  As mRNA is 
eventually translated into protein, it is usually assumed that there is some sort of 
correlation between the levels of mRNA and protein. But, there are presumable 
reasons for the poor correlations generally reported between the level of mRNA 
and the level of protein, and these may not be mutually exclusive. First, there are 
many complicated and varied post-transcriptional mechanisms involved in turning 
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mRNA into protein that are not yet sufficiently well-defined to be able to compute 
protein concentrations from mRNA; second, proteins may differ substantially in 
their in vivo half-lives; and/or third, there is a significant amount of error and noise 
in both protein and mRNA experiments that limit our ability to get a clear picture 
(Greenbaum, Colangelo et al. 2003). For the purposes of the in vitro evaluation 
of JAB1 expression profile in primary PASMC-BMPR2+/W9X mutants, the protein 
levels will be taken into account only to deduce that dysregulation of JAB1 protein 
expression is BMPR2 mutation specific and to satisfy the second aim of this 
project.  
 
4.4.3 SELECTIVE ENHANCEMENT OF BMP SIGNALLING WITH BMP4 
INHIBITS PROLIFERATION OF BMPR2 MUTANT PASMC CELLS 
 
TGF-β1 and BMPs as BMP2, 4 and 7 exerts potent effects on vascular smooth 
muscle cells in vitro, including inhibition of proliferation, extracellular matrix 
synthesis and cell differentiation (Morrell, Yang et al. 2001). Recently, (Long, 
Ormiston et al. 2015) reported the first use of BMP7 ligand to target and enhance 
endothelial BMPR-II signalling and reverse established PAH in animal model of 
disease (BMPR2+/R899X mouse). This study complements the previous mentioned 
research by the in vitro inhibition of proliferation of BMPR2 mutant PASMC cells 
by selective BMP4 treatment (Figure 4-4). Expression of mutant BMPR-II in 
PAECs promotes apoptosis and a release of factors that stimulate proliferation of 
PASMCs (Yang, Long et al. 2011). These factors belong to the paracrine 
signalling and their excessive release act as growth factors that induce PASMC 
proliferation or chemokines to recruit circulating inflammatory cells. This later 
effect might also be a second stimulus which is involved in the initiation of the 
HPAH that results from defects in BMPR-II expression, as BMPR-II also regulates 
PAECs endothelial cell barrier function (Burton, Ciuclan et al. 2011). All the above 
contribute to vascular remodelling in PAH. TGF-β1 and FGF2 molecules induce 
the BMP/TGF-β signalling inhibitory pathway for arterial muscularization, 
reducing cell growth and apoptosis. In case of TGF-β1 and BMPR-II deficient 
cells, an increase also in IL-6, 8 expression and NF-κB activation has also been 
observed (Davies, Holmes et al. 2012). The significant difference in proliferation 
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between primary PASMC BMPR2+/+ and BMPR2+/W9X cells in this 
experimentation validates the proliferative potential of the BMPR2 mutant 
PASMCs, while the antiproliferative effect of BMP4-ligant selective stimulation of 
BMP pathway (Figure 4-4), contributes to significant reversal of PAH phenotype 
on these cells, fulfilling also the third aim of this project. 
 
4.4.4 BMPR2 HAPLOINSUFFICIENCY POTENTIATES TGF-Β SIGNALLING 
IN PULMONARY ARTERIAL HYPERTENSION 
 
As already shown, cell proliferation was increased in human PASMC-
BMPR2+/W9X mutant cells compared with WT cells. To explain this increase in 
proliferation rate plus the effect of reduced levels of BMPR-II and BMP signalling, 
the potentiation of TGF-β signalling up-regulation was investigated in the mutant 
cells. TGF-β superfamily ligands signal through both SMAD-dependent and 
SMAD-independent pathways. SMAD signalling occurs via either SMAD2/3 
(TGF-β) or SMAD1/5/8 (ΒMP), which translocate to the nucleus with the common 
SMAD4 to directly regulate target gene transcription (Runo, Loyd 2003). BMPs 
and TGF-βs have been both been reported to activate SMAD-independent 
mitogen-activated protein kinase (MAPK) signalling pathways, including ERK1/2, 
JNK and p38 MAPK. As previously mentioned, p38 MAPK has been shown to be 
an alternative SMAD-independent signalling pathway downstream of BMPR-II 
and other TGF-β superfamily receptors (Rudarakanchana, Flanagan et al. 2002). 
Therefore, it was questioned whether p38 MAPK intracellular signalling was 
altered in the presence of the mutant p.W9X BMPR-II receptor, as in vivo BMPR2 
mutations in PAEC and PASMC cells may drive PAH through multiple potentially 
indepentdent downstream mechanisms, including proliferation, apoptosis, 
inflammation and thrombosis (Majka, Hagen et al. 2011). In relevance and 
similarity with the above-mentioned studies, significantly elevated activated levels 
of p38 MAPK were observed with or without BMP4-ligand stimulation (Figure 4-
6). Next, it has been investigated whether TAK1, a known activator of the p38 
MAPK pathway and intermediary of TGF-β signalling, is involved in exerting the 
proliferative activity in mutant cells. Indeed, the levels of activated TAK1 protein 
were significantly up-regulated in mutant cells, with or without BMP4 treatment, 
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as shown in Figure 4-6. The TGF-β signalling pathways are activated in human 
and experimental PAH models (i.e BMPR2+/R899X mice) where BMPR2 is mutated, 
inducing PASMC cells in a pro-proliferative and anti-apoptotic state, promoting 
activation of MAPK pathways via TAK1 and p38 MAPK phosphorylation in vivo 
(Nasim, Ogo et al. 2012). Specifically, BMP/TGF-β signalling cascade regulates 
TAK1 by increasing the expression of x-linked inhibitor of apoptosis protein 
(XIAP) through its binding to the TD of BMP type I and II receptors. Then XIAP 
binds TAK-1 binding-protein (TAB1) that recruits TAK1 leading to its 
phosphorylation (Augeri, Langenfeld et al. 2016). This SMAD-independent 
mechanism is also activated during embryonic developmental stages and is 
required for embryo ventralization (Augeri, Langenfeld et al. 2016). 
The TAK1 pathway has been shown to activate ERK phosphorylation, which is 
increased in PAH-PASMCs (Nasim, Ogo et al. 2012). Aberrant ERK activation 
has been described in the pulmonary vasculature of advanced PAH patients, 
implicating up-steam activation of Ras/Raf/MEK/ERK in disease pathogenesis. 
Inhibition of dysregulated Ras/Raf/ERK signalling may be useful in reversing 
vascular remodelling in PAH. Raf and ERK1/2 (Ras/Raf/ERK) signalling is 
constitutively activated after BMPR2 knock-down in human pulmonary EC cells 
(Awad, Elinoff et al. 2016). Further to that, Raf inhibitors might rescue the 
abnormal proliferation of mutated PAEC or PASMC cells (Awad, Elinoff et al. 
2016). The proliferative PASMC and PAEC cell phenotype, infiltration of activated 
inflammatory cells, vascular remodelling and plexogenic lesions are all 
considered hallmarks of advanced PAH. Also, activation of p38 MAPK has 
detrimental effects in PASMCs and PAECs and is linked to cardiac hypertrophy 
and heart failure. Pharmacological inhibition of p38 MAPk reverses hypoxia 
induced proliferation in rat pulmonary artery fibroblasts exposed to chronic 
hypoxia or in the monocrotanline rat model of PAH (Awad, Elinoff et al. 2016). 
Taken together, these data suggest that the enhanced proliferation of primary 
PASMC-BMPR2+/W9X mutants is mediated via the SMAD-independent TAK1-p38 
MAPK pathway. Furthermore, the TGF-β canonical pathway was examined and 
a small but significant shift in increase of phosphorylated SMAD2/3 protein levels 
was identified, when the cells were treated with BMP4, strengthening the notion 
that canonical TGF-β signalling is up-regulated in cases of defective BMP 
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signalling due to a PAH-related BMPR2 mutation (Morrell 2006). All the above 
analysis of BMP/TGF-β signalling cascade in primary PASMC-BMPR2+/W9X cells 
fulfils the third aim of this project and provides further insight on the signalling 
intermediaries that are activated in a SMAD-dependent or SMAD-independent 
manner in diseased PASMC cells.  
Expanding the analysis on BMP and TGF-β signalling cascades in PAH, it has 
been demonstrated that aged BMPR2+/R899X mice are susceptible to PAH and 
elevated RVSP, along with dysregulation of multiple SMAD-independent 
pathways like p38 MAPK and p42/44 phosphorylation (West, Harral et al. 2008). 
In reality, dysfunctional BMP/TGF-β signalling is more widespread than 
suggested by BMPR2 mutations alone, in primary and severe PAH. The 
monocrotaline rat model of PAH exhibited elevated MPAP and RVHI after 28 
days of disease induction, where JAB1 and p38 MAPK levels of expression were 
significantly higher than of those in atorvastatin-treatment and control groups 
(Gao, Zhu et al. 2010). Heme oxygenase-1 (HO-1), the rate-limiting enzyme in 
heme catabolism, has been shown to be protective against vascular and lung 
injury. It has been shown that HO-1 induction is independent of SMAD1/5 
signalling, but dependant on activation of p38 MAPK in PASMCs harbouring 
BMPR2 KD mutations (Yang, Lee et al. 2007). So, bringing back BMPR2 
mutations in the spotlight, it has been proved that gene transfer of BMPR2 is 
enabling BMP4 and BMP7 expression, partially restoring the BMP signal and 
mediating the growth arrest and differentiation of PASMCs (Yu, Deng et al. 2008). 
Correlating that with the key finding of this study as of BMP signalling 
enhancement after BMP4-ligand stimulation in BMPR2 mutant cells, it is rational 
to infer that the abnormal proliferation of PAH cells can be rescued resulting in 
reversal of the PAH phenotype during disease progression.  
To conclude, while the general notion is that activation of TGF-β signalling 
pathway generally represses BMP-mediated SMAD1/5 signalling in PASMC cells 
via SMAD3 pathway (Upton, Davies et al. 2013), it has also been demonstrated 
in a previous study that TGF-β could also stimulate SMAD1/5 signalling in 
PASMC and fibroblast cells through ALK1 receptor (Zhang, Du et al. 2017). 
Reciprocally, impaired BMP signalling may potentiate TGF-β cascade and 
SMAD2/3 activation, suggesting an opposing balance between the two signalling 
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pathways, a notion which is also enhanced by the fact that BMP stimulation 
restores the SMAD2/3 signalling in steady-state levels (Han, Hong et al. 2013). 
However, the biological relevance of this signalling cross-talk in PASMC cells is 
depicted upon injury and/or initiation of PH disease, in which aberrant growth of 
PASMCs facilitates cell motility, growth and survival, attributes that activate the 
anti-proliferating effect of both TGF-β and BMP signalling cascades (Eickelberg, 
Morty 2007). Both pathways promote apoptosis of PASMCs either in healthy or 
PAH state (Zhang, Du et al. 2017), whereas when compared with the 
endothelium, BMP signalling via BMPR-II seems to play an opposite role in 
PAECs, because BMPR-II promotes PAEC survival and protects them against 
apoptosis (Eickelberg, Morty 2007) 
 
4.4.5 JAB1 IS A MASTER REGULATOR OF BMP AND TGF-Β SIGNALLING 
 
In order to investigate the potential differential regulation of BMP/TGF-β signalling 
balance mediated by JAB1 in a SMAD-dependent and SMAD-independent 
manner in a generic cell line, JAB1 transfection studies revealed a significant 
activation of SMAD2/3 pathway, along with significant activation of TAK1 protein 
in HeLa cells compared with transfected with empty vectors controls (Figure 4-
7). When the Jab1-transfected cells were subjected in BMP4-ligand stimulation, 
the activated levels of TAK1 protein were again present, but activated SMAD2/3 
signalling was restored to normal as in the control case (Figure 4-7). Surprisingly, 
the ID1 mRNA level of expression was up-regulated in all cases, both in HeLa 
cells and an immortalized PASMC cell line, that was employed to represent 
normal healthy PASMC in the vasculature (Figure 4-8). While ID1 down-
regulation would be the number one expectation in defective BMP signalling, this 
finding could be explained by the fact that upon inhibition of BMP signalling, the 
TGF-β signalling cascade is activated via up-regulation of phosphorylated TAK1, 
which then causes the increase of ID1 expression. Supportive to that, ID1 is also 
target of TAK1-mediated signalling, and more specifically, this SMAD-
independent cascade is activated upon BMP signalling inhibition and subsequent 
activation of TGF-β signalling cascade (Augeri, Langenfeld et al. 2016). On the 
contrary, it has been previously shown that JAB1 can bind ID1 and ID3 proteins, 
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resulting to their ubiquitin-dependent proteolytic degradation mediated by the 
COP9 signalosome (Bounpheng, Dimas et al. 1999). However, it has also been 
demonstrated and previously analysed that, JAB1 down-regulates the I-SMAD7, 
which essentially acts in a negative-feedback loop to regulate the intensity or 
duration of the TGF-β signal (Kim, Lee et al. 2004). I-SMAD6 preferentially 
inhibits BMP signalling whereas I-SMAD7 both BMP and TGF-β signalling 
cascades, by binding to the activated BMP type-I receptors and further bind to 
Smurf-1 and 2, inducing the ubiquitin-mediated degradation of the receptors 
(Miyazono, Maeda et al. 2005). Thus, JAB1-mediated down-regulation of I-
SMAD7 results in enhanced activation of SMAD2/3 signalling with subsequent 
activation of the TGF-β target genes, as the ID transcription factors.  
For the first time and upon the findings of this study, JAB1 can be characterized 
as a Master Regulator of BMP and TGF-β signalling pathways for the following 
reasons: a) It has been proven within the context of this study that JAB1 down-
regulates BMPR-II via ubiquitin-mediated proteolytic degradation, b) It 
antagonizes BMP and TGF-β signalling by inducing SMAD5 and the common 
SMAD4 degradation via ubiquitin-mediated proteolysis (Haag, Aigner 2006, Wan, 
Cao et al. 2002), c) It regulates TGF-b signalling and down-stream target ID1, by 
binding to I-SMAD7 and promoting its degradation via ubiquitin-mediated 
proteolysis (Kim, Lee et al. 2004), d) Its over-expression promotes impairment of 
BMP signalling via SMAD-dependant pathways and activation of mitogenic 
cascades as of p38 MAPK and TAK1 via SMAD-independent signalling (this 
study), and e) it represses the expression of the BMP/TGF-β down-stream targets 
ID1 and ID3 by direct binding and promoting their degradation via ubiquitin-
mediated proteolysis (Berse, Bounpheng et al. 2004). Thus, BMP/TGF-β 
signalling pathways are regulated differentially at all main stages of the signal 
transduction by JAB1 protein, a synergistic rational outcome which combines the 
findings of this study along with the finding of previous on the field 
experimentation, also fulfilling the forth aim of this project. 
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4.4.6 SHRNA KNOCK-DOWN OF JAB1 REVERSES ABNORMAL 
PROLIFERATION IN PAH 
 
To elucidate the potential anti-proliferative effect of JAB1 suppression in BMPR2 
mutant primary PASMC cells, RNAi interference technique was employed in order 
to efficiently knock-down the endogenous levels of JAB1 mRNA transcript in 
primary PASMC-BMPR2+/W9X cells. As it has been previously demonstrated (Figure 
4-4), p.W9X PASMCs exhibit abnormal proliferation rates, indicative to the 
disease phenotype in cases where BMPR2 haploinsufficiency is the inherited 
molecular mechanism for primary PH. Indeed, the PAH phenotype was rapidly 
developed after 48h in case of the transfected with Scramble shRNA mutants 
compared to the Scramble shRNA-transfected healthy controls (Figure 4-9). A 
phenotype that was efficiently rescued at the same time by transfection of healthy 
and mutant PASMCs with human anti-JAB1 shRNA (Figure 4-9). Thus, it has 
been confirmed for the first time that JAB1 is required for human BMPR2 mutant 
PASMCs in order to exhibit pro-proliferating responses, and subsequent 
depletion of JAB1 protein through specific shRNA knock-down rescues their PAH 
pathogenic phenotype. This novel finding also fulfils the fifth and last aim of this 
project. 
Previous studies have also addressed the importance of JAB1 depletion 
regarding the cell proliferation in various experimental systems. Yoshida et al., 
2010, targeted the JAMM motif of Jab1 in mouse embryonic fibroblasts (MEF) 
and JAB1 depletion prevented progression of the cell cycle at multiple points, 
highlighting also the importance of this motif in the oncogenic activity of the JAB1 
protein. JAB1 is also inhibited after interaction with the cytokine macrophage 
migration inhibitory factor (MIF), along with the JAB1-stimulus enhanced AP-1 
and JNK activity (Kleemann, Hausser et al. 2000). Furthermore, X-linked 
intellectual disability gene CUL4B also targets JAB1 for degradation via 
proteolytic degradation, potentiating the up-regulation of BMP signalling and 
suggesting another way to target the oncogenic properties of JAB1 (He, Lu et al. 
2013). Of note, micro-mass cultures of limb buds from JAB1flox/flox conditional 
knock-out mice, that was created as a model for chondrocyte differentiation 
during early limb development, interestingly exhibited decreased BMP signalling 
response of down-stream targets ID1 and Ihh (Bashur, Chen et al. 2014). This 
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controversy could be explained by the fact that JAB1 elimination may result in 
suppression of BMP signalling in certain cells as osteochondral progenitors 
(OPC), due to enhancement of I-SMAD7 BMP-inhibitory activity, thus the down-
stream targets may be repressed as a final effect. Furthermore, it has been 
proved that JAB1 is over-expressed in hepatocellular carcinoma (HCC tissues) 
and peroxisome proliferator-activated receptor γ PPARγ ligands troglitazone and 
rosiglitazone could down-regulate the JAB1 protein expression in HCC cells 
(Hsu, Huang et al. 2008). In addition, depletion of JAB1 inhibits Ras-mediated 
tumorigenesis by inducing premature senescence in p53-null cells (Tsujimoto, 
Yoshida et al. 2012), and also inhibits proliferation in certain pancreatic cell lines 
(Fukumoto, Tomoda et al. 2006). In regards to cardiovascular disorders, 
depletion of JAB1 in HEK293T cells expressing the type A and B receptors of the 
vasoconstricting peptide endothelin-1, resulted in increased cell surface levels of 
the receptors, as they can also be JAB1 targets for ubiquitin-mediated proteolysis 
and degradation (Nishimoto, Lu et al. 2010). Therefore, JAB1 may play a key role 
in regulation of the physiological control of blood pressure, cardiac function, and 
also in genesis and development of CVD such as atherosclerosis, cardiac 
remodelling accompanying chronic heart failure, and pulmonary hypertension 
(Nishimoto, Lu et al. 2010).  
There is no up to date developed RNAi-based therapeutic approach for PAH. It 
often requires a delivery vehicle to transport the siRNA/shRNA molecules that 
target complementary mRNA stands for degradation, thus inhibiting gene 
expression. However, clinical advancements that permit non-invasive topical 
delivery of siRNA specific for the treatment of asthma and respiratory syncytial 
virus (RSV) have already been development and currently they are tested in 
Phase II clinical trials (Burnett, Rossi et al. 2011). For JAB1 shRNA delivery, a 
systemic or ex vivo delivery is proposed as a first RNAi therapeutical approach, 
initially by re-infusion of modified cells into an animal model of PAH disease.  
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4.5 CONCLUSION AND FURTHER WORK 
 
JAB1 appears to be a master regulator of BMP and TGF-β signalling pathways 
in PAEC and PASMC cells, functioning by differential regulation of all stages of 
the pathways cascades. It regulates the signalling balance of both main pathways 
in a SMAD-dependant manner, targeting for proteolysis via ubiquitin-mediated 
degradation the SMAD5, co-SMAD4 and I-SMAD7. Furthermore, it acts up-
stream of BMP pathway, by promoting the proteolytic degradation of BMPR-II 
and also down-stream of BMP/TGF-β signalling cascades, by suppressing ID1 
and ID3 transcription factors through ubiquitination. In addition to that, JAB1 can 
also promote ID protein expression via up-regulation of SMAD2/3 signalling, if its 
prior act was to down-regulate the BMP signal via repression of I-SMAD7 or 
BMPR-II protein expression, counter-balancing the cross-talk of the two main 
pathways.  The role of JAB1 as a master regulator of BMP/TGF-β signalling is 
more complex as it can also regulate the pathways in a SMAD-independent 
manner, promoting the activation of TAK1 and p38 MAPK mitogenic cascades, 
thus enhancing the pro-proliferative state of healthy and/or BMPR2 mutated 
PASMC cells, whereas it can also down-regulate p38 MAPK protein expression 
in other cell types such as cancerous cell lines. However, JAB1 up-regulation 
itself seems to be BMPR2 mutation specific in PASMC cells, explaining the 
enhanced BMPR-II down-regulation of expression in certain PAH cases, which 
the profound loss of BMPR-II is well beyond of that can be explained by 
haploinsufficiency mechanism. This study also facilitated to validate the anti-
proliferative effect of BMP4-ligand stimulation on hyper-proliferating BMPR2 
mutant PASMC cells, highlighting the suppressive regulatory role of BMP 
signalling on cell proliferation and differentiation. Finally, successful knock-down 
of JAB1 in healthy and BMPR2 mutant PASMC cells resulted in control of their 
proliferation, a result which is indicative of the essential role of JAB1 protein in 
positively regulating the cell proliferation. This later finding may well set JAB1 as 
a rational clinical target for manipulation in the treatment of PAH.  
The proposed future directions, based on these finding, include the transfection 
of BOEC cells with constructs harbouring non-BMP defects (such as Caveolin-1 
(CAV-1)/ Potassium Channel Subfamily K Member 3 (KCNK3)) in order to assess 
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JAB1 level and effect upon signalling down-regulation. Finally, these fundamental 
science studies should be expanded into the two up to date (hypoxia and 
monocrotaline) murine models of disease. If to continue working in the field, a 
recommended allowing suitable time for the above-mentioned experimentation, 
would be a 2-3-year study, for further cell signalling experimentation and in vivo 
studies in animal models.  
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CHAPTER 5: HAPLOINSUFFICIENCY OF 
THE NOTCH1 RECEPTOR AS A CAUSE 
OF ADAMS-OLIVER SYNDROME WITH 
VARIABLE CARDIAC ANOMALIES 
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5.1 INTRODUCTION 
 
Adams-Oliver syndrome (AOS) is a rare disorder characterized by congenital limb 
defects and scalp cutis aplasia. In a proportion of cases relatively close to 20%, 
notable cardiac involvement and HHT along with PH are also apparent. The up 
to date clinical investigations report that 13.4% of AOS cases have been 
associated with CHD and a further 10% crude estimate of that cases develop 
PAH at birth or at later time in their lives. Despite recent advances in the 
understanding of the genetic basis of AOS, for the majority of affected subjects 
the underlying molecular defect remains unresolved (Southgate, Sukalo et al. 
2015). This study aimed to identify novel genetic determinants of AOS.  
*5.3 Section was contributed in Southgate, Sukalo, Karountzos et al., 2015 paper, 
that was risen from an international collaboration of studies and the NOTCH1 
signalling experimentation of this study. 
 
5.1.1 PRELIMINARY EXPERIMENTATION** 
 
Whole-exome sequencing was performed for 12 unrelated probands, each with 
a clinical diagnosis of AOS, as per the guidelines by Snape et al., 2009. AOS was 
segregating as an autosomal dominant trait and the patients were negative for 
ARHGAP31 and RBPJ mutations. Screening a cohort of 52 unrelated AOS 
subjects, 8 additional unique NOTCH1 mutations were detected, including three 
de novo amino-acid substitutions, all within the ligand-binding domain. Congenital 
heart anomalies were noted in 47% (8/17) of NOTCH1-positive probands and 
affected family members. 
**The extensive analysis of the Methods and Materials that were employed for 
this investigation, is described in (Southgate, Sukalo et al. 2015), including patient 
cohorts, exome sequencing and mutation detection.  
**The extensive analysis of the preliminary Results such as the clinical features 
of NOTCH1 positive families and the identification of novel NOTCH1 variants are 
also reported in detail in (Southgate, Sukalo et al. 2015) 
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5.1.2 NOTCH1 MISSENSE MUTATIONS ARE LOCATED WITHIN CRITICAL 
FUNCTIONAL DOMAINS 
 
The MutationTaster2,19 PolyPhen-2,20 and/or SIFT prediction software21 were 
employed to identify the pathogenicity of the nine NOTCH1 missense mutations 
that identified in this study; five of them have been predicted as probably 
damaging (Appendix D – Table D-2). Specifically, four mutations (p.P407R, 
p.R448Q, p.C449R and p.C456Y) occur in or adjacent to the ligand-binding 
domain, specified by EGF repeats 11-13 (Figure 5-1A, Figure 5-2A), with the 
remaining mutations to span across the length of the receptor. The majority lie 
within highly conserved regions of the NOTCH1 protein, and are highly conserved 
across species (Figure 5-1). In addition, certain cysteine residues are affected by 
the identified protein mutations p.C449R, p.C456Y and p.C1374R, which possibly 
disrupt key disulphidic bonds that are critical of the EGF-like domains structure 
(Figure 5-2). By contrast, the TM domain p.A1740S mutation is not conserved in 
other vertebrate species apart mammals, and has a less clear impact upon the 
receptor’s structural integrity (Figure 5-1).  
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A. 
 
 
 
 
 
 
 
Figure 5-1 Location and conservation of NOTCH1 mutations  
A) Schematic of the NOTCH1 protein highlighting the critical functional domains. The 
AOS mutations identified in this study are arrayed below the schematic. Truncating 
mutations are marked in green type and orange depicts missense mutations. B) 
Conservation of the 6 missense mutations across species. Conserved residues are 
highlighted in orange. The 4th, 5th and 6th conserved cysteines within the EGF domains 
are boxed. Accession numbers: H. sapiens: NP_060087.3; M. mulatta: AFH32544.1; C. 
lupus familiaris: XP_005625490.1 (predicted); M. musculus: NP_032740.3; G. gallus: 
NP_001025466.1; X. tropicalis: NP_001090757.1; D. rerio: NP_571377.2; T. rubripes: 
XP_003975158.1 (predicted); D. melanogaster: NP_476859.2. (Southgate, Sukalo et al. 
2015) 
2314 aa 
B. 
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B. EGF11:  
 
 
 
 
 
 
 
Figure 5-2 NOTCH1 functional effects 
A) Ball and stick representation of the 3-dimensional structure of human NOTCH1 EGF 
repeats 11-13. The positions of the adjacent AOS mutations p.R448Q and p.C449R are 
highlighted by the solid red arrows. The p.C456Y mutation is similarly marked. The solid 
black arrows indicate the disulfide bonds which would be abolished by the p.C449R and 
p.C456Y mutations, respectively. The side chains of the key Ca2+ ion coordinating 
residues (Asp452, Glu455 and Asp469) and Glu424 are indicated. Water molecules have 
been removed for clarity. Figure produced from the crystal structure (PDB ID: 2VJ3)22 
using the PyMOL Molecular Graphics System. B) EGF11 repeat harbouring the 
missense mutations c.1343G>A and c.1345T>C, C) Schematic of the EGF11 repeat 
structure presenting the disruption of the di-sulphide bridge between cysteines 5 and 6 
that may be caused by the p.C449R mutation (Southgate, Sukalo et al. 2015) 
A. 3-D structure of human NOTCH1 EGF repeats 11-13. 
C. Disruption of di-sulphide bridges 
  1234 GACGTGGATGAGTGCTCGCTGGGTGCCAACCCCTGCGAGCATGCGGGCAAGTGCATCAACACGCTG 
   412 -D--V--D--E--C--S--L--G--A--N--P--C--E--H--A--G--K--C--I--N--T--L- 
                    1                    2                 3 
  1300 GGCTCCTTCGAGTGCCAGTGTCTGCAGGGCTACACGGGCCCCCGATGCGAGATCGACGTCAACGAG 
   434 -G--S--F--E--C--Q--C--L--Q--G--Y--T--G--P--R--C--E--I--D--V--N--E- 
                    4     5                          6 
A. 
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5.1.3 ASSESSMENT OF NOTCH1 SIGNALLING IN AOS PATIENTS 
 
For the purposes of this study, the NOTCH1 canonical signalling and more 
specifically mRNA transcripts of the receptor along with the key down-stream 
targets HEY1 and HES1, were investigated in regards to novel NOTCH1 
mutations identified in AOS patient clinical samples. A potential down-regulation 
of the NOTCH1 expression levels along with HEY1/HES1 reduction was 
expected by impaired signalling due to the missense and frameshift mutations 
that were investigated in vivo and in vitro.  
Notch crosstalk with BMP signalling was reviewed in an excellent article that 
focused on regulation of oscillatory gene expression (Beets, Huylebroeck et al. 
2013). In endothelial cells, BMP signalling is generally thought to cooperate with 
Notch signalling to induce quiescence and promote vessel maturation and 
arterialization. Recent reports have highlighted this cooperative crosstalk 
between DLL4/NOTCH1 and the BMP9-ALK1-SMAD1/5 pathway. While the role 
of NOTCH3 has been extensively investigated in cases of PAH and the 
interactions of Notch signalling with the BMP/TGF-β pathway have been 
addressed (Zong, Ouyang et al. 2016, Andersson, Sandberg et al. 2011), it was 
significant to investigate a hypothesised molecular bridge between AOS and 
PAH. For this purpose, a potential cross-talk of NOTCH1 with BMP signalling was 
assessed in regards of certain AOS-associated mutations of NOTCH1 and their 
direct impact with BMP signalling intermediaries and down-stream target.  
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5.2 AIMS 
 
• To assess the in vivo levels of mutant mRNA transcripts of NOTCH1, 
HEY1 and HES1 of three AOS patients harbouring NOTCH1 mutation 
(c.1343G>A and c.1649dupA (2 cases)), by quantitative RT-PCR of RNA 
extracted from peripheral blood. 
• To assess the in vitro levels of NOTCH1 mRNA receptor in HeLa cell line, 
after transient transfections with mutated NOTCH1 constructs harbouring 
missense AOS-associated NOTCH1 mutations (c.1220C>G, c.1343G>A, 
c.4120T>C and c.5128g>T), by quantitative RT-PCR analysis of cultured 
cells. 
• To investigate the impact of c.1343G>A and c.1649dupA NOTCH1 AOS-
associated mutations on BMP signalling in HeLa cell line, by qPCR 
analysis of the in vivo patient data, and by Western blotting analysis after 
transient transfections of mutated NOTCH1 receptor into HeLa cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                   HAPLOINSUFFICIENCY OF THE NOTCH1 RECEPTOR AS A CAUSE OF AOS CHAPTER 5 
 
129 
 
5.3 RESULTS 
 
5.3.1 NOTCH1 HAPLOINSUFFICIENCY IS IMPLICATED IN AOS 
PATHOGENESIS 
 
The NOTCH1 mutant mRNA transcripts were assessed by quantitative real-time 
PCR studies using RNA extracted from peripheral blood of three AOS patients 
harbouring NOTCH1 mutations c.1343G>A and c.1649dupA (2 cases). The 
receptors transcript levels were significantly reduced compared to an unaffected 
healthy individual (Control), demonstrating an approximation of 50% expression 
reduction in all in vivo tested samples (Figure 5-3A). Whilst institutional ethical 
constraints precluded detailed cardiac evaluation of the control subject, it was 
made clear by personal testimony that there was no family history of 
developmental abnormalities relating to AOS-CHD.  
In addition, transient transfection of mutagenized NOTCH1 constructs were 
conducted to investigate the functional impact of missense mutations, for which 
patient RNA was not available. Quantitative RT PCR of total RNA extracted from 
transfected HeLa cells also demonstrated a significant decrease of NOTCH1 
expression when compared to cells transfected with a full-length WT construct; 
this in vitro experiment also provided independent verification of NOTCH1 down-
regulation for the c.1343G>A mutation, along with the c.1220C>G, c.4120T>C 
and c.5218G>T mutations (Figure 5-4). 
To further interrogate the effect of NOTCH1 mutations on down-stream signalling 
targets, gene expression studies were employed to quantify the levels of HEY1 
and HES1 transcripts in patient-derived RNA samples. Subjects harbouring the 
c.1649dupA frameshift mutation exhibited a particularly marked reduction of 
HEY1 transcript levels by comparison to wild-type control (p=0.0004). By 
contrast, down-regulation of HEY1 expression was less profound for the 
c.1343G>A missense mutation (Figure 5-3B). In addition, HES1 mRNA levels 
were reduced in the c.1649dupA patients (p=0.0004); however, no significant 
deviation to the wild-type control was observed in the c.1343G>A sample (Figure 
5-3C). 
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  Table 5-1 Summary of identified NOTCH1 variants 
Exon Coding variant Protein 
variant 
Variant 
type 
Protein 
domain 
7 c.1220C>G p.P407R Missense EGF 10 
8 c.1343G>A p.R448Q Missense EGF 11 
8 c.1345T>C p.C449R Missense EGF 11 
8 c.1367G>A p.C456Y Missense EGF 11 
10 c.1649dupA p.Y550* Frameshift EGF 14 
25 c.4120T>C p.C1374R Missense EGF 35 
26 c.4663G>T p.E1555* Nonsense LNR 3 
26 
 
c.4739dupT 
 
p.M1580Ifs*30 
 
Frameshift 
 
- 
28 c.5218G>T p.A1740S Missense TM 
32 c.6049_6050delTC p.S2017Tfs*9 Frameshift ANK 4 
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Figure 5-3 Real-time PCR of NOTCH1-positive patient samples  
Graphs show levels of gene expression for A) NOTCH1, B) HEY1 and C) HES1. Relative 
quantification (RQ) of mRNA transcripts are calculated relative to the WT baseline and 
normalised to GAPDH and ACTB levels.  
 
Key:  ***p<0.0001; **p<0.001; *p≤0.01 
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Figure 5-4 Real-time quantitative PCR of cells transiently transfected with mutagenized 
NOTCH1 cDNA constructs  
All missense mutation show reduced NOTCH1 expression by comparison to cells 
transfected with a full-length wild-type construct (WT). Relative quantification (RQ) of 
gene expression is calculated relative to the WT baseline and normalised to GAPDH and 
ACTB.   
 
Key:  ***p<0.0001; **p=0.0017; *p=0.0148 
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5.3.2 POTENTIAL CROSS-TALK BETWEEN NOTCH1 AND BMP 
SIGNALLING 
 
For the purposes of identifying a novel cross-talk in molecular level between the 
defective NOTCH1 signalling cascade in the AOS patients with related cardiac 
and vascular abnormalities, and the BMP signalling pathway, quantitative RT-
PCR was employed to identify potential ID1 dysregulation in vivo. The missense 
NOTCH1 c.1343G>A mutation and the c.1646dupA frameshift mutation cases 
were once more examined and very interestingly in both cases ID1 mRNA levels 
ware up-regulated (Figure 5-5 A1-A2). To further interrogate this novel finding in 
vitro, transient transfection of WT, c.1343G>A and c.1646dupA NOTCH in HeLa 
cells was performed to examine the functional impact of the NOTCH1 missense 
and frameshift mutation on SMAD1/5 signalling. 48h later the cells were 
harvested and Western blotting analysis revealed significantly higher 
phosphorylated levels of SMAD1/5 protein in both WT and mutated NOTCH1 
receptor over-expression (Figure 5-5 C1-C2). The effect of WT NOTCH1 over-
expression on ID1 mRNA levels in HeLa cells was also assessed by qPCR and 
was also positively correlated with NOTCH1 up-regulation (Figure 5-5 B1-B2).  
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Figure 5-5 In vivo and in vitro ID1 destabilization in the present of NOTCH1 mutations 
(A1 - A2) Real-time PCR of NOTCH1-positive patient samples. Graphs show levels of 
gene expression for NOTCH1 and ID1. Interestingly, ID1 transcript levels are up-
regulated in patient samples. Relative quantification (RQ) of mRNA transcripts are 
calculated relative to the WT baseline and normalised to ACTB levels. (B1) Real-time 
quantitative PCR of HeLa cells transiently transfected with WT NOTCH1 cDNA construct. 
(B2) ID1 mRNA levels significantly up-regulated when WT NOTCH1 has been ectopically 
over-expressed. Relative quantification (RQ) of gene expression is calculated relative to 
C1. Immunoblot C2. Densitometry 
A1 A2 
B1 B2 
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the control baseline (cells transfected with empty vector) and normalised to ACTB. (C1) 
Immunoblots of endogenous p-SMAD1/5 and SMAD5 of HeLa cells transiently 
transfected with mutagenized NOTCH1 and WT cDNA constructs. (C2) Both mutations 
plus WT show increased p-SMAD1/5 expression by comparison to cells transfected with 
empty plasmid (control). Data are means ±SD of 3 independent experiments; *P<0.05, 
**P < 0.01, ***P< 0.001 and vs the control group, RM one-way ANOVA
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5.4 DISCUSSION 
 
5.4.1 HAPLOINSUFFICIENCY OF THE NOTCH1 RECEPTOR AS A CAUSE 
OF ADAMS-OLIVER SYNDROME WITH VARIABLE CARDIAC ANOMALIES 
 
There is an uncommon great degree of locus heterogeneity for this serious issue 
of morphogenesis termed AOS. Molecular and genetic studies successfully 
provided essential knowledge on the identification of multiple causative genes, 
and further the relevant molecular pathways to the disease pathogenesis. Yet, 
there is significant unexplained locus heterogeneity with underlying molecular 
genetic determinants, nevertheless uncharacterized for the majority of cases.  It 
is possible that AOS may represent a cluster of related phenotypes, analogous 
to RASopathies or cliopathies (Davis, Katsanis 2012, Patel, Taylor et al. 2004). 
Up to date, there are several proposed mechanisms to explain limb reduction and 
scalp defects in AOS. For example, vascular obstruction by thromboses during 
embryonic development is a known cause of TTLD, or endothelial cell dysfunction 
is a root cause of AOS (Hoyme, Jones et al. 1982, Toriello, Graff et al. 1988, 
Swartz, Sanatani et al. 1999). Denuted or reduplicated internal elastic laminae in 
AOS-blood vessels, blood vessel stenosis due to irregular vascular smooth 
muscle cells coverage, and tortuous ectatic vessels along with a general paucity 
of small to medium blood vessels are common findings in autopsy of AOS-
vasculopathy related cases, suggesting pericyte dysfunction as the basic 
pathophysiological mechanism in AOS (Patel, Taylor et al. 2004). Both Stittrich 
et al., 2014, and Southgate et al., 2015, reports added up to this glowing list of 
wide variety of AOS-related vascular defects, identifying AOS-subjects with 
pathological conditions cutis marmorata, venous ectasia, thrombophilia, portal 
hypertension, pulmonary hypertension and right- and left-sided CHD. While 
relevant academic and clinical bibliography reports the unclear mechanism of 
how NOTCH1 mutations and further loss of function cause AOS, it is of critical 
importance to highlight the dysregulated NOTCH1 signalling due to prevention of 
translation of effective stabilization of the receptor homotetramers after ligand 
binding interactions, as Notch signalling strength is the critical element in 
determining the normal development of the vasculature (Petrovic, Formosa-
Jordan et al. 2014).  
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Southgate et al., 2015, documented 10 novel germline NOTCH1 mutations 
identified in 12 AOS clinically diagnosed probands and a 50 unrelated AOS-
patient cohort with autosomal dominant and sporadic forms of AOS. Of interest, 
a significant high proportion of probands (5/11; 45%) diagnosed with a congenital 
heart abnormality, a percentage considerably higher of reported literature cases 
25, 26. In addition, 47% (8/17) of all affected variant carries had been diagnosed 
with a congenital heat anomaly as well (Appendix D – Table D-1). Taken together, 
NOTCH1 variants may represent a subtype of AOS, associated with cardiac 
malformations. Equally importantly, cutis marmorata telangiectatica congentica 
and several portal vein abnormalities were observed in NOTCH1-positive cases, 
thus NOTCH1 variants may also represent a distinct subtype of AOS associated 
with cardiovascular defects. To further support these associations, NOTCH1 
mutations in 5 AOS kindreds with cardiac spectrum defects were reported in a 
correlated study undertaken by Stittrich et al., 2014.  
In the context of this research, the emerged defective NOTCH1 signalling 
pathway is highlighted in regards to AOS pathogenesis. Existing literature reports 
numerus times the vital role of Notch family of single-pass transmembrane 
receptors in multiple cellular processes including cell fate in bilaterally symmetric 
multicellular eukaryotes, during embryogenesis and development of the 
cardiovascular system 27. Mutations of Notch components across the whole 
signalling cascade, underlie CHDs in humans and mice; for instance, Jag1 gene 
and at a lesser extent NOTCH2 mutations are responsible for the majority of 
cases in Alagille syndrome (Oda, Elkahloun et al. 1997), or embryonic lethality 
and cardiocascular defects (High, Lu et al. 2008). Interestingly, distinct NOTCH2 
truncating variants are responsible for Hajdu-Cheney syndrome, an osteolytic 
developmental disorder with pleiotrofic effects analogous to the NOTCH1 
receptor. Furthermore, craniofacial abnormalities, impairment of limb 
development and positive regulation of angiogenesis and osteogenesis have 
been reported in vivo for mice lacking Jag2 ligand or conditionally targeting 
NOTCH1 and NOTCH2 receptors (Francis, Radtke et al. 2005, Pan, Liu et al. 
2005). However, more functional studies regarding NOTCH1 receptor have to be 
undertaken for elucidation of the importance of its signalling cascade, during 
human fetal development.  
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In mammalian cells, the canonical NOTCH1 signalling is stimulated by ligand 
binding (Jag1/2, Delta-like1/3/4) through direct contact of adjacent cells, followed 
by proteolytic cleavage of NICD, which in turn forms transcriptional complexes 
with RBPJ and other co-activators (Figure 1-11). Furthermore, RBPJ regulates 
the expression of certain members of HEY and HES families of transcription 
factors, which have prominent role in cardiovascular development along with 
vasculogenesis and vascular remodelling (Fischer, Schumacher et al. 2004). 
Therefore, stimulation of HEY1 and HES1 it is known to be a direct readout of 
signalling activation.  
This study focuses in 10 missense, nonsense or frameshift NOTCH1 mutations, 
all identified by Southgate et al., 2015 that four out of ten are predicted protein 
trancating mutations most likely subject to NMD. Five of the six identified 
missense mutations are located with EGF-like domains of the receptor (Table 5-
1). This particular domain is responsible for the ligand-binding activation of 
signalling, chelating Ca2+ and is characterized by a core-β-pleated sheet, 3 
disulphide bonds along with a series of variable loops (Hambleton, Valeyev et al. 
2004). p.R448, p.C449R and p.C456Y lie within the EGF11 region, most likely 
disrupting the tertiary structure and affecting ligand interaction and/or Ca2+ 
binding (Figures 5-1 and 5-2). More specifically, the side chains of Arg448 and 
Glu424 interact electrostatically as it illustrated at the X-ray structure of this region 
(Figure 5-2); therefore p.R448Q mutation makes this interaction unstable. In 
addition, p.C449R and p.C456Y mutations potentially break the disulphide bonds 
between Cys440 and Cys449, and between Cys456 and Cys469 respectively. An 
imminent outcome of these breakages is the disruption of the adjacent Ca2+ 
stability coordinated by the side chains Asp469, Glu455 and Asp452 (Figure 5-
2). There is no up to date 3-dimentional structure of EGF35 region, but it is highly 
anticipated that Cys1374 mutation exerts similar effects. Furthermore, EOGT 
functions as an O-linked Nacetylglucosamine (GlcNAc) transferase, which 
catalyses the addition of an O-GlcNAc moiety to the 36 EGF-like repeats of the 
receptor in both Drosophilla and mouse (Sakaidani, Ichiyanagi et al. 2012). 
Although, AOS-associated EOGT gene functions have not yet been fully 
elucidated in humans, it is notable that 4 of the 5 EGF-domain missense identified 
mutations are located within the C5XXGXS/TGXXC6 motif located between the 
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fifth and sixth conserved cysteines, which is target of EOGT for O-glycose or O-
fucose modification. Moreover, the p.A1740S transmembrane mutation is also 
investigated in terms of defective signalling, although the functional impact on the 
receptor is unknown. Taken together, these findings suggest that the structural 
integrity of NOTCH1 receptor is affected by the majority of the identified missense 
mutations, thus its vital signalling activity is highly compromised.  
In the context of this research, gene expression studies have been performed to 
demonstrate that NOTCH1 expression is down-regulated in AOS-subjects 
harbouring NOTCH1 mutations in vivo. The control subject was a single healthy 
female aged 26 years old. Additional controls have been employed as part of the 
experimental design of the real-time PCR studies (Figure 5-3). Further in vitro 
transient transfection studies have been designed and undertaken to support and 
corroborate the in vivo data. Indeed, the generated data (Figure 5-4) support the 
prediction of NOTCH1 transcript loss by NMD or potential perturbation of mRNA 
stability, in case of the missense mutations. To further support the notion of 
NOTCH1 dysregulated signalling, the down-stream targets HEY1 and HES1 at a 
lesser extent, were down-regulated in vivo for the tested NOTCH1 mutations. Of 
interest, perturbation of both HEY1 and HES1 expression vary between the 
mutations tested, indicating allele-specific effects on downstream signalling 
(Southgate, Sukalo et al. 2015). Despite the limited available number of patient 
samples, HEY1 down-regulation suggests a common mechanism in AOS 
molecular pathology. Moreover, these data are highly compatible with the 
previous hypothesis that RBPJ mutations, a known causal factor in AOS 
pathogenesis, contribute to dysregulated Notch signalling. Taken together, these 
data solidify the project hypothesis; that loss-of-function haploinsufficiency of 
ηαυ1 is an important factor in AOS pathogenesis. They also provide a genotype-
phenotype correlation between NOTCH1 mutation and AOS-subjects with 
cardiac anomalies. Therefore, the first two aims of this project have been fulfilled 
both in vivo and in vitro case studies of NOTCH1 key missense and frameshift 
mutations, with subsequent receptor and down-stream targets down-regulation, 
a verified result which supports the notion of dysregulated NOTCH1 signalling in 
AOS with variable cardiac abnormalities.  
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5.4.2 SIGNALLING CROSS-TALK BETWEEN NOTCH1 AND BMP 
PATHWAYS 
 
This study also provides novel evidence of synergism between NOTCH1 and 
BMP signalling in a proportion of AOS-associated cases. The loss in regulation 
of NOTCH1 and NOTCH3 signalling, has been recently associated with the 
pathogenesis of several lung diseases, such as chronic obstructive pulmonary 
disease, asthma, pulmonary fibrosis, PAH, lung cancer and lung lesions in some 
congenital diseases (Zong, Ouyang et al. 2016). In the case of PAH and NOTCH3 
signalling in particular, the pathway is activated in primary human coronary artery 
and vascular smooth muscle cells, with several biological implications including 
reduction of cell proliferation rates and resistance to PAH development under 
hypoxic situations (Campos, Wang et al. 2002, Li, Zhang et al. 2009). Further 
molecular studies in the field, empowered the notion that spontaneous PAH in 
mouse models may arise via the dysregulation of Notch signalling (Yu, Mao et al. 
2013). While a direct convergence between Notch and BMP/TGF-β signalling is 
already evident in relevant bibliography, highlighting the NICD interactions with 
SMAD3 for TGF-β and SMAD1 for BMP signalling, there is no up to date study to 
bridge at a molecular lever AOS NOTCH1 signalling with potential alterations in 
BMP signalling. Thus, novel experimentation was designed to elucidate the 
potential synergism of BMP signalling in case of defective AOS-NOTCH1 
signalling, both in vivo and in vitro. Indeed, ID1 transcription levels were 
significantly up-regulated in AOS-patients harbouring p.R448Q and p.Y550* 
NOTCH1 mutations. Of note, phosphorylated SMAD1/5 levels were also 
significantly up-regulated in transient transfections studies of the above mutations 
in a generic cell line, a finding which correlates with the hypothesis of BMP 
signalling activation upon dysregulated NOTCH1 signalling and fulfils the last aim 
of the project. Taken together, these data agree with the general notion of BMP 
signalling cooperation, and synergistic and subsequent antagonism of BMP-
SMAD and Notch-mediated signalling pathways that have been demonstrated in 
EC and VSMC cultures (Beets, Huylebroeck et al. 2013, Rostama, Peterson et 
al. 2014). 
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5.5 CONCLUSION AND FURTHER WORK 
 
This report solidifies NOTCH1 mutations as the primary cause of AOS, in a 
proportion of cases in the cohort study (17%), while establishes NOTCH1 as an 
important genetic factor in AOS with associated cardiovascular complications. 
This finding warrants further epidemiological investigation in a future AOS-cohort 
study, that will be examined for cardiovascular complications. The functional 
studies have indicated links to previously associated genes of this condition, 
which together accentuate the central importance of NOTCH1 signalling in a 
series of key developmental systems in human embryogenesis. Further X-ray 
crystallography studies of the identified NOTCH1 missense mutations of the 
EGF-like domain will also elucidate the extend of the structural perturbation of the 
receptor and subsequent impairment of the signalling cascade. Finally, the cross 
talk of BMP and NOTCH1 signalling is highlighted as a synergistic effect in AOS 
pathology, underlined by forms of non-canonical signalling and potentiating the 
suppressive BMP cell signalling effect in AOS-cases of dysfunctional NOTCH1 
signalling and further cardiovascular defects. A future goal of research could be 
established in regards the potential BMP signalling up-regulation in AOS-subjects 
that suffer from certain vasculopathies and/or PAH.  If to continue working in the 
field, a recommended allowing suitable time-frame for the above-mentioned 
experimentation, would be a 2-3 years’ study, as X-ray crystallographic studies 
along with tissue-based work would require a substantial amount of time for the 
evolution of this crucial research on AOS and PAH linkage, in terms of aberrant 
signalling and cardiovascular malformations. 
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In order to summarise the findings regarding the differential regulation of the BMP 
and TGF-β signalling pathways mediated by JAB1 and its control of several target 
genes in healthy and/or disease state, a schematic was produced (Figure 6-1). 
 
 
 
 
Figure 6-1 JAB1 as a Master Regulator of BMP and TGF-β signalling 
Upon BMP or TGF-β ligand stimulation, the type-II receptors activate and phosphorylate 
through their kinase domain, type I receptors. In turn, type-I receptors phosphorylate R-
SMADs 1/5/8 (for BMP signal) or R-SMADS2/3 (for TGF-β signal) and through 
association with the common-SMAD4 they form trimers which translocate to the nucleus 
and form complexes with other transcription co-factors, regulating SMAD-dependant 
gene expression. The receptor complexes could also activate SMAD-independent 
signalling such as TAK1 and p38MAPK pathways. Inhibitory SMADs 6 (for BMP 
signalling) and 7 (for TFG-β signalling) act as negative regulators of BMP/TGF-β 
signalling, targeting the activated receptor complexes for proteasomal degradation. As it 
has been shown within the context of this study, pulmonary arterial endothelial and 
smooth muscle cells undergo differential regulation of the signal transduction by JAB1 
protein, in all main steps of the BMP/TGF-β signalling cascades, by targeting for 
proteasomal degradation BMP type II receptor, co-SMAD4, SMAD5, I-SMAD7, and the 
transcription factors ID1 and ID3. Furthermore, JAB1 over-expression can up-regulate 
SMAD2/3 signalling and activate the mitogenic cascades of TAK1 and p38 MAPK, via 
SMAD-independent signalling. In certain cell types as carcinomas, JAB1 over-
expression could lead to down-regulation of p38 MAPK, as it has been demonstrated in 
this study’s early findings.  
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The main aim of this study was to examine the respective roles of JAB1 and 
NOTCH1 in the development of cardiovascular disorders. Previous studies have 
shown both proteins to be involved in BMP signalling pathways; JAB1 has been 
identified as a BMPR-II interacting protein, whilst NOTCH1 intracellular domain 
interacts with SMADs and enhances the canonical NOTCH1 signalling 
(Andersson et al. 2011). We therefore seek to better understand the processes 
by which these pathways are regulated and their function in cardiac disease 
pathogenesis, both with and without a PAH phenotype. 
A principal study goal was to verify the interaction of JAB1 and BMPR-II in vivo 
and in vitro for which evidence has been presented in HeLa and HEK293T 
generic cell lines. Moreover, over-expression of monomeric JAB1 has been 
shown to modulate the down-regulation of BMPR-II. Further BMP4-ligand 
stimulation of the BMP pathway did not alter the mechanistic effect of JAB1 on 
down-stream BMPR-II outcomes, in particular the effect on SMAD1/5 activation, 
thus it was considered definitive. An additional feature that was identified was the 
up-regulation of JAB1 protein expression in PASMC cells harbouring two 
distinctive HPAH BMPR2 mutations. However, this finding did not come into 
synergy with a third HPAH BMPR2 mutation that has been extensively studied, 
indicating that JAB1 dysregulation is BMPR2 mutation specific in PAH cells. 
Through the study of JAB1 and BMPR-II protein interaction, a novel finding has 
been identified, whereby JAB1 down-regulation of BMPR-II is mediated via the 
proteasomal pathway in the normal and/or disease circulation. Thus, the currently 
unsolved elevated receptor loss in PAH progression could be explained through 
this identified protein-protein interaction with JAB1. Taken together, these data 
provide insights into the role of this interaction, that when disrupted, may lead to 
a disease phenotype. Further functional studies may elucidate the minimal JAB1 
interacting regions, by domain, with the BMPR-II receptor and the definition of the 
real-time interaction of BMPR-II with JAB1 by fluorescence resonance energy 
transfer (FRET) analysis. 
In recent studies, JAB1 has been characterized as an oncogene (Hsu et al. 2008, 
Yoshida, et al. 2010, Shackleford and Claret 2010), and here the tumorigenic 
potential of JAB1 is indicated by demonstrating increased proliferation of JAB1-
transfected cells by comparison to control. However, present studies have not 
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examined this finding in the context of monoclonal growth of tested cells. These 
data are important in the context of PAH because they may play a significant role 
for explanation of the uncontrolled proliferation of PAECs and PASCMs in 
disease state. The up-regulation of JAB1 remains to be extensively investigated 
in multiple human PAH lines with a range of in vivo mutations and primary murine 
cells to determine whether genotype may influence JAB1 level. It would also be 
of interest to examine stable clones expressing a BMPR-II KD mutation, such as 
p.D485G, a highly penetrant missense mutation.  
In case of BMPR2 mutant PASMC cells, it has also been demonstrated that 
selective BMP4 treatment inhibited their abnormal proliferation, a finding that 
verifies the reported use of TGF-β1 and BMPs as BMP2, 4 and 7 anti-proliferative 
effects on vascular smooth muscle cells (Morrell, Yang et al. 2001), and 
complements the first use of BMP7 ligand to target and enhance endothelial 
BMPR-II signalling and reverse established PAH in animal model of disease 
(Long, Ormiston et al. 2015). Further experimentation on PASMC cells indicated 
that BMPR2 haploinsufficiency potentiates TGF-Β signalling in PAH, mainly via 
mitogenic SMAD-independent signalling pathways such p38MAPK and TAK1, 
underlining the importance of restoration of the BMP signal and its suppressive 
role on cell proliferation. Taken together, this study underscore a role for BMP4 
as a vascular stability and quiescence factor and provide a translational 
framework for delivery of the BMP ligand as a treatment strategy for PAH.  
This study mainly characterizes JAB1 as a master regulator of BMP and TGF-β 
signalling pathways, because as it has been shown it differentially regulates their 
signalling balance, by mainly repressing or enhancing at a lesser extent the 
relevant up-stream, intermediaries and down-stream transcription factors. The 
manner in which JAB1 mediates regulation of the BMP/TGF-β signal indicates 
that is happening via SMAD-dependent or SMAD-independent pathways, as it 
was verified in a generic cell line. More specifically, it has been evidenced that 
JAB1 over-expression down-regulates BMPR-II protein expression, along with 
SMAD5, co-SMAD4 and I-SMAD7, whereas JAB1 dysregulation could shift the 
BMP and TGF-β balance towards the later, potentiating ID1 expression via either 
repressing the I-SMAD7 or activating SMAD non-canonical signalling by TAK1 
up-regulation. In addition, p38 MAPK activation by JAB1 over-expression was 
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considered to be cell type specific, because an opposite effect on p38 MAPK 
regulation was observed in HeLa cells that JAB1 was ectopically over-expressed. 
Most importantly and through RNAi interference studies, the endogenous knock-
down of JAB1 from healthy and mutant PASMCs, managed to suppress cell 
proliferation and reverse abnormal proliferation in mutants, rescuing the PAH 
disease phenotype. Thus, JAB1 oncogenic activity may potentiate a clinical target 
for manipulation in the treatment of PAH.  
Novel patient data analysis has demonstrated that NOTCH1 gene expression is 
down-regulated in AOS subjects harbouring NOTCH1 mutation in vivo, 
supporting the initial prediction of transcript loss by molecular mechanisms as 
NMD or perturbation of mRNA stability (Cartegni et al. 2002). Transient 
transfection studies of mutant constructs further supported in vitro the patient 
data, solidifying the hypothesis that haploinsufficiency of the NOTCH1 receptor 
is a cause of AOS. Moreover, reduction of HEY1 and, to a lesser extent, HES1 
transcript levels confirms the prediction that these identified mutations potentially 
lead to dysregulated Notch signalling, as previously reported with mutations of 
the RBPJ gene in AOS (Hassed et al. 2012). Furthermore, reduction of HEY1, 
which is mainly associated with cardiovascular development (Fischer, 
Schumacher et al. 2004), is a fact which may explain the increased incidence of 
the reported cardiovascular findings in these patients. In the context of NOTCH1 
defective signalling, future X-Ray crystallographic studies should be employed to 
assess the effects of the identified missense mutations of NOTCH1 in the 
extracellular domain, specifically in EGF repeats 11-13 encoding the ligand-
binding domain. Finally and within the context of this study, novel compelling 
evidence of synergism between NOTCH1 and BMP signalling has been identified 
in a proportion of AOS-associated cases. While BMP and Notch signalling cross-
talk is well described in available bibliography, this was the first time that a 
BMP/NOTCH1 molecular bridge has been investigated, linking defective AOS-
associated NOTCH1 signalling with up-regulated BMP signalling both in vivo and 
in vitro cases. This later finding may be indicative of potentiation of the 
suppressive BMP regulatory effect in AOS-cases of dysfunctional NOTCH1 
signalling and further cardiovascular defects. In summary, these data support the 
hypothesis that AOS may be a disorder of vasculogenic origin, and further provide 
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novel evidence of a genotype-phenotype correlation between NOTCH1 
mutations and AOS-related congenital heart defects.  
 
6.1 CONCLUSION 
 
During PAH progression, JAB1 protein is up-regulated under certain BMPR2 
mutations, a dysregulation which results in down-regulation of the BMPR-II 
receptor via ubiquitin-mediated proteolysis and further impairment of BMP 
signalling. JAB1 over-expression potentiates cells into a proliferative and anti-
apoptotic response, promoting a differentiated phenotype. In addition, the 
BMP/TGF-β signalling balance is greatly affected by JAB1 dysregulation, both in 
SMAD-dependant and SMAD-independent manners. Thus, JAB1 can be 
characterized as a master regulator of the BMP and TGF-β signalling pathways. 
Finally, haploinsufficiency of the NOTCH1 receptor has also been identified as 
the primary cause of AOS, and an important genetic factor in AOS with 
associated cardiovascular complications.  
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Buffer recipes and SDS-PAGE conditions 
Extraction Buffer for co-IPs  
 
20mM HEPES pH 7.5 
100mM NaCl 
10% Glycerol 
1% Triton X-100 
20 mM sodium fluoride (NaF),  
1 mM sodium orthovanadate (Na3VO4), 
1 mM phenylmethylsulfonyl fluoride (PMSF), 
10x Protein Inhibitors Cocktail 
dH2O 
 
General Extraction Buffer for WBs 
 
1M Tris base Ph 7.4 
5M NaCl 
1M MgCl2 
10% SDS 
1% Triton X-100 
20 mM sodium fluoride (NaF),  
1 mM sodium orthovanadate (Na3VO4), 
1 mM phenylmethylsulfonyl fluoride (PMSF), 
10x Protein Inhibitors Cocktail 
dH2O 
 
 
SDS-PAGE Running Buffer  
 
25mM Tris 
192mM Glysine 
0.1% SDS 
dH2O 
 
Transfer Buffer (for Western blotting) 
 
25mM Tris 
192mM Glycine 
20% Methanol 
dH2O 
 
SDS Sample-Loading Buffer 
 
50mM Tris-HCl pH 6.8 
2% SDS 
10% Glycerol 
1% β-mercaptoethanol 
12.5 mM EDTA 
0.02% bromophenol blue
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Growth curves of project key cell lines 
In order to study the growth and the doubling time of the studied cell lines, HeLa 
and HEK293T cells were maintained for 6 days, and PASMC (WT) were 
maintained for 7 days, without media change (Figure 1). The Population Doubling 
Time (PDT) from the linear part of the each curve was defined using the formula: 
PDT = (t2 - t1)/3, 32 x (log n2 - log n1) (Hayflick, 1973), where t is time and n 
number of cells (Figure 1). The PDTs of HeLa, HEK293T and PASMC cells were 
27.23h, 17.89h and 35.00h respectively.  
 
The hTERT-immortalized PASMC-Bmpr2+/R899X cell line was discarded from 
experimentation, because of abnormal proliferation (Figure 2). Whilst not 
investigated, the human Telomerase Reverse transcriptase (hTERT) treatment 
of primary cells for immortalization may cause altering of their phenotypic 
characteristics and proliferation rates.  
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Figure A-1 Growth curves of human PASMC (WT), HeLa and HEK293T cell lines 
 The PDT for A) PASMC cells was 37.00h, for B) HeLa cells was 27.23h and for C) 
HEK293T cells was 17.89h. The results of 3 independent experiments in technical 
triplicates (mean ±SD) are shown. 
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Figure A-2 Abnormal proliferation of hTERT PASMC-BMPR2+/R899X cell line 
A) 10x Optical Magnification of hTERT PASMC-BMPR2+/R899X and WT cells in 5 days 
culture experiments. B) A significant difference in proliferation between p.R899X cells 
and control at day 5 was identified. Mutant cells were behaving in an abnormal and 
unexpected way, slowing down their proliferation compared to healthy cells, for all 
experimentation that took place in our laboratories. The cells were found to be 
inappropriate for further proliferation and transfection studies, within the context of the 
project. P values were calculated by Sidak’s multiple comparison test in a 2 way Analysis 
of Variance (ANOVA). 
Key: ****p<0.0001 
A 
B 
APPENDIX C 
 
154 
 
 
 
 
 
 
 
 
 
CHAPTER 9: APPENDIX C 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX C 
 
155 
 
Transient Transfections 
 
Chemical methods (Figures 1-3) 
 
Non-liposomal reagents: Fugene HD (Promega) and Turbofectin 8.0 
Liposomal Reagents: Lipofectamine 2000 and Lipofectamine 3000 
Detection time: 48h post transfection 
Generic cell lines: HeLa and HEK293T 
Ragent (uL) :  pDNA (ug) ratio of 3:1 after optimization in each above case 
(Lipofectamine 2000 and Fugene HD have similar results with 2.5:1 as well) 
 
Cell viabilities and transfection efficiencies in HeLa cell line, 48h post-
transfection. The viabilities were verified using Trypan Blue stain, after repeated 
experimentation in 6 well plates / 10cm dishes. 
Reagent Viability (48h) Efficiency of 
Transfection (48h) 
Fugene HD 95% 44% 
Turbofectin 8.0 90% 50% 
Lipofectamine 2000 60% 50 % 
Lipofectamine 3000 80% 45% 
 
Comments:  
1) 24h post transfection time is limited in efficient gene expression (verified 
by WB) 
2) JAB1 – BMPR-II interaction, due BMPR-II down-regulation after ectopic 
Jab1 expression, visible at 48h 
3) Experiments with HEK293T cells gave better Western blotting results in 
regards to ectopic expression of Jab1; yet after 48h and due to high 
proliferation rate of the cells the episome copies are being reduced. 
4) Extremely low reproducibility of positive results – loss of valuable lab. 
Time 
5) No transfection of hTERT Pulmonary Arterial Smooth Muscle Cells 
(verified by WB) 
6) High laboratory costs due time (t/c media and flasks, reagents, 
antibodies for WB) 
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Electroporation / Microporation (Neon System – Life Technologies) 
(Figure 4) 
 
Detection time: 24h post transfection 
Generic cell lines: HeLa and hTERT-PASMC 
Cell viabilities: Highly comparable to Control cells in optimised experiments 
(remains to be verified by TB staining)  
 
Comments: 
1) The transfection efficiency in hTERT PASMCs reaches up to 66% with 
1200V, 20msec, 2 pulses, but with less viability (when compared to 
control cells). 
2) Cost effective (app. £4 per transfection) 
3) Highly reproducible results (the mini-optimization experiment in HeLa 
cells was repeated twice, using 10ul and 100ul tips) 
4) The cells can be transfected with pDNA, si/miRNA and protein (no need 
for specific reagents per experiment) 
5) Universal electroporation buffer for all cells types. 
6) Reduced experimental time by 1 day (no need for pre-transfection cell 
plating and overnight incubation) 
7) Triple transfections will be performed and further be assessed with WB 
technique. 
8) Easy handling of the equipment even for beginners / storage of optimal 
settings per cell type. 
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Transfection efficiencies 
Figure C-1 Identification of Transfection Efficiencies of various liposomal and non-liposomal transfection reagents using myc-tagged JAB1 pDNA 
in HeLa cell line. Immunoblots of myc-tagged JAB1 and A-Tubulin (endogenous control) in HeLa cells transfected with 2 or 4μg of myc-JAB1 
pDNA, utilizing various commercial liposomal and non-liposomal formulations of transfection reagents (liposomal: K2, Metafectane Pro, 
Lipofectamine 2000 and Lipofectamine 3000; non-liposomal: Fugene HD and Turbofectin 8.0). 3x105 cells per well were plated in 6 well plates 
the day before transfection in order to accomplish an 80% confluence on the following day. The cells were transfected according to manufacturer’s 
instruction at a 3:1 ratio of reagent(μl) to DNA(μg) and the transfection media was changed after 6 hours of incubation time. The cells were lysed 
for protein collection after 48h of total incubation time. Lipofectamine 3000, Fugene HD and TurboFectin 8.0 gave optimal results in transfection 
efficiencies and Fugene HD transfected samples retained high levels of viability after 48h incubation time (viability was assessed microscopically). 
APPENDIX C 
 
158 
 
 
Figure C-2 Identification of Transfection Efficiencies of various liposomal and non-liposomal transfection reagents using myc-tagged JAB1 pDNA 
in HEK293T cell line. Immunoblots of myc-tagged JAB1 and A-Tubulin (endogenous control) in HEK293T cells transfected with 2 or 4μg of myc-
JAB1 pDNA, utilizing various commercial liposomal and non-liposomal formulations of transfection reagents (liposomal: K2, Metafectane Pro, 
Lipofectamine 2000 and Lipofectamine 3000; non-liposomal: Fugene HD and Turbofectin 8.0). 5x105 cells per well were plated in 6 well plates 
the day before transfection in order to accomplish an 80% confluence on the following day. The cells were transfected according to manufacturer’s 
instruction at a 3:1 ratio of reagent(μl) to DNA(μg) and the transfection media was changed after 6 hours of incubation time. The cells were lysed 
for protein collection after 48h of total incubation time. Interestingly, only a small fold increase in ectopic JAB1 expression is observed between 
the 2 and the 4μg of pDNA transfected samples, utilizing Lipofectamine 3000. The above reagents did not affect significantly the viability of the 
cells after 48h incubation time (viability was assessed microscopically. 
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Figure C-3 Optimisation of commercial liposome and non-liposomal transfection reagents. A transfection titration experiment with K1, 
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Lipofectamine 2000, Lipofectamine 3000, Metafectane PRO and Fugene HD in various Transfection Reagent volumes to plasmid DNA ratios 
(5:1. 4:1, 3:1, 2:1 and 1:1) and fluorescent analysis of HeLa cells transfected with eGFP protein and incubated for 48h in 37oC - 5% CO2, 
revealed the best ratios for each reagent as indicated above. Fugene HD gave undoubtedly the best transfection efficiency amongst them with 
the lowest toxicity effect on the cells with reagent to DNA ratio of 3:1  
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Figure C-4 Optimised electroporation parameters for HeLa and hTERT-PASMC cell lines 
A) 75% transfection efficiency in Hela cells after a mini optimization experiment – 24h 
post-transfection time – minimal amount of pDNA encoding GFP, verifying the 
application note of life technologies (1005V, 35msec, 2 pulses, 100ul tip), 10x 
magnification, B) 40% transfection efficiency in hTERT-PASMCs after a full optimization 
experiment – 24 well plate - 24h post-transfection time – minimal amount of pDNA 
encoding GFP, novel data for hTERT PASMC transfection using the Neon System. 
(1100V, 20msec, 1 pulse, 10ul tip), 10x magnification. The electroporator device was 
Neon® Transfection System (ThermoFisher SCIENTIFIC). 
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Supplementary data on AOS affected subjects and 
identified NOTCH1 variants 
 
In this section, the clinical characteristics of AOS affected subjects harbouring 
NOTCH1 mutations, are summarized in Table 1 along with pedigree structures 
and sequence chromatograms of identified NOTCH1 mutations, that are 
illustrated in Figure 1.   
Moreover, the predicted pathogenicity of the identified NOTCH1 variants is 
identified in Table 2 (MutationTaster2,19 PolyPhen-2,20 and/or SIFT prediction 
software21). 
*All the Figures and Tables of this section can be also found online in {{102 
Southgate,L. 2015}} paper. 
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 Table D-1 Clinical characteristics of AOS subjects harbouring NOTCH1 mutations 
Subject 
ID 
Country of 
origin 
Current 
Age 
Sex 
Scalp 
ACC 
TTLD 
Cardiac or 
Vascular Features 
[Age at 
Diagnosis] 
Echocardiographic 
Assessment [Age at 
Assessment] 
Other features [Age 
at Diagnosis] 
1-II:1* 
 
 
 
 
UK 
29 y Male ++ + ND Not assessed 
Undefined heart 
murmur 
1-II:2 28 y Male ++ + ND Not assessed 
Undefined heart 
murmur 
1-II:4 35 y Female – ++ 
[34 y]: AR; AS; 
CMTC on 
abdomen and legs 
[34 y]: mild AS and AR 
(PV: 2.04 m/s, PG: 
16.65 mm Hg), mildly 
increased velocities 
through pulmonary 
valve (2.06 m/s) and 
descending aorta (2 
m/s) 
– 
1-III:1 17 y Male + ++ ND Not assessed – 
1-III:2 10 y Female – – [9 yr]: AR 
[9 yr]: mild AR (PV: 
2.21 m/s, PG: 19.54 
mm Hg), mildly 
increased velocities 
through pulmonary 
valve (1.91 m/s) and 
descending aorta (2.3 
m/s) 
– 
2-II:1* 
 
Italy 
27 y Male + – 
[15 d]: BAV; CoA; 
PMV; [5 mo]: 
subclavian flap 
coarctectomy 
[15 d]: nonstenotic PMV 
with mild regurgitation 
Reference: 
Dallapiccola et al15 
1992 (patient 2) 
3-II:3 Germany 35 y Male – + None [34 y]: normal – 
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3-III:1* 8 y Male ++ + None [7 yr]: normal – 
4-I:2  
 
 
 
 
 
Italy 
47 y Female – – AR; AS 
[47 y]: thick fibrotic 
semilunar valves; 
moderate AR (PG: 34 
mm Hg, MG: 20 mm 
Hg); mild to moderate 
LVH 
Long palpebral 
fissures 
4-II:1* 25 y Female + ++ 
[15 d]: AS; CoA; 
PMV; VSD 
[15 d]: subaortic 
membranous VSD; 
severe AS (PG: 80 mm 
Hg, MG: 60 mm Hg); 
PMV with valvular 
insufficiency 
Long palpebral 
fissures 
5-II:1* UK 10 y Male ++ – 
[1 d]: PA-VSD; [6 
d]: right MBTS; [2 
yr]: Rastelli 
correction 
[1 d]: PA, VSD Fallot 
type; [10 y]: some 
narrowing of shunt, free 
pulmonary regurgitation 
[5 y]: portal vein 
thrombosis; portal 
hypertension; T-cell 
lymphopenia; 
complex learning 
disability; autism 
6-II:1* Russia Deceased Female ++ + 
[In utero]: truncus 
arteriosus 
communis type I; [1 
d]: VSD 
[1 d]: membrane VSD, 
right-sided aortic bow 
descending on left-
hand side 
– 
7-II:1* Italy 8 y Male + + None [7 y]: normal 
Bilateral 
cryptorchidism; 
bilateral abdominal 
wall hernia; 
hypertelorism; 
downslanting 
palpebral fissures 
8-II:1* Italy 15 y Male + + [1 d]: CMTC [15 y]: normal Epilepsy; dyslexia 
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9-II:1* Germany 33 y Female + ++ ND Not assessed – 
10-II:1* France 16 y Female ++ ++ 
[3.5 y]: ASD; 
surgically closed at 
4 y; arteriography: 
EHPVT, 
hepatopetal and 
hepatofugal 
collateral veins 
[3.5 y]: ASD, suspected 
portopulmonary 
hypertension (mPAP: 
30 mm Hg); [7 yr]: 
mPAP: 45 mm Hg, 
PVR: 8.1 Wood U/m2, 
PWP: <15 mm Hg; [12 
yr]: mPAP: 27 mm Hg 
with Sildenafil treatment 
[3.5 y]: HSM and 
portal hypertension 
with GI bleeding; 
OPV. Reference: 
Girard et al,16 2005 
(patient 1); Franchi-
Abella et al,17 2014 
11-II:1* Greece 19 y Male ++ ++ 
[6.5 y]: 
arteriography: 
EPVO, large 
hepatofugal 
coronary vein, tiny 
hepatopetal 
cavernoma 
[6.5 y]: normal;  
       [14 y]: normal 
[6.5 y]: HSM and 
portal hypertension; 
OPV.  
Reference: Girard et 
al,16 2005 (patient 
2); Franchi-Abella et 
al,17 2014 
 
Subject identifiers refer to the pedigree structures in Figure 1. The proband for each family is marked with an asterisk. – indicates absent; +, 
present (for ACC: +, small defect [<5 cm]; ++, large defect [>5 cm] with underlying osseous skull defect; for TTLD: +, feet or hands only; ++, both 
feet and hands affected); ACC, aplasia cutis congenita; AR, aortic regurgitation; AS, aortic valve stenosis; ASD, atrial septal defect; BAV, bicuspid 
aortic valve; CMTC, cutis marmorata telangiectatica congenita; CoA, coarctation of the aorta; EPVO, extrahepatic portal vein obstruction; EHPVT, 
extrahepatic portal vein thrombosis; GI, gastrointestinal; HSM, hepatosplenomegaly; LVH, left ventricular hypertrophy; MBTS, modified Blalock–
Taussig shunt; MG: median gradient; mPAP, mean pulmonary arterial pressure (measured by right heart catheterization); Nd, not determined; 
OPV, obliterative portal venopathy; PA, pulmonary atresia; PG, peak gradient; PMV, parachute mitral valve; PV, peak velocity; PVR, pulmonary 
vascular resistance; PWP, pulmonary wedge pressure; TTLD, terminal transverse limb defects; and VSD, ventral septal defect. 
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Table D-2 Predicted pathogenicity of identified NOTCH1 variants 
Variant MutationTaster2 PolyPhen-2 SIFT 
p.P407R 
Disease causing 
(prob: 
0.999976877874958) 
Probably damaging 
(0.968) 
Tolerated 
(0.326) 
p.R448Q 
Disease causing 
(prob: 
0.999999768941672) 
Probably damaging 
(0.984) 
Damaging 
(0.009) 
p.C449R 
Disease causing 
(prob: 
0.999999999999999) 
Probably damaging 
(1.000) 
Damaging 
(0.001) 
p.Y550* Disease causing 
(prob: 1) 
n/a n/a 
p.C1374R 
Disease causing 
(prob: 
0.999999999999986) 
Probably damaging 
(0.999) 
Damaging (0) 
p.E1555* Disease causing 
(prob: 1) 
n/a n/a 
p.M1580Ifs*30 Disease causing 
(prob: 1) 
n/a n/a 
p.A1740S 
Polymorphism 
(prob: 
0.980152316967981) 
Benign (0.134) 
Damaging 
(0.027) 
p.S2017Tfs*9 Disease causing 
(prob: 1) 
n/a n/a 
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Figure D-1 Pedigree structures and sequence chromatograms of identified NOTCH1 
mutations 
Asterisks denote the families included in the exome sequencing discovery cohort. 
Probands are marked by the black arrows and asymptomatic carriers are indicated with 
black dots. For de novo mutations, paternity was confirmed by microsatellite analysis 
(data not shown). Key: +, wild-type allele; −, mutant allele
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Miscellaneous data 
 
 
Figure E-1 Example of Lowry Assay standard curve with DC Protein micro-Assay Kit 
(BIO-RAD) for protein quantitation of cell culture extracts  
 
 
 
Figure E-2 Example of the quality of RNA isolation samples using RNeasy Plus Mini Kit 
(QIAGEN)  
The 18S and 28S ribosomal RNA bands are clearly visible in the intact RNA samples, 
that were used for cDNA synthesis and qPCR following relative quantification of 
expression of transfected Notch1 mutations in HeLa cells (see Figure 5-4).   
APPENDIX E 
 
171 
 
Figure E-3 JAB1 down-regulation of expression after shRNA specific knock-down 
A) Indicative preliminary immunoblotting revealing effective JAB1 down-regulation of 
protein expression, after transient transfections with 5ug/transfection per 1million HeLa 
cells, of Scrumble (control) or shRNAs against Jab1 mRNA. α-Τubulin was used as 
endogenous control. B) Densitometric analysis in arbitrary units (%) from the 
immunoblots for JAB1 shRNA knock-downs. Data are means ±SD of 3 independent 
experiments; **P < 0.01 vs the control group, RM one-way ANOVA. 
A. Immunoblot 
B. Densitometry 
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